UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2018~~

2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to

Commission file number:

001-36167

Karyopharm Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware		26-3931704
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

85 Wells Avenue, 2nd Floor Newton , MA		02459
(Address of principal executive offices)		(Zip Code)

~~(617)~~

(
617
)

658-0600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock , $0.0001 par value	KPTI	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation

S-T (§

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule

12b-2

of the Exchange Act.


Large accelerated filer	☐ ☒	Accelerated filer	☒ ☐

~~Non-accelerated~~ ~~filer~~	☐
Non-accelerated filer	☐	Smaller reporting company	☐

		Emerging growth company	☒ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

☐

Indicate by check mark whether the registrant is a shell company (as defined inRule

12b-2

of the Exchange Act). Yes

☐

☒

As of ~~November 2, 2018,~~October 29, 2019, there were ~~60,707,876~~62,790,043 shares of Common Stock, $0.0001 par value per share, outstanding.

Table of Contents

TABLE OF CONTENTS


	PART I—FINANCIAL INFORMATION


Item 1.	Condensed Consolidated Financial Statements (Unaudited)		3
	Condensed Consolidated Balance Sheets		3
	Condensed Consolidated Statements of Operations		4
	Condensed Consolidated Statements of Comprehensive Loss		5
	Condensed Consolidated Statements of Cash Flows		6
	Condensed Consolidated Statements of Stockholders’ Equity		7
	Notes to Condensed Consolidated Financial Statements		7 8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		24 29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		31 36
Item 4.	Controls and Procedures		31 36

	~~PART II—OTHER INFORMATION~~

~~Item 1A.~~ PART II—OTHER INFORMATION	~~Risk Factors~~
		33
~~Item 6.~~	~~Exhibits~~		68
Item 1.	Legal Proceedings		37
Item 1.A.	Risk Factors		37
Item 6.	Exhibits		78
	Signatures		69 79

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements (Unaudited).

Karyopharm Therapeutics Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share amounts)

   September 30,
2018 December 31,
2017
Assets

Current assets:

Cash and cash equivalents
   $ 101,600 $ 68,997
Short-term investments
   105,170 77,472
Prepaid expenses and other current assets
   4,792 1,754
Restricted cash
   —   200


Total current assets
   211,562 148,423
Property and equipment, net
   2,914 2,185
Long-term investments
   4,804 29,396
Restricted cash
   712 290


Total assets
   $ 219,992 $ 180,294


Liabilities and stockholders’ equity

Current liabilities:

Accounts payable
   $ 2,238 $ 5,665
Accrued expenses
   29,155 21,445
Deferred revenue
   9,362 21,921
Deferred rent
   256 303
Other current liabilities
   556 133


Total current liabilities
   41,567 49,467
Deferred revenue, net of current portion
   4,532 —
Deferred rent, net of current portion
   2,815 1,363


Total liabilities
   48,914 50,830
Stockholders’ equity:

Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
   —   —
Common stock, $0.0001 par value; 100,000,000 shares authorized; 60,664,857 and 49,533,150 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
   6 5
Additionalpaid-in capital
   786,763 625,017
Accumulated other comprehensive loss
   (153 ) (217 )
Accumulated deficit
   (615,538 ) (495,341 )


Total stockholders’ equity
   171,078 129,464


Total liabilities and stockholders’ equity
   $ 219,992 $ 180,294


	September 30, 2019				December 31, 2018
Assets
Current assets:
Cash and cash equivalents		$	168,004			$	118,021
Short-term investments			99,525				210,178
Accounts receivable			7,928				—
Inventory			100				—
Prepaid expenses and other current assets			5,310				6,413

Total current assets			280,867				334,612
Property and equipment, net			3,240				3,863
Operating lease right-of-use assets			10,904				—
Long-term investments			2,022				2,001
Restricted cash			712				716

Total assets		$	297,745			$	341,192

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	3,068			$	4,332
Accrued expenses			32,421				32,493
Deferred revenue			1,053				9,362
Operating lease liabilities			1,583				—
Deferred rent			—				390
Other current liabilities			1,077				327

Total current liabilities			39,202				46,904
Convertible senior notes			107,962				102,664
Deferred royalty obligation			73,589				—
Operating lease liabilities, net of current portion			13,643				—
Deferred revenue, net of current portion			3,479				4,532
Deferred rent, net of current portion			—				3,922

Total liabilities			237,875				158,022
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; NaN issued and outstanding			—				—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 62,705,481 shares issued and outstanding at September 30, 2019; 100,000,000 shares authorized; 60,829,308 shares issued and outstanding at December 31, 2018			6				6
Additional paid-in capital			884,585				857,156
Accumulated other comprehensive loss			(30	)			(244	)
Accumulated deficit			(824,691	)			(673,748	)

Total stockholders’ equity			59,870				183,170

Total liabilities and stockholders’ equity		$	297,745			$	341,192

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Karyopharm Therapeutics Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except share and per share amounts)

   Three Months Ended,
September 30, Nine Months Ended
September 30,
   2018 2017 2018 2017
License and other revenue
   $ 239 $ —   $ 30,130 $ 71
Operating expenses:

Research and development
   36,427 25,237 122,482 72,440
General and administrative
   12,966 5,818 30,076 18,717


Total operating expenses
   49,393 31,055 152,558 91,157


Loss from operations
   (49,154 ) (31,055 ) (122,428 ) (91,086 )
Other income (expense):

Interest income
   1,098 454 2,260 1,266
Other expense
   (13 ) (26 ) (20 ) (70 )


Total other income, net
   1,085 428 2,240 1,196


Loss before income taxes
   (48,069 ) (30,627 ) (120,188 ) (89,890 )
Income tax provision
   (14 ) (13 ) (9 ) (54 )


Net loss
   $ (48,083 ) $ (30,640 ) $ (120,197 ) $ (89,944 )


Net loss per share—basic and diluted
   $ (0.79 ) $ (0.65 ) $ (2.17 ) $ (2.00 )


Weighted-average number of common shares outstanding used in net loss per share—basic and diluted
   60,586,511 47,141,146 55,465,261 44,974,945


	Three Months Ended, September 30,								Nine Months Ended September 30,
	2019				2018				2019				2018
Revenues:
Product revenue, net		$	12,821			$	—			$	12,821			$	—
License and other revenue			328				239				9,976				30,130

Total revenues			13,149				239				22,797				30,130
Operating expenses:
Cost of sales			1,013				—				1,013				—
Research and development			26,270				36,427				90,761				122,482
Selling, general and administrative			25,267				12,966				77,032				30,076

Total operating expenses			52,550				49,393				168,806				152,558

Loss from operations			(39,401	)			(49,154	)			(146,009	)			(122,428	)
Other income (expense):
Interest income			1,137				1,098				4,320				2,260
Interest expense			(3,093	)			—				(9,180	)			—
Other income (expense)			10				(13	)			(36	)			(20	)

Total other (expense) income, net			(1,946	)			1,085				(4,896	)			2,240

Loss before income taxes			(41,347	)			(48,069	)			(150,905	)			(120,188	)
Income tax provision			(20	)			(14	)			(38	)			(9	)
										��
Net loss		$	(41,367	)		$	(48,083	)		$	(150,943	)		$	(120,197	)

Net loss per share—basic and diluted		$	(0.67	)		$	(0.79	)		$	(2.46	)		$	(2.17	)

Weighted-average number of common shares outstanding used in net loss per share—basic and diluted			62,092,841				60,586,511				61,297,249				55,465,261

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Karyopharm Therapeutics Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)

(in thousands)

   Three Months Ended
September 30, Nine Months Ended
September 30,
   2018 2017 2018 2017
Net loss
   $ (48,083 ) $ (30,640 ) $ (120,197 ) $ (89,944 )


Comprehensive income

Unrealized gain on investments
   110 25 105 50
Foreign currency translation adjustments
   (3 ) 50 (41 ) 134


Comprehensive loss
   $ (47,976 ) $ (30,565 ) $ (120,133 ) $ (89,760 )


	Three Months Ended September 30,								Nine Months Ended September 30,
	2019				2018				2019				2018
Net loss		$	(41,367	)		$	(48,083	)		$	(150,943	)		$	(120,197	)

Comprehensive income (loss)
Unrealized (loss) gain on investments			(59	)			110				250				105
Foreign currency translation adjustments			(32	)			(3	)			(36	)			(41	)

Comprehensive loss		$	(41,458	)		$	(47,976	)		$	(150,729	)		$	(120,133	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Karyopharm Therapeutics Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

   Nine Months Ended
September 30,
   2018 2017
Operating activities

Net loss
   $ (120,197 ) $ (89,944 )
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization
   541 539
Net amortization of premiums and discounts on investments
   280 903
Stock-based compensation expense
   13,378 15,906
Changes in operating assets and liabilities:

Prepaid expenses and other current assets
   (3,039 ) 18
Accounts payable
   (3,425 ) (2,867 )
Accrued expenses and other liabilities
   8,139 6,423
Deferred revenue
   (8,027 ) 1,050
Deferred rent
   1,405 (207 )


Net cash used in operating activities
   (110,945 ) (68,179 )
Investing activities

Purchases of property and equipment
   (1,270 ) (7 )
Proceeds from maturities of investments
   94,378 94,033
Purchases of investments
   (97,662 ) (74,017 )


Net cash (used in) provided by investing activities
   (4,554 ) 20,009
Financing activities

Proceeds from the issuance of common stock, net of issuance costs
   145,706 52,323
Proceeds from the exercise of stock options and shares issued under employee stock purchase plan
   2,627 463


Net cash provided by financing activities
   148,333 52,786
Effect of exchange rate on cash, cash equivalents and restricted cash
   (9 ) 181


Net increase in cash, cash equivalents and restricted cash
   32,825 4,797
Cash, cash equivalents and restricted cash at beginning of period
   69,487 50,142


Cash, cash equivalents and restricted cash at end of period
   $ 102,312 $ 54,939


Reconciliation of cash, cash equivalents and restricted cash reported within the condensed
consolidated balance sheets

Cash and cash equivalents
   $ 101,600 $ 54,450
Short-term restricted cash
   —   200
Long-term restricted cash
   712 289


Total cash, cash equivalents and restricted cash
   $ 102,312 $ 54,939


	Nine Months Ended September 30,
	2019				2018
Operating activities
Net loss		$	(150,943	)		$	(120,197	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			730				541
Net amortization of premiums and discounts on investments			(1,242	)			280
Amortization of debt discount and issuance costs			5,298				—
Stock-based compensation expense			11,742				13,378
Changes in operating assets and liabilities:
Accounts r eceivable			(7,928	)			—
Inventory			(100	)			—
Prepaid expenses and other current assets			1,108				(3,039	)
Operating lease right-of-use assets			807				—
Accounts payable			(1,215	)			(3,425	)
Accrued expenses and other liabilities			569				8,139
Operating lease liabilities			(797	)			—
Deferred revenue			(9,362	)			(8,027	)
Deferred rent			—				1,405

Net cash used in operating activities			(151,333	)			(110,945	)
Investing activities
Purchases of property and equipment			(156	)			(1,270	)
Proceeds from maturities of investments			202,454				94,378
Purchases of investments			(90,329	)			(97,662	)

Net cash provided by (used in) investing activities			111,969				(4,554	)
Financing activities
Proceeds from the issuance of common stock, net of issuance costs			14,563				145,706
Proceeds from the exercise of stock options and shares issued under employee stock purchase plan			1,124				2,627
Proceeds from deferred royalty obligation, net			73,682				—

Net cash provided by financing activities			89,369				148,333
Effect of exchange rate on cash, cash equivalents and restricted cash			(26	)			(9	)

Net increase in cash, cash equivalents and restricted cash			49,979				32,825
Cash, cash equivalents and restricted cash at beginning of period			118,737				69,487

Cash, cash equivalents and restricted cash at end of period		$	168,716			$	102,312

Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets
Cash and cash equivalents		$	168,004			$	101,600
Long-term restricted cash			712				712

Total cash, cash equivalents and restricted cash		$	168,716			$	102,312

Supplemental disclosures:
Deferred financing costs in a ccrued expenses at period end		$	93			$	—
Operating lease right-of-use assets obtained in exchange for operating lease liabilities		$	11,711			$	—
Cash paid for amounts included in the measurement of operating lease liabilities		$	2,096			$	—

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Karyopharm Therapeutics Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands, except share amounts)

Common Shares

Shares

Amount

Additional
Paid-In
Capital

Accumulated
Other
Comprehensive
Income
(Loss)

Accumulated
Deficit

Total
Stockholders’
Equity
Balance at June 30, 2019



60,965,505




$
6




$
865,726




$
61





$
(783,324
)




$
82,469


Vesting of restricted stock

5,000

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

100,525

—

577

—

—

577

Issuance of common stock, net of issuance costs of $0.3 million

1,634,451

—

14,563

—

—

14,563

Stock-based compensation expense

—

—

3,719

—

—

3,719

Unrealized loss on investments

—

—

—

(59
)
—

(59
)
Foreign currency translation adjustment

—

—

—

(32
)
—

(32
)
Net loss

—

—

—

—

(41,367
)
(41,367
)

Balance at September 30, 2019

62,705,481
$
6
$
884,585
$
(30
) $
(824,691
) $
59,870

Balance at June 30, 2018

60,501,260
$
6
$
781,176
$
(260
) $
(567,455
) $
213,467

Vesting of restricted stock

—

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

163,597

—

812

—

—

812

Stock-based compensation expense

—

—

4,775

—

—

4,775

Unrealized gain on investments

—

—

—

110

—

110

Foreign currency translation adjustment

—

—

—

(3
)
—

(3
)
Net loss

—

—

—

—

(48,083
)
(48,083
)

Balance at September 30, 2018

60,664,857
$
6
$
786,763
$
(153
) $
(615,538
) $
171,078

Balance at December 31, 2018

60,829,308
$
6

857,156
$
(244
) $
(673,748
) $
183,170

Vesting of restricted stock

10,000

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

231,722

—

1,124

—

—

1,124

Issuance of common stock, net of issuance costs of $0.3 million

1,634,451

—

14,563

—

—

14,563

Stock-based compensation expense

—

—

11,742

—

—

11,742

Unrealized gain on investments

—

—

—

250

—

250

Foreign currency translation adjustment

—

—

—

(36
)
—

(36
)
Net loss

—

—

—

—

(150,943
)
(150,943
)

Balance at September 30, 2019

62,705,481
$
6
$
884,585
$
(30
) $
(824,691
) $
59,870

Balance at December 31, 2017

49,533,150
$
5
$
625,053
$
(217
) $
(495,341
) $
129,500

Vesting of restricted stock

103,800

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

502,483

—

2,627

—

—

2,627

Issuance of common stock, net of issuance costs of $0.2 million

10,525,424

1

145,705

—

—

145,706

Stock-based compensation expense

—

—

13,378

—

—

13,378

Unrealized gain on investments

—

—

—

105

—

105

Foreign currency translation adjustment

—

—

—

(41
)
—

(41
)
Net loss

—

—

—

—

(120,197
)
(120,197
)

Balance at September 30, 2018

60,664,857
$
6
$
786,763
$
(153
) $
(615,538
) $
171,078

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Karyopharm Therapeutics Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in thousands except share and per share data)~~

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Karyopharm Therapeutics Inc., a Delaware corporation, ~~(the “Company”),~~ have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required byRegulation

S-X,

Rule

10-01.

Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In ~~the~~our opinion, ~~of management,~~ all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, ~~the Company~~we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, ~~2018~~2019 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, ~~2018.~~2019. For further information, refer to the financial statements and footnotes included in ~~the Company’s~~our Annual Report onForm

10-K

for the year ended December 31, ~~2017~~2018 as filed with the Securities and Exchange Commission (“SEC”) on ~~March 15, 2018.~~

~~At September 30, 2018,~~February 28, 2019.

In July 2019, the ~~Company had $211,574~~U.S. Food and Drug Administration (“FDA”) approved XPOVIO

(selinexor) in ~~cash, cash equivalents and short- and long-term investments. The Company has had recurring losses and incurred a loss of $120,197~~combination with dexamethasone for the nine months ended September 30, 2018. Net cash used in operations for the nine months ended September 30, 2018 was $110,945. The Company expects that cash, cash equivalents and short- and long-term investments at September 30, 2018, in addition to the approximately $166,900treatment of ~~net proceeds the Company raised in the private placement of the Notes (see Note 12) in October 2018, will be sufficient to fund its current operating plans and capital expenditure requirements for~~adult patients with relapsed or refractory multiple myeloma (“RRMM”) who have received at least ~~twelve months from~~four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Following accelerated approval by the ~~date of issuance of the financial statements contained in thisForm 10-Q~~ ~~while it establishes the commercial infrastructure for a potential launch of selinexor~~FDA, XPOVIO became commercially available in the United ~~States.~~

States in July 2019.

Basis of Consolidation

The condensed consolidated financial statements at September 30, ~~2018~~2019 include the accounts of (i) the Company, (ii) Karyopharm Securities Corp. (a wholly-owned Massachusetts corporation of the Company incorporated in December 2013), (iii) Karyopharm Europe GmbH (a wholly-owned German Limited Liability Company formed in August 2014), (iv) Karyopharm Therapeutics ~~(Bermuda) Ltd. (a~~Inc. and our wholly-owned ~~Bermuda subsidiary of the Company formed in March 2015), and (v) Karyopharm Israel Ltd. (a wholly-owned Israeli subsidiary of the Company formed in June 2018).~~subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The significant accounting policies used in preparation of these condensed consolidated financial statements onForm

10-Q

for the ~~three and~~ nine months ended September 30, ~~2018~~2019 are consistent with those discussed in Note 2 to the financial statements in ~~the Company’s~~our Annual Report onForm

10-K

for the year ended December 31, ~~2017,~~2018, except as it relates to product revenue recognition, accounts receivable, inventory, cost of sales, and deferred royalty obligations, as discussed below, and the adoption of new accounting standards during the ~~first~~ nine months ~~of 2018~~ended September 30, 2019, as discussed ~~below.~~

in Note 2. There were no changes to our accounting policy for license and asset sale agreements, as disclosed in our

evenue
r
ecognition policy in Note 2 to the financial statements in our Annual Report on Form
10-K
for the year ended December 31, 2018, during the nine months ended September 30, 2019.

Product Revenue Recognition

~~The Company~~

We adopted Accounting Standards Update

(“ASU”)

2014-09,

Revenue from Contracts with Customers (~~ASC 606)~~

, as well as subsequent amendments, which were codified in Financial Accounting ~~Standard~~Standards Board

(“FASB”)

Accounting Standards Codification (“ASC”) 606, on January 1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for the three and nine month periods ended September 30, 2018 reflect the application of ASC 606 while the reported results for the three and nine month periods ended September 30, 2017 were prepared under the guidance of ASC 605,~~Revenue Recognition~~ ~~(ASC 605), which is also referred to herein as “legacy GAAP” or the “previous guidance”. The~~ adoption of ASC 606 did not have a material impact on ~~the Company’s~~our consolidated financial position, results of operations, stockholder’s equity or cash flows as of the adoption date, as no transition adjustment for any of ~~the Company’s~~our contracts with customers was required.

ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, ~~an entity recognizes~~we recognize revenue when ~~its~~our customer obtains control of promised goods or services, in an amount that reflects the consideration which ~~the entity expects~~we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that ~~an entity determines~~we determine are within the scope of ASC 606, ~~the entity performs~~we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) ~~the entity satisfies~~we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, ~~the Company assesses~~we assess the goods or services promised within each

contract and ~~determines~~determine those that are performance obligations and assesses whether each promised good or service is distinct. ~~The Company~~We then ~~recognizes~~recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

~~The Company generates revenue from license~~

In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients.

Table of Contents

In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or ~~similar~~less. However, no such costs have been incurred to date. In addition to distribution agreements with ~~pharmaceutical companies~~our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for ~~the development~~government mandated and/or privately negotiated rebates, chargebacks, and ~~commercialization of certain of its product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technologicalknow-how,~~ ~~delivery of drug substances, research and development services, and participation on certain committees~~discounts with ~~the counterparty. Payments made by the customers may includenon-refundable~~ upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.

~~If a license~~respect to the ~~Company’s intellectual property~~purchase of our products.

In the context of ASC 606, each unit of XPOVIO that is ~~determined to be~~ordered by our customers represents a distinct ~~from the other~~ performance ~~obligations identified in the arrangement, the Company recognizes the transaction price allocated to the license as revenue upon transfer of~~obligation that is completed when control of the license. The Company evaluates all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services thatproduct is ~~distinct. Optional future services where any additional consideration paid~~transferred to the ~~Company reflects their standalone selling prices do not provide~~customer. Accordingly, we recognize product revenue when the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations.

The Company utilizes judgment to determine the transaction price. In connection therewith, the Company evaluates contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method. Milestone payments that are not within theobtains control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, forour product, which ~~the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Companyre-evaluates~~ the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative~~catch-up~~ ~~basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.~~

~~The Company then determines whether the performance obligations or combined performance obligations are satisfied over time or~~occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and ~~if over~~remitted to governmental authorities, they will be excluded from revenue.

Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the ~~appropriate~~most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of ~~measuring progress~~possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for ~~purposes~~relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of ~~recognizing~~the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue ~~fromnon-refundable,~~ ~~upfront fees.~~ recognized under the contracts with our customers will not occur in a future period.

The ~~Company evaluates~~following are the ~~measure~~components of ~~progress,~~variable consideration related to product revenue:

Cash discounts and distributor fees:

We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as ~~applicable,~~a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).

Product returns:

Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product’s expiration date and ending twelve months after the product’s expiration date). We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel. Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable.

Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and ~~if necessary, adjusts~~other qualitative considerations.

Chargebacks:

Chargebacks for fees and discounts represent the ~~measure~~estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us. Our customers charge us for the discount provided to the healthcare entities. Chargebacks are generally determined at the time of ~~performance and~~resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue ~~recognition.~~

~~When consideration~~ is ~~received, or such consideration is unconditionally due, from~~recognized, resulting in a ~~customer prior to transferring goods or services~~reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.

Table of Contents

Government rebates

: We are subject to discount obligations under state Medicaid programs, Medicare, the ~~terms~~Department of Veterans Affairs (“VA”), the Department of Defense (“DOD”), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a ~~contract,~~current liability, which is included as a ~~contract~~component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability ~~is recorded within deferred revenue. Contract liabilities within deferred revenue are~~under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, ~~after control~~but which remains in distribution channel inventories at the end of the ~~goods or services~~reporting period.

Other incentives:

Other incentives offered by us include

co-payment

assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug

co-payments

by the patient. We calculate the accrual for co-payment assistance based on estimates of claims and the average

co-payment

assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is ~~transferred~~recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.

Product revenue reserves and allowances:

As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recoded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of September 30, 2019 and, therefore, the transaction price was not reduced further during the three months ended September 30, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known.

Accounts Receivable

In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor customers. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of September 30, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.

Inventory

Prior to regulatory approval, we expensed costs relating to the ~~customer~~production of inventory as research and ~~all revenue recognition criteria have been met.~~

~~For arrangements that include sales-based royalties, including sales-based milestone payments,~~development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and ~~a license of intellectual property~~the future economic benefit is ~~deemed~~expected to be ~~the predominant item to which the royalties relate, the Company recognizes revenue~~realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the ~~later~~lower of ~~when~~cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a

first-in,

first-out

basis.

Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products.

Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.

Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales ~~occur~~requirements as cost of sales. The determination of whether inventory costs will be realizable is based on our estimates. If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales.

Table of Contents

Cost of Sales

Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or ~~when~~obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances.

Deferred Royalty Obligation

We treat the ~~performance~~liability related to net revenues, as discussed further in Note 12, as a deferred royalty obligation, ~~to which some or all~~amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense

thereon

using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty ~~has been allocated has been satisfied (or partially satisfied).~~

obligation, and record interest expense using

the

imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized.

Liquidity

At September 30, 2019, we had $269.6 million in cash, cash equivalents and investments. We have had recurring losses and incurred a loss of $150.9 million for the nine months ended September 30, 2019. Net cash used in operations for the nine months ended September 30, 2019 was $151.3 million. We expect that our cash, cash equivalents and investments at September 30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to fund current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements, during which time we plan to continue to commercialize XPOVIO in the United States, which commenced in July 2019.

2. Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In February 2016, the FASB issued ASU No.

2016-02,

Leases (Topic 842)

(“ASU

2016-02”).

ASU

2016-02

supersedes the lease guidance under FASB ASC Topic 840,

Leases

, resulting in the creation of FASB ASC Topic 842,

Leases

(“ASC 842”). The new standard requires that all lessees (i) recognize, on the balance sheet, liabilities to remit lease payments and

right-of-use

assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii) disclose qualitative and quantitative information about its leasing arrangements.

In July 2018, the FASB issued ASU No.

2018-10,

Codification Improvements to Topic 842, Leases

(“ASU

2018-10”)

and ASU No.

2018-11,

Leases (Topic 842) Targeted

Improvements

(“ASU

2018-11”).

The amendments in ASU

2018-10

and ASU

2018-11

provide additional clarification and implementation guidance on certain aspects of ASU

2016-02

and have the same effective and transition requirements as ASU

2016-02,

as detailed ~~above,~~below. ASU

2018-11

provides entities the ~~Company~~option to not provide comparative period financial statements and instead apply the transition requirements as of the effective date of ASU

2016-02.

ASU

2016-02,

ASU

2018-10,

and ASU

2018-11

are effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. We adopted ~~ASC 606 on~~the standard effective January 1, ~~2018. Under~~2019 using the ~~modified retrospective~~optional transition method the Company applied ASC 606 to all contracts within scope as of January 1, 2018. Under the practical expedient concerning contract modifications contained in the transitional provisions of ASC 606, the Companyunder ASU

2018-11

and, therefore, prior period financial information has not been retrospectively ~~restated its contracts for modifications~~adjusted.

Pursuant to the guidance under ASU

2016-02,

we elected the optional package of practical expedients to leases that commenced prior to the ~~earliest period presented,~~effective date, which allowed us to not reassess: (i) whether expired or existing contracts contain leases; (ii) lease classification for any expired or existing leases; and ~~instead has reflected~~(iii) initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of which we elected, including: (i) a policy to not record

right-of-use

assets and leases on the ~~aggregate effect~~balance sheet for short-term leases that qualify and (ii) a policy to not separate lease and

non-lease

components for certain classes of ~~all modifications when identifying~~underlying assets on contracts entered into or modified after the ~~satisfied and unsatisfied performance obligations, determining~~effective date. We did not elect the ~~transaction price and allocating~~use of hindsight in estimating the transaction price. Qualitatively, the effect of applying this practical expedient is not material to the periods presented in the consolidated financial statements. As more fully discussed in Note 3, Asset Purchase and License Agreements, only the Company’s arrangement with Ono Pharmaceutical Co., Ltd. was determined to have unsatisfied performance obligations as of the adoption date. However, the pattern of revenue recognition was not affected and, therefore, no transition adjustment was recorded to the opening balance of accumulated deficit on January 1, 2018. All other agreementslease term for leases subject to transition ~~which only included~~to the ~~Company’s arrangement with Anivive Lifesciences Inc., were unaffected by the adoption~~new standard.

Table of ~~ASC 606 in all periods presented~~Contents

As summarized in the table below, the standard had a material impact on our condensed consolidated ~~financial statements~~balance sheet as of September 30, 2019, specifically through ~~application~~recognition of

right-of-use

assets of $11.7 million and lease liabilities of $16.0 million for our existing operating lease for office space in Newton, MA on the ~~modified retrospective transition method.~~

~~In August 2016,~~effective date. The difference between the ~~Financial Accounting Standards Boards (“FASB”) issuedASU 2016-15,~~ ~~Classification~~operating lease

right-of-use

assets and operating lease liabilities is due to the change in classification of ~~Certain Cash Receipts~~deferred rent and ~~Cash Payments~~~~(“ASU 2016-15”).~~ ~~This~~lease incentives through December 31, 2018 from liabilities to a reduction in our operating lease

right-of-use

assets. However, the standard ~~addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adoptedASU 2016-05~~ ~~effective January 1, 2018 and the adoption~~ did not have a material impact on ~~the Company’s statements of cash flows.~~

~~In October 2016, the FASB issuedASU No. 2016-16,~~~~Accounting for Income Taxes: Intra-Entity Asset Transfers of Assets Other than Inventory (Topic 740)~~. Topic 740 eliminates the ability to defer the tax expense related to intra-entity asset transfers other than inventory. Under this standard, entities recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The Company adopted Topic 740 effective January 1, 2018 and the adoption did not have a material impact on the Company’s financial position or results of operations.

~~In November 2016, the FASB issuedASU No. 2016-18,~~ ~~Statement of Cash Flows (Topic 230): Restricted Cash~~~~. This standard requires that a~~our condensed consolidated statement of ~~cash flows explain the change during the period in the total of cash, cash equivalents~~operations and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the~~beginning-of-period~~ ~~andend-of-period~~ total amounts shown on the statement of cash flows. The Company adopted this standard effective January 1, 2018 and reclassified restricted cash in the statements of cash flows to be included in the cash and cash equivalents balance. The standard resulted in the reclassification of $490 and $479 into cash, cash equivalents and restricted cash within the beginning of period balance on the condensed consolidated statements of cash flowscomprehensive loss for the ~~nine-month periods ended September 30, 2018~~three and 2017, respectively. This adoption also resulted in an immaterial adjustment to the effect of exchange rate on cash, cash equivalents and restricted cash during the nine-month period ended September 30, 2017.

~~In May 2017, the FASB issuedASU 2017-09,~~~~Compensation-Stock Compensation (Topic 718)~~~~(“ASU 2017-09”)~~~~Scope of Modification Accounting~~.~~ASU 2017-09~~ provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered~~non-substantive.~~ ~~The Company adopted this standard effective January 1, 2018 and the adoption did not have a material impact on the Company’s consolidated financial statements.~~

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted and led to significant changes to U.S. tax law. Also on December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), allowing companies to record the effects of the TCJA on a provisional basis during a measurement period not to extend beyond one year of the enactment date. SAB 118 was codified into ASC 740 by~~ASU 2018-05.~~ The Company recorded a reduction to its deferred tax asset for $42,763 and a corresponding reduction to its valuation allowance related to implementing applicable provisions of the TCJA during the year ended December 31, 2017. During the nine months ended September 30, ~~2018, there was no further information or change in estimates related to the provisional amount recognized during the year ended December 31, 2017.~~

~~Recently Issued Accounting Standards~~

~~On August 17, 2018, the SEC issued an amendment toRule 3-04~~ of~~Regulation S-X,~~ ~~which extended the annual disclosure requirement of reporting changes in stockholders’ equity to interim periods. Such disclosures are~~2019, as expense for our existing operating leases continues to be ~~provided in a note to~~recognized consistent with the ~~financial statements or in a separate financial statement and requires both theyear-to-date~~ ~~information and subtotals for each interim period. On September 25, 2018, the SEC issued guidance under a Compliance and Disclosure Interpretation (C&DI 105.09) to clarify the effective date~~recognition pattern before adoption of the ~~requirement. Under~~new standard. Please refer to Note 10, “Leases” for further information.


	January 1, 2019 Prior to ASC 842 Adoption			ASC 842 Adjustment				January 1, 2019 as Adjusted
Consolidated balance sheet data (in thousands):
Operating lease and right-of-use assets (1)		$	—		$	11,711			$	11,711
Deferred rent (2)		$	390		$	(390	)		$	—
Deferred rent non-current (2)		$	3,922		$	(3,922	)		$	—
Operating lease liabilities (3)		$	—		$	1,175			$	1,175
Non-current operating lease liabilities (3)		$	—		$	14,848			$	14,848

(1)	Represents capitalization of operating lease right-of-use assets, offset by reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.

(2)	Represents reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.

(3)	Represents recognition of operating lease liabilities.

We implemented internal controls to enable the ~~guidance in C&DI 105.09, the Company plans to implement this updated disclosure requirement beginning with the first quarter 2019Form 10-Q.~~

preparation of financial information upon adoption.

In June 2018, the FASB issuedASU No.

2018-07,

Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

(“ASU

2018-07”)~~.ASU~~.

ASU

2018-07

largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance ~~will be effective for the Company~~was adopted on January 1, ~~2019. The Company is currently evaluating the potential~~2019 and it did not have a material impact ~~that this guidance may have~~ on ~~its~~our condensed consolidated financial statements.

~~In February 2016, the FASB issuedASU No. 2016-02,~~ ~~Leases (Topic 842)~~. The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for the Company on January 1, 2019. In July 2018, the FASB issued~~ASU 2018-11,~~~~Leases (Topic 842) Targeted~~~~Improvements~~, that gives entities the option to not provide comparative period financial statements and instead apply the transition requirements as of the effective date of the new standard. The Company plans to adopt the new standard using this optional method.

~~Pursuant to the guidance underASU No. 2016-02,~~ the Company also plans to elect the optional package of practical expedients, which will allow the Company to not reassess: (i) whether expired or existing contracts contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The new standard also allows entities to make certain

~~policy elections, some of which the Company also plans to elect, including: (i) a policy to not record short-term leases on the balance sheet and (ii) a policy to not separate lease andnon-lease~~ components. The Company is currently working through lease contract scoping, design and implementation of transition related controls, and finalization of accounting elections. The Company is still assessing the impact this standard will have on its consolidated financial statements and disclosures; however, it anticipates that the new standard will result in the Company recording additional right of use assets and corresponding liabilities on its consolidated balance sheet.

In July 2018, the FASB issued ASUNo.

2018-09,

Codification ~~Improvements.~~ Improvements

(“ASU

2018-09”).

This amendment makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standards Codification. The ~~majority of the~~ amendments ~~in ASUNo. 2018-09~~ ~~will be~~are effective for ~~the Company in~~ annual periods beginning after December 15, ~~2018.~~2018 and were adopted effective January 1, 2019. The ~~Company~~adoption of these amendments did not have a material impact on our condensed consolidated financial statements.

In November 2018, the FASB issued ASU No.

2018-18,

Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606

(“ASU

2018-18”).

The amendments in ASU

2018-18

clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU

2018-18

are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The amendments in ASU

2018-18

should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January 1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note 5, “License and Asset Purchase Agreements,” were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.

On August 17, 2018, the SEC issued an amendment to Rule

3-04

of Regulation

S-X,

which extended the annual disclosure requirement of reporting changes in stockholders’ equity to interim periods. Such disclosures are to be provided in a note to the financial statements or in a separate financial statement and requires both the

year-to-date

information and subtotals for each interim period. On September 25, 2018, the SEC issued guidance under a Compliance and Disclosure Interpretation (“C&DI 105.09”) to clarify the effective date of the requirement. Under the guidance in C&DI 105.09, we implemented this updated disclosure requirement beginning with the Form

10-Q

for the quarterly period ended March 31, 2019, specifically through inclusion of the comparative condensed consolidated statements of stockholders’ equity.

Table of Contents

Recently Issued Accounting Standards

In June 2016, the FASB issued ASU No.

2016-13,

Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

(“ASU

2016-13”).

ASU

2016-13

requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For

available-for-sale

debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU

2016-13

are effective for interim and annual fiscal periods beginning after December 15, 2019. We are currently evaluating the effects the adoption of ASU~~No. 2018-09~~

2016-13

will have on ~~its~~our consolidated financial statements ~~results of operations~~ and ~~cash flows.~~

related disclosures.

In August 2018, the FASB issued ASUNo.

2018-13,

Fair Value Measurement—Disclosure Framework-Changes to the Disclosure Requirement for Fair Value ~~Measurement.~~ Measurement

(“ASU

2018-13”).

The amendments in ASU~~No.~~

2018-13

modify the disclosure requirements on fair value measurements in ASC 820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The ~~amendment~~amendments under ASU~~No.~~

2018-13

are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. ~~The Company is~~We are currently evaluating the effects the adoption of ASU~~No.~~

2018-13

will have on ~~its~~our consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASUNo.

2018-15,

Intangible-Goodwill and OtherInternal-Use Software (Subtopic350-40)~~.ASUNo.~~

(“ASU

2018-15”).

ASU

2018-15

updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU~~No.~~

2018-15

are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. ~~The Company does~~We do not expect the adoption of ASU ~~No. 2018 15~~

2018-15

to have a material impact on ~~its results~~our consolidated financial statements.

3. Product Revenue

To date, our only source of ~~operations, financial position, or~~product revenue has been from the U.S. sales of XPOVIO, which we began shipping to our customers in July 2019. For the three months ended September 30, 2019, we recorded a total of $

2.1

million as a reduction of revenue consisting primarily of distribution fees and cash ~~flows.~~

3.discounts, as well as reserves for chargebacks, rebates and returns.

4. Inventory

The following table presents our inventory of XPOVIO at September 30, 2019 and December 31, 2018 (in thousands):


	September 30, 2019			December 31, 2018
Raw materials and work in process		$	—		$	—
Finished goods			100			—

Total inventory		$	100		$	—

At September 30, 2019, all of our inventory was related to XPOVIO, which was approved by the FDA in July 2019, at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expense in the period incurred. At September 30, 2019, we have determined a reserve related to XPOVIO inventory is not required.

Table of Contents

5. License and Asset Purchase Agreements

Antengene License Agreement

Effective May 23, 2018 (the “Antengene Effective Date”), ~~the Company~~we entered into a License Agreement (“Antengene License Agreement”) with Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (“Antengene”) and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People’s Republic of China, pursuant to which ~~the Company~~we granted Antengene exclusive rights to develop and commercialize, at its own cost,

(i) selinexor, ~~the Company’s~~our lead, novel, oral Selective Inhibitor of Nuclear Export (“SINE”) compound, (ii) eltanexor, ~~the Company’s~~our second-generation oral SINE compound, and(iii)

KPT-9274, ~~the Company’s~~

our

first-in-class

orally bioavailable small molecule that is a

non-competitive

dual modulator of PAK4 and NAMPT, each for the diagnosis, treatment and/or prevention of all human oncology indications (the “Oncology Field”), as well as (iv) verdinexor, ~~the Company’s~~our lead compound in development for the treatment of viral indications for the diagnosis, treatment and/or prevention of certain human

non-oncology

indications (the

“Non-Oncology

Field”) (the “Antengene Licensed Compounds”). ~~The Company~~We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the Oncology Field in mainland China and Macau and licensed the development and commercial rights to Antengene for

KPT-9274

in the Oncology Field and verdinexor in the

Non-Oncology

Field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam (the “Antengene Territory”).

Pursuant to the terms of the Antengene License Agreement, ~~the Company~~we received an upfront payment of ~~$11,703,~~$11.7 million, and could receive up to ~~$105,000~~$105.0 million in milestone payments if certain development goals are achieved and up to ~~$45,000~~$45.0 million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty based on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, upon Antengene’s election and the parties’ full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the “Antengene Manufacturing Election”), ~~the Company~~we will grant to Antengene

non-exclusive

rights to manufacture the Antengene Licensed Compounds and products containing such compounds in or outside of the Antengene Territory solely for development and commercialization in the fields in the Antengene Territory.

As part of the Antengene License Agreement, Antengene will also have the right to participate in global clinical studies of the Antengene Licensed Compounds and will bear the cost and expense for patients enrolled in clinical studies in the Antengene Territory. Antengene is responsible for seeking regulatory and marketing approvals for the Antengene Licensed Compounds in the Antengene Territory, as well as any development of the products specifically necessary to obtain such approvals. Antengene is also responsible for the commercialization of the Antengene Licensed Compounds in the Oncology Field and

Non-Oncology

Field, as applicable, in the Antengene Territory at its own cost and expense.

Until such time as Antengene elects to manufacture its own drug substance, ~~the Company~~we will furnish clinical supplies of drug substance to Antengene for use in Antengene’s development efforts pursuant to a clinical supply agreement to be entered into by ~~the Company~~us and Antengene, and Antengene may elect to have ~~the Company~~us provide commercial supplies of drug product to Antengene pursuant to a commercial supply agreement to be entered into by ~~the Company~~us and Antengene, in each case the costs of which will be borne by Antengene.

The Antengene License Agreement will continue in effect on a

product-by-product,

country-by-country

basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Antengene License Agreement may be terminated earlier by (i) either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Antengene on aproduct-by-product basis for certain safety reasons or on aproduct-by-product,country-by-country basis for any reason with 180 days’ prior notice or (iii) ~~the Company~~us in the event Antengene challenges or assists with a challenge to certain of ~~the Company’s~~our patent rights.

~~The Company~~

We assessed the Antengene arrangement in accordance with ASC 606 and concluded that the contract counterparty, Antengene, is a customer. ~~The Company~~We identified the following material promises under the contract: (i) exclusive licenses for each Antengene Licensed Compound, (ii) initial data transfers for each Antengene Licensed Compound, which consisted of regulatory data compiled by ~~the Company~~us for the Antengene Licensed Compounds as of the Antengene Effective Date, and (iii) obligations to stand-ready to provide an initial clinical supply for each Antengene Licensed Compound. ~~The Company~~We also identified immaterial promises under the contract relating to information exchanges and participation on operating committees and other working groups. Separately, ~~the Company~~we also identified certain customer options that would create an obligation for ~~the Company~~us if exercised by Antengene, including (i) additional data transfers for each Antengene Licensed Compound, which would consist of the transfer of additional regulatory data compiled by ~~the Company~~us for each Antengene Licensed Compound after the Antengene Effective Date, (ii) obligations to provide additional clinical supply and related substance supply for each Antengene Licensed Compound upon request by Antengene, (iii) manufacturing technology transfers and licenses for each Antengene Licensed Compound under the Antengene Manufacturing Election, as detailed above, and (iv) options for a backup compound, which represents Antengene’s option to select a replacement compound in the event it elects to discontinue the development of the Antengene Licensed Compounds (the “Antengene Transfer Options”). The Antengene Transfer Options

Table of Contents

individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Antengene License Agreement. Finally, ~~the Company~~we also identified certain other customer options that would create a manufacturing obligation for ~~the Company~~us if exercised by Antengene, including for commercial supply. These options do not represent a material right, as they are not offered at a significant and incremental discount.

In further evaluating the promises detailed above, ~~the Company~~we determined that the exclusive licenses, initial data transfers, and stand-ready obligation to provide initial clinical supply for each Antengene Licensed Compound were not distinct from one another, and must be combined as four separate performance obligations (the “Antengene Combined License Obligation for selinexor”, “Antengene Combined License Obligation for eltanexor”, “Antengene Combined License Obligation for

KPT-9274”

and “Antengene Combined License Obligation for verdinexor”). This is because, for each Antengene Licensed Compound, Antengene requires the initial data transfer and initial clinical supply to derive benefit from the exclusive licenses, since ~~the Company~~we did not grant manufacturing licenses to any of the Antengene Licensed Compounds at contract inception. ~~The Company~~We also determined that each of the Antengene Transfer Options represents a distinct performance obligation. Based on these determinations, ~~the Company~~we identified eight performance obligations at the inception of the Antengene License Agreement, including (i) the Antengene Combined License Obligation for selinexor, (ii) the Antengene Combined License Obligation for eltanexor, (iii) the Antengene Combined License Obligation for

KPT-9274,

(iv) the Antengene Combined License Obligation for verdinexor, and the four components of the Antengene Transfer Options, including (v) the material right for additional data transfer, (vi) the material right for additional clinical supply and related substance supply, (vii) the material right for manufacturing technology transfer and license, and (viii) the material right for the option for a backup compound.

~~The Company~~

We further determined that the

up-front

payment of ~~$11,703~~$11.7 million constituted the entirety of the consideration ~~to be~~ included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. ~~The Company~~We determined that substantially all of the total standalone selling price in the arrangement is derived from the four Antengene Combined License Obligations for selinexor, eltanexor,

KPT-9274

and verdinexor. In connection therewith, ~~the Company~~we also estimated the standalone selling price for each of the material rights within the Antengene Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, ~~the Company~~we allocated the ~~$11,703~~$11.7 million transaction price amongst the Antengene Combined License Obligations as follows: ~~$9,363~~$9.4 million for selinexor, ~~$1,053~~$1.0 million for eltanexor, ~~$1,053~~$1.1 million for

KPT-9274,

and ~~$234~~$0.2 million for verdinexor. ~~The Company believes~~We believe that a change in the assumptions used to determine ~~its~~our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

Upon execution of the Antengene License Agreement, the only fixed component of the transaction price included the ~~$11,703~~$11.7 million

up-front

payment owed to ~~the Company.~~us. As referenced above, ~~the Company is~~we are eligible to receive additional payments of up to ~~$105,000~~$105.0 million in milestone payments if certain development goals are achieved and up to ~~$45,000~~$45.0 million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, ~~the Company~~we would receive cost reimbursement in connection with Antengene’s election to receive additional clinical supply for the Antengene Licensed Compounds in the future. The future regulatory milestones and cost reimbursement for providing additional clinical supply of the Antengene Licensed Compounds, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price at contract inception and/or through September 30, ~~2018,~~2019, because the amounts were fully constrained as of September 30, ~~2018.~~2019. As part of ~~its~~our evaluation of the constraint, ~~the Company~~we considered numerous factors, including that receipt of such amounts is outside ~~the control~~ of ~~the Company.~~our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Antengene, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property licenses granted to Antengene and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as ~~the Company’s~~our accounting policy. ~~The Company~~We will

re-evaluate

the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.

Through the nine months ended September 30, ~~2018, the Company has~~2019, we recognized no$9.4 million in revenue under the Antengene License ~~Agreement. Revenue will be recognized for (i)~~Agreement, as the Antengene Combined License Obligation for selinexor ~~once~~was satisfied when the initial clinical supply of selinexor iswas delivered ~~which is currently expected to occur before December 31, 2018.~~during the second quarter of 2019. Revenue will be recognized for ~~(ii)~~ the Antengene Combined License Obligation for eltanexor, ~~(iii)~~ the Antengene Combined License Obligation for

KPT-9274,

and ~~(iv)~~ the Antengene Combined License Obligation for verdinexor once ~~the Company’s completes both initial data transfer and the~~our promise ~~to stand-ready~~ to provide initial clinical supply of each of the Antengene Licensed ~~Compound~~Compounds in the future is fulfilled. ~~The Company~~We currently ~~expects such promises will~~expect the initial clinical supply of

KPT-9274

to be ~~fulfilled more than 12~~delivered within the next twelve months, ~~from~~and the ~~balance sheet date~~initial clinical supplies of ~~September 30, 2018.~~eltanexor and verdinexor are expected to be delivered in the fourth quarter of 2020. Accordingly, and as of September 30, ~~2018,~~2019, the ~~entire $11,703~~remaining $2.3 million of the upfront payment represents a contract liability, (i) ~~$9,363~~$1.1 million of which was included in deferred revenue and is classified as a current liability ~~in the condensed consolidated balance sheet~~ and (ii) ~~$2,340~~$1.2 million of which was included in deferred revenue and is classified as a

non-current ~~liability in the condensed consolidated balance sheet.~~

liability.

Table of Contents

Biogen Asset Purchase Agreement

On January 24, 2018, ~~the Company~~we entered into an Asset Purchase Agreement (the “APA”) and Letter Agreement with Biogen MA Inc., a Massachusetts corporation and subsidiary of Biogen, Inc. (“Biogen”).

Under the terms of the APA and Letter Agreement, ~~the Company~~we sold to Biogen exclusive worldwide rights to develop and commercialize ~~the Company’s~~our oral SINE compound

KPT-350

and certain related assets with an initial focus in amyotrophic lateral sclerosis ~~(��~~(“ALS”) (the “Transfer of IP”), and also granted Biogen: (i) an exclusive worldwide license under certain of ~~the Company’s~~our intellectual property to ~~manufacture~~

anufacture or have manufactured

KPT-350 ~~(the~~

(the “Manufacturing License”), (ii) a technology transfer package, consisting of information and ~~the Company’s~~our

know-how

regarding the manufacture of

KPT-350 ~~(the~~

(the “Manufacturing Technology Transfer”), (iii) a right, at Biogen’s request, to have ~~the Company~~us provide transition assistance regarding manufacturing and other matters (the “Transition Assistance”), (iv) existing inventory of

KPT-350 ~~(the~~

(the “Inventory”), (v) an initial supply of

KPT-350 ~~(the~~

(the “Initial Supply”), and (vi) a right, at Biogen’s request, to have ~~the Company~~us manufacture and supply the active pharmaceutical ingredient for an additional supply of

KPT-350 ~~(the~~

(the “Additional Supply”). In consideration for these rights, ~~the Company~~we received an upfront payment of ~~$10,000,~~$10.0 million, and iswe are eligible to receive additional payments of up to ~~$142,000~~$142.0 million based on the achievement by Biogen of future specified development milestones, and up to ~~$65,000~~$65.0 million based on the achievement by Biogen of future specified commercial milestones. ~~The Company~~We will also be eligible to receive tiered royalty payments that reach low double-digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a

country-by-country

basis.

~~The Company~~

We and Biogen have made customary representations and warranties and agreed to customary covenants in the APA, including covenants requiring Biogen to use commercially reasonable efforts to develop

KPT-350

in specified neurological indications, including ALS, in any of the United States, United Kingdom, France, Spain, Germany or Italy. The APA will continue in effect until the expiration of all royalty obligations, provided that the APA may be terminated earlier by Biogen, subject to the requirements that Biogen (i) negotiate in good faith with ~~the Company~~us regarding an assignment or license back to ~~the Company of~~us the purchased assets and (ii) not transfer or license the purchased assets to a third party unless such third party assumes Biogen’s obligations to ~~the Company~~us under the APA.

~~The Company~~

We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Biogen, is a customer. ~~The Company~~We identified the following material promises in the arrangement: the Transfer of IP and the Manufacturing License. ~~The Company~~We also identified immaterial promises under the contract that were not deemed performance obligations. ~~The Company~~We further determined that other promises for Additional Supply and Transition Assistance represented customer options, which would create an obligation for ~~the Company~~us if exercised by Biogen. Since no additional or material consideration is owed to ~~the Company~~us by Biogen upon exercise of the customer options for Additional Supply and Transition Assistance, ~~the Company~~we determined

that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement. ~~The Company~~We then determined that the Transfer of IP and the Manufacturing License were not distinct from one another and must be combined as a performance obligation (the “Combined Performance Obligation”). This is because Biogen requires the Manufacturing License to derive benefit from the Transfer of IP. Based on these determinations, as well as the considerations noted above with respect to the material rights for Additional Supply and Transition Assistance, ~~the Company~~we identified three distinct performance obligations at the inception of the contract: (i) the Combined Performance Obligation, (ii) the material right for Additional Supply, and (iii) the material right for Transition Assistance.

~~The Company~~ We further determined that the

up-front

payment of ~~$10,000~~$10.0 million constituted the entirety of the consideration ~~to be~~ included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, ~~the Company~~we estimated the stand-alone selling price of the (i) Combined Performance Obligation, (ii) material right for Additional Supply, and (iii) material right for Transition Assistance, and determined that the stand-alone selling price of the material rights for Additional Supply and Transition Assistance were insignificant based on various quantitative and qualitative considerations. Accordingly, ~~the Company~~we further determined that the allocation of the transaction price to the material rights for Additional Supply and Transition Assistance was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, ~~the Company~~we determined that substantially all of the ~~$10,000~~$10.0 million transaction price should be allocated to the Combined Performance Obligation. ~~The Company believes~~We believe that a change in the assumptions used to determine ~~its~~our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

Upon execution of the APA, the transaction price included only the ~~$10,000~~$10.0 million

up-front

payment owed to ~~the Company. The Company~~us. We may receive further payments upon the achievement of certain regulatory and sales milestones, as detailed above, as well as tiered royalty payments that reach low double-digits based on future net sales. The future regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts ~~are~~were fully constrained as of September 30, ~~2018.~~2019. As part of ~~its~~our evaluation of the constraint, ~~the Company~~we considered numerous factors, including that receipt of such milestones is outside ~~the control of the Company.~~our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Biogen, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as ~~the Company’s~~our accounting policy. ~~The Company~~We will

re-evaluate

the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.

~~During the nine months ended September 30, 2018, the Company~~

Table of Contents

We recognized ~~$10,000~~$10.0 million of revenue asduring the first quarter of 2018, which was when it had satisfied its promises under the Combined Performance Obligation by transferring the underlying promised ~~goods during the first quarter of 2018.~~

goods.

Ono License Agreement

Effective October 11, 2017 (the “Ono Effective Date”), ~~the Company~~we entered into a license agreement (the “Ono License Agreement”) with Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (“Ono”), pursuant to which ~~the Company~~we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor, for the diagnosis, treatment and/or prevention of all human oncology indications (the “Ono Field”) in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong, as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (the “Ono Territory”) (the “Ono Exclusive License”). Pursuant to the terms of the Ono License Agreement, ~~the Company~~we received an upfront payment of ¥2.5 billion (US$~~21,916~~21.9 million on the date received), and could receive up to ¥10.15 billion (approximately US$~~90,500~~90.5 million at the exchange rate as of the Ono Effective Date) in milestone payments if certain development goals are achieved and up to ¥9.0 billion (approximately US$~~80,200~~80.2 million at the exchange rate as of the Ono Effective Date) in milestone payments if certain sales milestones are achieved, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, upon Ono’s election and the parties’ full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the “Ono Manufacturing Election”), ~~the Company~~we will grant to Ono

non-exclusive

rights to manufacture selinexor, eltanexor and products containing such compounds in or outside of the Ono Territory solely for development and commercialization in the Ono Field in the Ono Territory.

As part of the Ono License Agreement, Ono will also have the right to participate in global clinical studies of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory. Ono is responsible for seeking regulatory and marketing approvals for selinexor and eltanexor in the Ono Territory, as well as any development of the products specifically necessary to obtain such approvals. Ono is also responsible for the commercialization of products containing selinexor or eltanexor in the Ono Field in the Ono Territory at its own cost and expense.

Subject to the Ono Manufacturing Election, ~~the Company~~we will furnish clinical supplies of drug substance to Ono for use in Ono’s development efforts pursuant to a clinical supply agreement to be entered into by ~~the Company~~us and Ono, and Ono may elect to have ~~the Company~~us provide commercial supplies of drug product to Ono pursuant to a commercial supply agreement to be entered into by ~~the Company~~us and Ono, in each case the costs of which will be borne by Ono.

The Ono License Agreement will continue in effect on a

product-by-product,

country-by-country

basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Ono License Agreement may be terminated earlier by (i) either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Ono on aproduct-by-product basis for certain safety reasons or on aproduct-by-product,country-by-country basis for any reason with 180 days’ prior notice or (iii) ~~the Company~~us in the event Ono challenges or assists with a challenge to certain of ~~the Company’s~~our patent rights.

~~The Company~~

e assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Ono, is a customer. ~~The Company~~We identified the following material promises under the contract: (i) the Ono Exclusive License for selinexor and eltanexor, (ii) initial data transfer for selinexor and eltanexor, which consisted of regulatory data compiled by ~~the Company~~us for the licensed compounds and products as of the Ono Effective Date, (iii) initial clinical supply for selinexor, which consisted of units of clinical supply for Ono to conduct its Phase I Trial, and (iv) an obligation to stand-ready to provide initial clinical supply for eltanexor. ~~The Company~~We also identified immaterial promises under the contract relating to information exchanges, and participation on operating committees and other working groups. Separately, ~~the Company~~we also identified certain customer options that would create an obligation for ~~the Company~~us if exercised by Ono, including the (i) additional data transfer for selinexor and eltanexor, which would consist of the transfer of additional regulatory data compiled by ~~the Company~~us for the licensed compounds and products after the Ono Effective Date, (ii) additional clinical supply and related substance supply for selinexor and eltanexor, which would consist of supplying Ono with units and substance of selinexor and eltanexor incremental to the initial clinical supply for selinexor and the obligation to stand-ready to provide initial clinical supply for eltanexor, as noted above, (iii) manufacturing technology transfer and license for selinexor and eltanexor under the Ono Manufacturing Election, as detailed above, and (iv) options for a backup compound, which represents Ono’s option to select a replacement compound in the event it elects to discontinue the development of either of the licensed compounds (the “Ono Transfer Options”). The Ono Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Ono License Agreement. ~~The Company~~We also identified certain other customer options that would create a manufacturing obligation for ~~the Company~~us if exercised by Ono, including commercial supply. This option is referred to herein as the “Ono Manufacturing Option.” The Ono Manufacturing Option does not represent a material right, as it is not offered at a significant and incremental discount.

Table of Contents

In further evaluating the promises detailed above, ~~the Company~~we determined that the (i) Ono Exclusive License, initial data transfer, and initial clinical supply for selinexor and (ii) Ono Exclusive License, initial data transfer, and obligation to stand-ready to provide initial clinical supply of eltanexor were not distinct from one another, and must be combined as two separate performance obligations (the ~~“Ono~~

“Ono Combined License Obligation for selinexor” and the “Ono Combined License Obligation for eltanexor”). This is because, for both selinexor and eltanexor, Ono requires the initial data transfer and clinical supply to derive benefit from the Ono Exclusive License since ~~the Company~~we did not grant manufacturing licenses for selinexor and eltanexor at contract inception. ~~The Company~~We also determined that each of the Ono Transfer Options represents a distinct performance obligation. Based on these determinations, ~~the Company~~we identified six distinct performance obligations at the inception of the Ono License Agreement, including (i) the Ono Combined License Obligation for selinexor, (ii) the Ono Combined License Obligation for eltanexor, and the four components of the Ono Transfer Options, including (iii) the material right for additional data transfer, (iv) the material right for additional clinical supply and related substance supply, (iv) the material right for manufacturing technology transfer and license, and (vi) the material right for the option for a backup compound.

~~The Company~~

We further determined that the

up-front

payment of ¥2.5 billion (US$~~21,916~~21.9 million on the date received) constituted the entirety of the consideration ~~to be~~ included in the transaction price at contract inception, which was allocated to the performance obligations based on ~~the Company’s~~our best estimate of their relative stand-alone selling prices. ~~The Company~~We determined that substantially all of the total standalone selling price in the arrangement is derived from the Ono Combined License Obligation for selinexor and the Ono Combined License Obligation for eltanexor. In connection therewith, ~~the Company~~we estimated the standalone selling price for each of the material rights within the Ono Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, ~~the Company~~we allocated the ¥2.5 billion (US$~~21,916~~21.9 million on the date received) upfront transaction price between the Ono Combined License Obligations as follows: ~~$19,724~~$19.7 million for selinexor and ~~$2,192~~$2.2 million for eltanexor. ~~The Company believes~~We believe that a change in the assumptions used to determine ~~its~~our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

Upon execution of the Ono License Agreement, the transaction price included only the ¥2.5 billion (US$~~21,916~~21.9 million on the date received)

up-front

payment owed to ~~the Company.~~us. As referenced above, ~~the Company is~~we are eligible to receive additional payments of up to ¥10.15 billion (approximately US$90.5 million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified development milestones and up to ¥9.0 billion (approximately US$80.2 million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified commercial milestones, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, ~~the Company~~we could receive cost reimbursement in connection with ~~its~~our promise to stand-ready to provide initial clinical supply for eltanexor in the future. The future regulatory milestones and cost reimbursement for providing initial clinical supply of eltanexor, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of

September 30, ~~2018.~~2019. As part of ~~its~~our evaluation of the constraint, ~~the Company~~we considered numerous factors, including that receipt of such amounts is outside ~~the control of the Company.~~our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Ono, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Ono and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as ~~the Company’s~~our accounting policy. ~~The Company~~We will

re-evaluate

the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.

As the initial clinical supply of selinexor was delivered in April 2018, the Ono Combined License Obligation for selinexor was determined to be fulfilled and revenue of ~~$19,724~~$19.7 million was recognized during the quarter ended

June

30, 2018. The transaction price allocated to the Ono Combined License Obligation for eltanexor will be recognized as revenue once ~~the Company’s~~our stand-ready promise to provide initial clinical supply of eltanexor in the future is fulfilled, which is the last remaining undelivered promise associated with the Ono Combined License Obligation for eltanexor. As of September 30, ~~2018, $2,192~~2019, $2.2 million of the Ono License Agreement upfront payment is included in deferred revenue and is classified as a

non-current ~~liability in the condensed consolidated balance sheet.~~

Given the determination that the license rights conveyed to Ono lacked standalone value from the initial clinical supply of product required for Ono to obtain benefit from the rights granted and the fact that no initial clinical supply had been provided to Ono as of December 31, 2017, the Company concluded that no revenue should be recognized under ASC 605. Arrangement consideration at the inception of the arrangement included the ¥2.5 billion (US$21,916 on the date received) upfront payment. All other forms of consideration such as milestones and royalties, were considered contingent consideration, with no amount allocable to deliverables at the inception of the arrangement. The Company concluded that the contingent consideration would be recognized when the underlying contingencies have been resolved, assuming all other revenue recognition criteria are met. As the accounting treatment for this agreement did not materially differ under ASC 605 and ASC 606, and no revenue was recognized under the Company’s previous accounting policy through December 31, 2017, no transition adjustment was recorded to the opening balance of accumulated deficit as of January 1, 2018. Accordingly, the upfront payment of ¥2.5 billion (US$21,916 on the date received), which represents a contract liability, was also included in deferred revenue as of December 31, 2017.

~~MMRF Research Agreement~~

The Company is a party to a research agreement with the Multiple Myeloma Research Foundation (“MMRF”). Under this research agreement, the Company is obligated to make certain payments to MMRF, including if the Company~~out-licenses~~ ~~selinexor. The terms of this research agreement do not apply to eltanexor,KPT-9274~~ or verdinexor. During the quarter ended September 30, 2018, the Company paid approximately $278 to MMRF, which reflects the amount owed to MMRF under the Antengene License Agreement transaction. In connection with the transaction pursuant to the Ono License Agreement, the Company paid to MMRF $1,972 of the upfront cash payment from Ono in the year ended December 31, 2017. The Company will be obligated to pay a percentage of any milestone payments from Antengene and Ono and a~~mid-single-digit~~ percentage of any royalty payments from Antengene and Ono. Such payments are recorded within research and development expense in the Company’s condensed consolidated statement of operations. As of September 30, 2018, a maximum of $3,750 in potential future obligations to MMRF are remaining under the MMRF research agreement.

liability.

Anivive License Agreement

On April 28, 2017 (the “Anivive Effective Date”), ~~the Company~~we entered into a license agreement (the “Anivive Agreement”) with Anivive Lifesciences, Inc. (“Anivive”), a biopharmaceutical company engaged in the research, development and commercialization of animal health medicines, pursuant to which ~~the Company has~~we have granted Anivive an exclusive, worldwide license to develop and commercialize verdinexor

(KPT-335)

for the treatment of cancer in companion animals (the “Anivive Exclusive License”). Pursuant to the terms of the Anivive Agreement, ~~the Company~~we received an upfront payment of ~~$1,000~~$1.0 million and a payment of ~~$250~~$0.3 million upon the completion of the technology transfer, which occurred during the year ended December 31, 2017. In addition, ~~the Company is~~we are eligible to receive potential clinical, regulatory and commercial development milestone payments totaling up to ~~$43,250,~~$43.3 million, as well as a low double-digit royalty based on Anivive’s future net sales of verdinexor following commercialization. The potential future milestone payments are composed of ~~$5,750~~$5.8 million based on achievement of clinical and regulatory milestone events and ~~$37,500~~$37.5 million based on achievement of sales milestone events.

~~The Company~~

Table of Contents

We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Anivive, is a customer. ~~The Company~~We identified the following material promises under the contract, the Anivive Exclusive License and the technology transfer, which consisted of regulatory data compiled by ~~the Company~~us for the licensed compound and product as of the Anivive Effective Date. ~~The Company~~We also identified immaterial promises under the contract that were not deemed performance obligations, including participating on a product advisory committee and sharing regulatory matter information. ~~The Company~~We further determined that other promises for (i) transfer of additional technology in the future, if developed by ~~the Company,~~us, and (ii) facilitating manufacturing and supply relationships with ~~the Company’s~~our third-party contract manufacturers represented customer options, would create an obligation for ~~the Company~~us if exercised by Anivive. Since no additional or immaterial consideration is owed to ~~the Company~~us by Anivive upon exercise of the customer options noted, ~~the Company~~we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement.

In further evaluating the promises detailed above, ~~the Company~~we determined that the Anivive Exclusive License and the technology transfer were not distinct from one another and must be combined as a performance obligation (the “Anivive Combined License Obligation”). This is because Anivive requires the technology transfer to derive benefit from the Anivive Exclusive License. Based on these determinations, ~~the Company~~we identified three distinct performance obligations at the inception of the contract: (i) the Anivive Combined License Obligation, (ii) the material right for transfer of additional technology in the future, if developed by ~~the Company,~~us, and (iii) the material right for facilitating manufacturing and supply relationships with ~~the Company’s~~our third-party contract manufacturers.

~~The Company~~

We further determined that the

up-front

payment of ~~$1,000~~$1.0 million upon contract execution, as well as the ~~$250~~$0.3 million upon completion of the technology transfer, constituted the entirety of the consideration ~~to be~~ included in the transaction price as of the transition date, January 1, 2018, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, ~~the Company~~we estimated the stand-alone selling price of the (i) Anivive Combined License Obligation, (ii) material right for transfer of additional technology in the future, if developed by ~~the Company,~~us, and (iii) the material right for facilitating manufacturing and supply relationships with ~~the Company’s~~our third-party contract manufacturers, and determined that the stand-alone selling price of the material rights noted were insignificant based on various qualitative considerations. Accordingly, ~~the Company~~we further determined that the allocation of the upfront payment to the material rights noted was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, ~~the Company~~we determined that substantially all of the ~~$1,250~~$1.3 million transaction price should be allocated to the Anivive Combined License Obligation. ~~The Company believes~~We believe that a change in the assumptions used to determine ~~its~~our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

As referenced above, the

up-front

payment of ~~$1,000~~$1.0 million upon contract execution, as well as the ~~$250~~$0.3 million upon completion of the technology transfer, constituted the entirety of the consideration ~~to be~~ included in the transaction price as of the transition date, January 1, 2018. ~~The Company is~~We are also eligible to receive additional payments up to ~~$5,750~~$5.8 million based on achievement of clinical and regulatory milestone events and up to ~~$37,500~~$37.5 million based on achievement of sales milestone events, as well as a low double-digit royalty based on Anivive’s future net sales of verdinexor following commercialization. The future regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts are fully constrained as of September 30, ~~2018.~~2019. As part of ~~its~~our evaluation of the constraint, ~~the Company~~we considered numerous factors, including that receipt of such milestones is outside ~~the control of the Company.~~our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Anivive, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Anivive and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as ~~the Company’s~~our policy. ~~The Company~~We will

re-evaluate

the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.

To date, ~~the Company~~we have recognized ~~$1,250~~$1.3 million of revenue associated with the Anivive Agreement. Revenue for the upfront payment and technology transfer milestone was recognized upon completion of the technology transfer in October 2017, as all promises under the Anivive Combined License Obligation had been fulfilled.

The Company reached similar conclusions when evaluating this agreement under its previous accounting policy, which was based on legacy guidance within ASC 605. When evaluating this agreement under ASC 605, the Company concluded that the licenses to verdinexor and technology transfer concerning the licensed product are essential to Anivive’s intended use of the license to develop and commercialize the licensed compound and represented a single unit of accounting. Other potential contractual obligations were evaluated and determined not to be deliverables at inception of the arrangement or were evaluated and determined to be immaterial to the arrangement and, therefore, not evaluated further in the Company’s analysis. Arrangement consideration at the inception of the arrangement included the $1,250 in upfront payments, which includes the milestone fee upon completion of the technology transfer. All other forms of consideration, such as milestones and royalties, were considered contingent consideration, with no amount allocable to deliverables at the inception of the arrangement. The Company concluded that the contingent consideration would be recognized when the underlying contingencies have been resolved, assuming all other revenue recognition criteria are met. Given the single unit of accounting and that the technology transfer would be the last item to be delivered within the unit of accounting, the Company concluded that revenue would be recognized upon the completion of delivery of the technology transfer assuming all other general revenue recognition criteria would be met as of that date. As the accounting treatment for this agreement did not materially differ under ASC 605 and ASC 606, and the upfront payment and technology transfer fee, totaling $1,250, was recognized as revenue during the year ended December 31, 2017 in accordance with the Company’s previous accounting policy, and would have also been recognized during the year ended December 31, 2017 in accordance with the Company’s accounting policy under ASC 606, no transition adjustment was recorded to the opening balance of accumulated deficit as of January 1, 2018.

6. Fair Value of Financial Instruments

Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses are presented ~~in the condensed consolidated financial statements~~ at amounts that approximate fair value at September 30, ~~2018~~2019 and December 31, ~~2017.~~

~~The Company is~~2018.

Table of Contents

We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:


Level 1 inputs		Quoted prices in active markets for identical assets or liabilities



Level 2 inputs		Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 inputs		Unobservable inputs that reflect ~~the Company’s~~our own assumptions about the assumptions market participants would use in pricing the asset or liability

Items classified as Level 2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. ~~The Company estimates~~We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. ~~The Company validates~~We validate the prices provided by ~~its~~our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.

In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level 3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 12, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1) our estimates of the probability and timing of related events; (2) the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3) our risk-adjusted discount rate that includes a company specific risk premium; (4) our cost of debt; (5) volatility; and (6) the probability of a change in control occurring during the term of the instrument. Our embedded derivative liability is described in Note 12, “Long-Term Obligations.”

The following table presents information about ~~the Company’s~~our financial assets that have been measured at fair value at September 30, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):


Description	Total			Quoted Prices in Active Markets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds		$	78,063		$	78,063		$	—		$	—
Investments:
Short-term:
Corporate debt securities			49,708			—			49,708			—
Commercial paper			36,440			—			36,440			—
U.S. government and agency securities			13,377						13,377
Long-term:
Corporate debt securities			2,022						2,022

Total financial assets		$	179,610		$	78,063		$	101,547		$	—

Table of Contents

The following table presents information about our financial assets that have been measured at fair value at December 31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):

Description
   Total    Quoted Prices
in Active
Markets
(Level 1)    Significant
Other
Observable
Inputs
(Level 2)    Significant
Unobservable
Inputs
(Level 3)
Financial assets

Cash equivalents:

Money market funds
   $ 70,876    $ 70,876    $ —      $ —
Investments:

Current:

Corporate debt securities
   87,205    —      87,205    —
Commercial paper
   8,988    —      8,988    —
U.S. government and agency securities
   2,477    —      2,477    —
Certificates of deposit
   6,500    —      6,500    —
Non-current:

Corporate debt securities (one to two year maturity)
   4,804    —      4,804    —








   $ 180,850    $ 70,876    $ 109,974    $ —


Description	Total			Quoted Prices in Active Markets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds		$	62,320		$	62,320		$	—		$	—
Corporate debt securities			6,823			—			6,823			—
Commercial paper			7,738			—			7,738			—
Investments:
Short-term:
Corporate debt securities			143,079			—			143,079			—
Commercial paper			43,978			—			43,978			—
U.S. government and agency securities			19,124			—			19,124			—
Certificate of deposit			3,997			—			3,997			—
Long-term:
Corporate debt securities (one to two year maturity)			2,001			—			2,001			—

		$	289,060		$	62,320		$	226,740		$	—

The following table presents information about the Company’s financial assets that have been measured at fair value at December 31, 2017 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):

Description
   Total    Quoted Prices
in Active
Markets
(Level 1)    Significant
Other
Observable
Inputs
(Level 2)    Significant
Unobservable
Inputs
(Level 3)
Financial assets

Cash equivalents:

Money market funds
   $ 41,805    $ 41,805    $ —      $ —
Investments:

Current:

Corporate debt securities
   66,253    —      66,253    —
Commercial paper
   6,720    —      6,720    —
Certificates of deposit
   2,500    —      2,500    —
U.S. government and agency securities
   1,999    —      1,999    —
Non-current:
            —
Corporate debt securities (one to two year maturity)
   26,916    —      26,916    —
U.S. government securities and agency securities
   2,480    —      2,480    —








   $ 148,673    $ 41,805    $ 106,868    $ —

7. Investments

The following table summarizes ~~the Company’s~~our investments in debt securities, classified as

available-for-sale,

as of September 30, ~~2018~~2019 (in thousands):

   Amortized Cost    Gross Unrealized
Gains    Gross Unrealized
Loss    Fair Value
Current:

Corporate debt securities
   $ 87,317    $ 6    $ (118 )    $ 87,205
Commercial paper
   8,988    —      —      8,988
U.S. government and agency securities
   2,500    —      (23 )    2,477
Certificates of deposit
   6,500    —      —      6,500
Non-current:

Corporate debt securities (one to two year maturity)
   4,817    —      (13 )    4,804








   $ 110,122    $ 6    $ (154 )    $ 109,974


	Amortized Cost			Gross Unrealized Gains			Gross Unrealized Loss				Fair Value
Short-term:
Corporate debt securities		$	49,692		$	19		$	(3)			$	49,708
Commercial paper			36,431			12			(3)				36,440
U.S. government and agency securities			13,367			10							13,377
Long-term:
Corporate debt securities			2,021			1							2,022

		$	101,511		$	42		$	(6	)		$	101,547

The following table summarizes ~~the Company’s~~our investments in debt securities, classified as

available-for-sale

as of December 31, ~~2017~~2018 (in thousands):

   Amortized Cost    Gross Unrealized
Gains    Gross Unrealized
Loss    Fair Value
Current:

Corporate debt securities
   $ 66,384    $ —      $ (131 )    $ 66,253
Commercial paper
   6,719    1    —      6,720
Certificates of deposit
   2,500    —      —      2,500
U.S. government and agency securities
   2,000    —      (1 )    1,999
Non-current:

Corporate debt securities (one to two year maturity)
   27,018    2    (104 )    26,916
U.S. government and agency securities
   2,500    —      (20 )    2,480








   $ 107,121    $ 3    $ (256 )    $ 106,868


	Amortized Cost			Gross Unrealized Gains			Gross Unrealized Loss				Fair Value
Short-term:
Corporate debt securities		$	143,254		$	3		$	(178)			$	143,079
Commercial paper			44,001			—			(23)				43,978
U.S. government and agency securities			19,131			10			(17)				19,124
Certificate of deposit			4,000			—			(3)				3,997
Long-term:
Corporate debt securities (one to two year maturity)			2,007			—			(6)				2,001

		$	212,393		$	13		$	(227	)		$	212,179

At September 30, ~~2018~~2019 and December 31, ~~2017, the Company~~2018, we held 4111 and 5479 debt securities, respectively, that were in an unrealized loss position. The aggregate fair value of debt securities in an unrealized loss position at September 30, ~~2018~~2019 and December 31, ~~2017~~2018 was ~~$81,222~~$23.1 million and ~~$96,623,~~$180.6 million, respectively. As of September 30, ~~2018, 6~~2019, 1 corporate debt ~~securities~~security with a fair value of ~~$12,246 had~~$1.0 million has been in a continuous unrealized loss position for more than 12 months. The unrealized ~~losses of $35~~loss related to ~~these~~this corporate debt ~~securities are~~security is included in accumulated other comprehensive loss as of September 30, ~~2018. As of December 31, 2017, no securities had been in a continuous~~2019. At September 30, 2019, we did not intend to sell the security with an unrealized loss position ~~for more than 12 months.~~

in accumulated other comprehensive income, and it is not likely that we will be required to sell this security before recovery of

its

amortized cost basis.

~~The Company reviews~~

Table of Contents

We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the condensed consolidated statements of operations if ~~the Company has~~we have experienced a credit loss and ~~has~~have the intent to sell the investment or if it is more likely than not that ~~the Company~~we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with ~~the Company’s~~our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The unrealized losses at September 30, ~~2018~~2019 and December 31, ~~2017~~2018 are attributable to changes in interest rates and ~~the Company does not~~we do 0t believe any unrealized losses represent other-than-temporary impairments.

~~6. Property and Equipment, net~~

~~Property and equipment, net consisted of the following (in thousands):~~

   Estimated Useful
Life Years    September 30,
2018    December 31,
2017
Laboratory equipment
   4    $ 593    $ 593
Furniture and fixtures
   5    601    381
Office and computer equipment
   3    408    378
Construction in process
   N/A    491    —
Leasehold improvements

Lesser of useful life
or lease term

   3,920    3,391




      6,013    4,743
Less accumulated depreciation and amortization
      (3,099 )    (2,558 )




      $ 2,914    $ 2,185

~~7. Accrued Expenses~~

~~Accrued expenses consisted of the following (in thousands):~~

   September 30,
2018    December 31,
2017
Research and development costs
   $ 18,118    $ 16,198
Payroll and employee-related costs
   7,349    3,982
Professional fees
   3,443    972
Other
   245    293




   $ 29,155    $ 21,445

8. Net Loss Per Share

Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. ~~The Company’s~~Our potentially dilutive shares, which include outstanding stock options and unvested restricted stock and restricted stock units, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

   Three and Nine Months Ended
September 30,
   2018    2017
Outstanding stock options
   8,962,643    7,049,007
Unvested restricted stock units
   25,000    425,850


	Three and Nine Months Ended September 30,
	2019		2018
Outstanding stock options		10,210,890		8,962,643
Unvested restricted stock units		834,600		25,000

We have the option to settle the conversion obligation for our 3.00% convertible senior notes issued October 2018, and due 2025, in cash, shares or any combination of the two. As such notes were not convertible as of September 30, 2019, they are not participating securities and do not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there was no impact on the calculation of dilutive loss per share during the three and nine months ended September 30, 2019.

9. Stock-based Compensation

Stock Options

A summary of ~~the Company’s~~our stock option activity and related information follows:

   Shares    Weighted-
Average
Exercise
Price
Per
Share    Weighted-
Average
Remaining
Contractual
Term
(years)    Aggregate
Intrinsic
Value
(in thousands)
Outstanding at December 31, 2017
   7,019,083    $ 13.77    7.4    $ 11,897
Granted
   3,232,350    $13.11
Exercised
   (458,989 )    $4.91
Canceled
   (829,801 )    $ 15.12





Outstanding at September 30, 2018
   8,962,643    $ 13.86    7.5    $ 50,973








Exercisable at September 30, 2018
   4,329,028    $ 15.52    6.0    $ 27,085


	Shares			Weighted- Average Exercise Price Per Share			Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		8,917,084			$	13.78		7.4		$	8,197
Granted		2,996,650				8.08
Exercised		(131,143	)			5.55
Canceled		(1,571,701	)			13.77

Outstanding at September 30, 2019		10,210,890				12.22		7.0		$	12,443

Exercisable at September 30, 2019		5,426,297			$	14.64		5.5		$	7,869

Total stock-based compensation expense related to stock options for the nine months ended September 30, 2019 and 2018 was $9.8 million and ~~2017 was $12,779 and $13,140,~~$12.8 million, respectively.

As of September 30, ~~2018,~~2019, there was ~~$36,766~~$28.7 million of total unrecognized stock-based compensation expense related to stock options. The expense is expected to be recognized over a weighted-average period of ~~2.9~~2.77 years.

Table of Contents

Restricted Stock Units

A restricted stock unit (“RSU”) represents the right to receive one share of ~~the Company’s~~our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of ~~the Company’s~~our common stock on the date of grant.

~~During the year ended December 31, 2017, the Company granted~~ We grant RSUs with service conditions that vest in 2 or 4 equal annual installments provided that the employee remains employed with ~~the Company~~us (“Time-Based RSUs”).

During the nine months ended September 30, 2019, we granted Time-Based RSUs under the 2013 Stock Incentive Plan (the “2013 Plan”) that vest in 4 equal annual installments. The following is a summary of ~~Time-Based~~ RSU activity ~~under~~for the 2013 ~~Stock Incentive~~ Plan for the nine months ended September 30, ~~2018:~~

   Number of
Shares
Underlying RSUs    Weighted-
Average
Grant
Date
Fair
Value
Unvested at December 31, 2017
   30,000    $ 10.52
Granted
   —      —
Forfeited
   —      —
Vested
   (5,000 )    10.27




Unvested at September 30, 2018
   25,000    $ 10.57

2019:


	Number of Shares Underlying RSUs			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2018		25,000			$	9.87
Granted		1,049,900				9.16
Forfeited		(230,300	)			9.24
Vested		(10,000	)			8.13

Unvested at September 30, 2019		834,600			$	9.18

The total stock-based compensation expense related to ~~Time-Based~~ RSUs for the nine months ended September 30, 2019 and 2018 was $1.2 million and ~~2017 was $118 and $2,243,~~$0.3 million, respectively.

As of September 30, ~~2018,~~2019, there was ~~$134~~$6.4 million of unrecognized compensation costs related to unvested Time-Based RSUs, which are expected to be recognized over a weighted-average period of ~~1.0~~3.34 years.

Separately, and during the year ended December 31, 2017, the Company granted performance-based RSUs, which vest upon the achievement of certain performance goals subject to the employee’s continued employment (“Performance-Based RSUs”). During the nine months ended September 30, 2018, the Company recognized $180 of stock-based compensation expense related to a portion of the Performance-Based RSUs when the associated performance goal became probable of achievement in the first quarter and was achieved in the second quarter. The remaining 98,800 Performance-Based RSUs were forfeited in July 2018 when the performance goal was not achieved.

Employee Stock Purchase Plan

~~The Company has~~

We have an Employee Stock Purchase Plan (“ESPP”) that permits eligible employees to enroll in~~six-month~~

six

-month

offering periods. Participants may purchase shares of ~~the Company’s~~our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first or last day of the applicable

six-month

offering period, whichever is lower. Purchase dates under the ESPP occur on or about May 1 and November 1 of each year. In 2013, ~~the Company’s~~our stockholders

approved the reservation of 242,424 shares of ~~the Company’s~~our common stock for issuance under the ESPP, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of ~~the Company’s~~our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the board of directors.

For the nine months ended September 30, 2019 and 2018, ~~and 2017, the Company~~we recorded stock-based compensation expense related to the ESPP of ~~$301~~$0.7 million and ~~$152,~~$0.3 million, respectively. As of September 30, ~~2018, 390,107~~2019, 720,676 shares of ~~the Company’s~~our common stock remained available for issuance under the ESPP. As of September 30, ~~2018,~~2019, there was ~~$48~~$0.1 million of total unrecognized stock-based compensation expense related to the ESPP. ~~The expense is expected~~

10. Leases

Operating Leases

We are party to ~~be recognized over a period of one month.~~

~~10. Commitments and Contingencies~~

~~In 2014, the Company entered into~~ an operating lease ~~and subsequent amendment to lease approximately 46,167~~of 98,502 square feet of office and research space in Newton, Massachusetts with a term through September 30, ~~2022. The lease provided~~2025 (the “Newton, MA Lease”). Pursuant to the Company with an allowance for improvements of $1,616 which was incurred in the first quarter of 2015. In February 2018, the lease was amended to extend the term of the lease to September 30, 2025 and expand the leased premises to approximately 62,143 square feet. In June 2018, the lease was further amended to expand the premise to a total of approximately 98,502 square feet with no change in lease term. The 2018 lease amendments provided the Company with an allowance for improvements of $2,131, of which $1,014 was incurred during the nine months ended September 30, 2018.

The Company evaluated the lease amendments and determined that the classification of the lease as an operating lease had not changed, and that the amendments did not constitute a new lease. As such, the unamortized balances of the existing deferred rent and tenant improvement allowances, along with the additions to deferred rent and tenant improvement allowances, will be amortized through September 30, 2025. All improvements were deemed normal tenant improvements, were recorded as leasehold improvements and deferred rent and will be recorded as a reduction to rent expense ratably over the lease term. The Company is recording rent expense on a straight-line basis through the end of the lease term, inclusive of the period in which there are no scheduled rent payments. The Company has recorded deferred rent on the condensed consolidated balance sheets at September 30, 2018 and December 31, 2017, accordingly. Finally, the Company hasNewton, MA Lease, we have provided a security deposit in the form of a cash-collateralized letter of credit in the amount of ~~$550.~~$0.6 million. The amount is classified within~~non-current~~ restricted ~~cash~~cash.

Upon the adoption of ASU

2016-02,

we recorded an operating lease

right-of-use

asset of $11.7 million and corresponding lease liability of $16.0 million related only to the Newton, MA Lease. As of December 31, 2018, there was a balance of $1.7 million and $2.6 million related to unamortized deferred rent and tenant incentive allowances, respectively, for the Newton, MA Lease, both accounted for as liabilities. These balances were deducted from the lease liability on the ~~condensed consolidated balance sheet.~~

~~In November 2014,~~Newton, MA Lease in arriving at the ~~Company signed a five-year~~

right-of-use

asset upon adoption of ASU

2016-02

on January 1, 2019.

The Newton, MA Lease provides for increases in future minimum annual rental payments, as defined in the lease agreement. The Newton, MA Lease also includes real estate taxes and common area maintenance (“CAM”) charges in the annual rental payments. As these charges were included in minimum annual rental payments as part of our accounting for the Newton, MA Lease

under ASC 840 through December 31, 2018, we have included such amounts in the calculation of the operating lease ~~agreement~~liability, consistent with ASC 842 and our accounting policy elections thereunder, as specified in ~~Munich, Germany for approximately 3,681 square feet of office space.~~Note 2, “Recent Accounting Pronouncements.” The operating lease iscost for the period February 2015 through January 2020. Pursuant to the lease agreement, the Company is obligated to make aggregate rent payments of €374 (approximately US$434) through January 31, 2020. The Company is recording rent expense on a straight-line basis through the end of the lease term, inclusive of the period in which there are no scheduled rent payments.

~~The Company recorded rent expense totaling $895 and $296 for the three months ended September 30, 2018 and 2017, respectively, and $1,700 and $894~~Newton, MA Lease for the nine months ended September 30, ~~2018~~2019 was $2.1 million, of which approximately $0.7 million was charges for CAM.

Table of Contents

In addition, we are party to short-term leases having a term of twelve months or less at the commencement date. We recognize short-term lease expense on a straight-line basis and ~~2017, respectively.~~

do not record a related

right-of

use asset or lease liability for such leases. These costs were insignificant for the nine months ended September 30, 2019.

Lease Commitments

As of September 30, 2019, future minimum lease payments under

non-cancellable

operating lease agreements for which we have recognized operating lease

right-of-use

assets and liabilities are as follows (in thousands):


Years end ing December 31,	Future Minimum Payments
2019		$	793
2020			3,200
2021			3,277
2022			3,447
2023 and thereafter			10,453

Total minimum lease payments		$	21,170
Less: present value adjustment			(5,944	)

Present value of minimum lease payments		$	15,226

As of September 30, 2019, the remaining lease term on the Newton, MA Lease was 5.9 years. The lease has a renewal option for an additional five years, although there is no economic penalty for failure to exercise the option. However, because we did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard, and the renewal option was not previously considered in our assessment of the lease term for the Newton, MA Lease before adoption of ASC 842, the renewal option was not considered as part of the lease term in calculating the operating lease

right-of-use

assets and liabilities as of January 1, 2019.

As a discount rate was not directly observable for our Newton, MA Lease, the discount rate used to calculate the net present value of future payments was our incremental borrowing rate calculated at transition based on the remaining lease term. Upon adoption and through September 30, 2019, the discount rate used to calculate the operating lease liability was 11.0%. The incremental borrowing rate is the rate of interest that the we would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. In determining the incremental borrowing rate, we considered (i) our estimated public credit rating, (ii) our observable debt yields, as well as other bonds in the market issued by other companies with similar credit ratings as us, and (iii) adjustments necessary for collateral, lease term, and inflation or foreign currency.

11. Equity

Underwritten Offerings

On May 7, 2018, ~~the Company~~we completed a

follow-on

offering under ~~its~~our shelf registration statement onForm

S-3 ~~(File~~

(File No.

333-222726)

pursuant to which ~~the Company~~we issued an aggregate of 10,525,424 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $14.75 per share. ~~The Company~~We received aggregate net proceeds of approximately ~~$145,720~~$145.7 million from the offering after deducting the underwriting discounts and commissions and other offering expenses.

~~On April 28, 2017, the Company completed afollow-on~~ ~~offering under its shelf registration statement onForm S-3~~ ~~(FileNo. 333-214489)~~ pursuant to which the Company issued an aggregate of 3,902,439 shares of common stock at a public offering price of $10.25 per share. The Company received net proceeds of approximately $37,900 from the offering after deducting the underwriting discount and commissions and offering expenses.

~~Controlled Equity Offering Sales Agreement~~

On December 7, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (as amended on November 7, 2016 and December 1, 2017, the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company issued and sold through Cantor an aggregate of 9,172,159 shares of the Company’s common stock, for net proceeds of

approximately $89,053. On August 2, 2018, the Company delivered written notice to Cantor terminating the Sales Agreement effective August 12, 2018. Under the Sales Agreement, Cantor sold shares of the Company’s common stock by methods deemed to be an~~“at-the-market”~~ offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The Company paid Cantor a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company’s common stock pursuant to the Sales Agreement and provided Cantor with customary indemnification and contribution rights.

Open Market Sale Agreement

On August 17, 2018, ~~the Company~~we entered into an Open Market Sale Agreement (the “Open Market Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which ~~the Company~~we may issue and sell shares of ~~its~~our common stock having an aggregate offering price of up to ~~$75,000~~$75.0 million (the “Open Market Shares”) from time to time through Jefferies (the “Open Market Offering”).

Under the Open Market Sale Agreement, Jefferies may sell the Open Market Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. ~~The Company~~We may sell the Open Market Shares in amounts and at times to be determined by ~~the Company~~us from time to time subject to the terms and conditions of the Open Market Sale Agreement, but ~~it has no~~we have 0 obligation to sell any of the Open Market Shares in the Open Market Offering.

~~The Company~~

Table of Contents

We or Jefferies may suspend or terminate the offering of Open Market Shares upon notice to the other party and subject to other conditions. ~~The Company has~~We have agreed to pay Jefferies commissions for its services in acting as agent in the sale of the Open Market Shares in the amount of up to 3.0% of gross proceeds from the sale of the Open Market Shares pursuant to the Open Market Sale Agreement. ~~The Company has~~We have also agreed to provide Jefferies with customary indemnification and contribution rights.

~~The Company has not~~

For the three and nine months ended September 30, 2019, we have sold ~~any shares to date~~an aggregate of 1,634,451 Open Market Shares under the Open Market Sale ~~Agreement.~~

Agreement, for net proceeds of approximately $14.6 million.

12. ~~Subsequent Event~~

Long-Term Obligations

3.00% Convertible Senior Notes due 2025

On October 16, 2018, ~~the Company~~we completed an offering of ~~$150,000~~$150.0 million aggregate principal amount of ~~the Company’s~~our 3.00% convertible senior notes due 2025 (the “Notes”). In addition, on October 26, 2018, ~~the Company~~we issued an additional ~~$22,500~~$22.5 million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act. ~~The net proceeds from~~In accordance with accounting guidance for debt with conversion and other options, we separately accounted for the ~~sale~~liability component (“Liability Component”) and the embedded conversion option (“Equity Component”) of the Notes by allocating the proceeds between the Liability Component and the Equity Component, due to our ability to settle the Notes in cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. In connection with the issuance of the Notes, we incurred approximately $5.6 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $2.2 million was ~~approximately $166,900, after deducting~~allocated to the ~~initial purchasers’ discounts~~Equity Component and ~~commissions~~recorded as a reduction to additional

paid-in

capital and ~~estimated offering expenses payable by~~$3.4 million was allocated to the ~~Company.~~

Liability Component and recorded as a reduction of the Notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over seven years.

The Notes are ~~governed by the terms of an indenture (the “Indenture”) between the Company, as issuer, and Wilmington Trust, National Association, as trustee (the “Trustee”). The Notes are~~our senior unsecured obligations ~~of the Company~~ and bear interest at a rate of 3.00% per year payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019. Upon conversion, the Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.

The Notes will be subject to redemption at our option, on or after October 15, 2022, in whole or in part, if the conditions described below are satisfied. The Notes will mature on

October 15, 2025

, unless earlier converted, redeemed or repurchased in accordance with their terms.

~~Prior~~ Subject to ~~October 15, 2022,~~satisfaction of certain conditions and during the ~~Company may not redeem the Notes. On or after October 15, 2022, the Company may redeem for cash all or a portion of~~periods described below, the Notes if the last reported sale price of the Company’s common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending within five trading days prior to the date on which the Company provides notice of redemption. The redemption price willmay be ~~equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the Notes.~~

~~The Notes are convertible into shares of the Company’s common stock~~converted at an initial conversion rate of 63.0731 shares of common stock per $1 principal amount of the Notes (equivalent to an initial conversion price of approximately $15.85 per share of common stock). The conversion rate will be subject to adjustment upon the occurrence of certain events as provided in the Indenture but will not be adjusted for any accrued and unpaid interest. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s election (subject to, and in accordance with, the settlement provisions of the Indenture).

Holders of the Notes may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time prior to the close of business on the business day immediately preceding ~~July~~

June 15, 2025

only ~~upon~~under the following circumstances:

(1)

during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least

trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day;

(2)

during the five business day period immediately after any five consecutive trading day period (the “Measurement Period”) in which the trading price per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;

(3)

if we call the Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or

(4)

upon the occurrence of specified corporate events as described within the indenture governing the Notes.

As of ~~certain circumstances.~~September 30, 2019, none of the above circumstances had occurred and as such, the Notes could not have been converted.

We may not redeem the Notes prior to October 15, 2022. On or after ~~July~~October 15, ~~2025 until the close of business on the second scheduled trading day immediately preceding the maturity date of the Notes, holders~~2022, we may ~~convert the Notes at any time.~~

The conversion rate is subject to customary anti-dilution adjustments. In addition, if certain corporate events described in the Indenture occur prior to the maturity date, the Company will increase the conversion rate for a holder that elects to convert its Notes in connection with such corporate event in certain circumstances. Furthermore, calling any Note for redemption will result in an increase in the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption in certain circumstances.

~~If the Company undergoes a “fundamental change,” as defined in the Indenture, holders may require the Company to repurchase~~redeem for cash all or ~~any portion~~part of ~~their~~the Notes at ~~a fundamental change repurchase~~our option if the last reported sale price ~~equal~~of our common stock equals or exceeds 130% of the conversion price then in effect for at least

trading days (whether or not consecutive) during any 30 consecutive trading day period ending within 5 trading

days prior to the date on which we send any notice of redemption. The redemption price will be 100% of the principal amount of the Notes to be ~~repurchased,~~redeemed, plus ~~any~~ accrued and unpaid interest, if any. In addition, calling any ~~to, but excluding, the~~convertible note for redemption will constitute a make-whole fundamental change ~~repurchase date.~~ with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances.

Table of Contents

The ~~Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% in principal~~initial carrying amount of the ~~outstanding~~Liability Component of $101.2 million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our

non-convertible

borrowing rate for similar debt. The Equity Component of the Notes ~~may declare~~of $67.9 million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Notes of $172.5 million and the fair value of the liability of the Notes of approximately $104.7 million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over seven years. The Equity Component is 0t remeasured as long as it continues to meet the conditions for equity classification.

The outstanding balances of the Notes as of September 30, 2019 consisted of the following (in thousands):


Liability component:
Principal	$	172,500
Less: debt discount and issuance costs, net		(64,538	)

Net carrying amount	$	107,962

Equity component:	$	65,641

We determined the expected life of the Notes was equal to its seven-year term. The effective interest rate on the Liability Component of the Notes was 11.85%. As of September 30, 2019, the

“if-converted

value” did not exceed the remaining principal amount of the Notes. The fair value of the Notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level 2 within the fair value hierarchy. The fair value of the Notes, which differs from their carrying value, is influenced by market interest rates, our stock price and stock price volatility. The estimated fair value of the Notes as of September 30, 2019 was approximately $156.3 million.

The following table sets forth total interest expense recognized related to the Notes during the nine months ended September 30, 2019 (in thousands):


	Nine Months Ended September 30, 2019
Contractual interest expense		$	3,882
Amortization of debt discount			5,045
Amortization of debt issuance costs			253

Total interest expense		$	9,180

Table of Contents

Future minimum payments on the Notes as of September 30, 2019 were as follows (in thousands):


Years ended December 31,	Future Minimum Payments
2019		$	2,588
2020			5,175
2021			5,175
2022			5,175
2023 and thereafter			188,025

Total minimum payments		$	206,138
Less: interest			(33,638	)
Less: unamortized discount			(64,538	)
Less: current portion			—

Convertible senior notes		$	107,962

Deferred Royalty Obligation

In September 2019, we entered into a Revenue Interest Financing Agreement (the “Revenue Interest Agreement”) with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P. (“HCR”) whereby HCR will receive payments from us

ered

percentage (the “Applicable Tiered Percentage”) of future net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties (the “Revenue Interests”). We received $75.0 million upon closing (the “First Investment Amount”) and have the right to receive an additional $75.0 million (the “Second Investment Amount” and together with the First Investment Amount, the “Investment Amount”) upon the achievement of future regulatory and commercial milestones and subject to the approval of both parties and customary closing conditions.

In exchange for the First Investment Amount, HCR will receive a tiered royalty in the

mid-single

digits based on worldwide net revenues of XPOVIO

and

any

of our

other future products

, including worldwi

net pro

t sales

and upfront payments, milestones, and royalties. The Applicable Tiered Percentage

are

subject to reduction in the future if a target based on cumulative U.S. net sales is met. Total royalty payments are capped at 185% of the Investment Amount.

If HCR has not received 65% of the Investment Amount by December 31, 2022 or 100% of the Investment Amount by December 31, 2024, we must make a cash payment sufficient to gross HCR up to such minimum amounts.

As the repayment of the funded amount is contingent upon worldwide net product sales and upfront payments, milestones, and royalties, the repayment term may be ~~immediately due~~shortened or extended depending on actual worldwide net product sales and ~~payable.~~

upfront payments, milestones, and royalties. The repayment period commenced on October 1, 2019 and expires on the earlier of (i) the date in which HCR has received cash payments totaling an aggregate of 185% of the Investment Amount or (ii) the legal maturity date of October 1, 2031. If HCR has not received payments equal to 185% of the Investment Amount by the twelve-year anniversary of the initial closing date, we shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received.

We have evaluated the terms of the Revenue Interest Agreement and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, we have accounted for the transaction as long-term debt.

We have evaluated the terms of the debt and determined that the repayment of 185% of the Investment Amount, less any payments made to date, upon a change of control is an embedded derivative that requires bifurcation from the debt instrument and fair value recognition. We determined the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 6. The aggregate fair value of the embedded derivative at issuance date is included in deferred royalty obligation. We will remeasure the embedded derivative to fair value each reporting period until the time the features lapse and/or termination of the Revenue Interest Agreement.

The effective interest rate as of September 30, 2019 was 17.3%. In connection with the Revenue Interest Agreement, we incurred debt issuance costs totaling $1.4 million. Debt issuance costs have been netted against the debt as of September 30, 2019 and are being amortized over the estimated term of the debt using the effective interest method

, adjusted on a prospective basis for changes in the underlying assumptions and inputs.

The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized.

Table of Contents

The carrying value of the deferred royalty obligation at September 30, 2019 was

$72.3

million based on $75.0 million of proceeds, net of fair value of the bifurcated embedded derivative liability and debt issuance costs incurred. The carrying value of the deferred royalty obligation approximates fair value at September 30, 2019 and was measured using Level 3 inputs.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this quarterly report.

FORWARD-LOOKING STATEMENTS

This Quarterly Report onForm

10-Q,

including the following discussion, contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report onForm

10-Q,

including statements regarding possible achievement of discovery and development milestones, including regulatory submissions and approvals, our future discovery and development efforts, our commercialization efforts, our collaborations and partnering agreements with third parties, our strategy, our future operations, financial position and revenues, projected costs, prospects, plans and objectives of management, are forward looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are not guarantees of future performance and our actual results could differ materially from the plans, intentions, expectations or results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, our ability to successfully commercialize XPOVIO

(selinexor), adverse results in our drug discovery and clinical development activities, decisions made by the U.S. Food and Drug Administration (FDA) and other regulatory authorities with respect to the development and commercialization of our drug candidates, our ability to raise additional capital to support our clinical development program and other operations, our ability to develop products of commercial value and to identify, discover and obtain rights to additional potential product candidates, our ability to obtain, maintain and enforce our intellectual property rights, the outcome of research and development activities and the fact that the preclinical and clinical testing of our compounds may not be predictive of the success of later clinical trials, our reliance on third-parties, competitive developments, the effect of current and future legislation and regulation and regulatory actions, as well as other risks described in this Quarterly Report onForm

10-Q,

our Annual Report onForm

10-K

for the year ended December 31, ~~2017 (2017~~2018 (2018 Form

10-K),

as filed with the Securities and Exchange Commission (SEC) on ~~March 15, 2018,~~February 28, 2019, and other filings with the SEC.

As a result of these and other factors, we may not actually achieve the plans, intentions, expectations or results disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

OVERVIEW

We are ~~a clinical-stage~~an oncology-focused pharmaceutical company ~~focused on~~dedicated to the discovery, development and ~~subsequent~~ commercialization of novel,

first-in-class

drugs directed against nuclear ~~transport~~export and related targets for the treatment of cancer and other major diseases. Our scientific expertise is focused on understanding the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing wholly-owned, novel, small molecule

elective

nhibitor of

uclear

xport

(

SINE

) compounds ~~that inhibit~~function by binding with and inhibiting the nuclear export protein exportin 1 (XPO1). ~~These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need.~~ Our ~~SINE compounds were the first oral XPO1 inhibitors in clinical development.~~

~~Our~~initial focus ishas been on seeking the regulatory approval and commercialization of our lead ~~drug candidate,~~SINE compound, selinexor,~~(KPT-330),~~ as an oral agent in cancer indications with significant unmet clinical ~~need, initially~~need.

In July 2019, the FDA approved XPOVIO

(selinexor) in combination with dexamethasone for ~~hematologic malignancies.~~the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON (

rtezomib,

elinexor and Dexame

has

e) study evaluating selinexor in combination with Velcade

(bortezomib) and

low-dose

dexamethasone is intended to serve as the confirmatory trial.

The accelerated approval of XPOVIO was based on results from the Phase 2b STORM (

elinexor

reatment

efractory

yeloma) trial, which was a multicenter,

single-arm,

open-label study of patients with RRMM. STORM Part 2 included 122 patients with RRMM who had previously received three or more anti-myeloma treatment regimens including an alkylating agent, glucocorticoids, bortezomib, carfilzomib, lenalidomide, pomalidomide, and an anti-CD38 monoclonal antibody; and whose myeloma was documented to be refractory to glucocorticoids, a proteasome inhibitor, an immunomodulatory agent, an anti-CD38 monoclonal antibody, and to the last line of therapy.

Table of Contents

In STORM Part 2, a total of 122 patients were treated with XPOVIO (80 mg) in combination with dexamethasone (20 mg) on Days 1 and 3 of every week. Eighty-three patients had RRMM that was documented to be refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. Treatment continued until disease progression, death, or unacceptable toxicity.

The major efficacy outcome measure was overall response rate (ORR), as assessed by an Independent Review Committee based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. The approval of XPOVIO was based upon the efficacy and safety in a prespecified subgroup analysis of the 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab, as the benefit-risk ratio appeared to be greater in this more heavily pretreated population than in the overall trial population.

For the STORM Part 2 study’s major efficacy outcome measure, the ORR was 25.3% in the subgroup of 83 patients, which included one stringent complete response, no complete responses, four very good partial responses and 16 partial responses. The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months.

Amongst the 202 patients enrolled in STORM Parts 1 and 2 who were treated with XPOVIO (80 mg) in combination with dexamethasone (20 mg) on days 1 and 3 weekly, the most common adverse reactions (incidence

20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections. The treatment discontinuation rate due to adverse reactions was 27%; 53% of patients had a reduction in the XPOVIO dose, and 65.3% had the dose of XPOVIO interrupted. The most frequent adverse reactions requiring permanent discontinuation in 4% or greater of patients who received XPOVIO included fatigue, nausea, and thrombocytopenia. The rate of fatal adverse reactions was 8.9%. Following accelerated approval by the FDA, XPOVIO became commercially available in the United States in July 2019.

In addition, we submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in January 2019 with a request for conditional approval of selinexor as a treatment for patients with heavily pretreated multiple myeloma based on the results of the STORM study. During March 2019, the EMA had inspectors conduct a Good Clinical Practices (GCP) inspection at our headquarters, which was also attended by the FDA, as well as inspections of two clinical sites that participated in Part 2 of the STORM study. While we did not receive any findings from the FDA, in May 2019, the EMA inspectors provided us a written inspection report seeking our responses to various questions and findings. We ~~then~~promptly addressed the questions and findings in the inspection report and submitted proposals to the EMA’s Committee for Medicinal Products for Human Use (CHMP). In September 2019, we received the Day 180 List of Outstanding Issues from CHMP, which identified two issues requiring resolution. First, CHMP requested that we reconfirm the IRC adjudicated response rate to justify a positive benefit-risk assessment and, second, CHMP requested that we address the findings from the GCP inspection and our corrective measures taken to justify that the clinical trial data are of sufficient quality to support a benefit-risk assessment. We are currently working with CHMP to address both topics and expect to receive a decision on the application in early 2020.

We plan to seek additional approvals for the use of selinexor in combination therapies to expand the patient populations that are eligible for selinexor, as well as to move selinexor towards front-line cancer therapy. We are also advancing the clinical development of selinexor in multiple solid tumor indications. ~~To date, over 2,800 patients have been treated with oral~~Oral selinexor is being evaluated in company- and investigator-sponsored clinical trials in advanced hematologic malignancies and solid tumors. Clinical trials evaluating selinexor include the Phase ~~2b STORM (~~S~~elinexor~~ T~~reatment~~ofR~~efractory~~M~~yeloma) study in multiple myeloma, the Phase~~ 1b/2 STOMP (

elinexor and Backbone

reatments

ultiple Myeloma

atients) study in combination with standard therapies in multiple myeloma, the Phase 2b SADAL (

elinexor

gainst

iffuse

ggressive

ymphoma) study in diffuse large

B-cell

lymphoma (DLBCL), the pivotal, randomized Phase 3 BOSTON (Bo~~rtezomib,~~S~~elinexor and Dexame~~t~~has~~one) study in multiple myeloma, ~~and~~ the Phase 2/3 SEAL (

linexor in

dvanced

iposarcoma) study in ~~liposarcoma.~~

~~On August 6,~~liposarcoma and the Phase 3 SIENDO (

elinexor/Placebo After Combination Chemotherapy

n Patients with advanced or recurrent

ENDO

metrial cancer) study. During 2018 and 2019, in addition to the results from the STORM study, we ~~announced~~reported positive

top-line

data from the ~~completion~~SADAL study, as well as new or updated interim data for the STOMP and SEAL studies.

Based on the positive results of the ~~rolling submission of~~SADAL study, we plan to submit a New Drug Application (NDA) to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with ~~penta-refractory multiple myeloma as a result of the positive outcome from the expanded cohort~~relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for ~~the STORM study. On October 5,~~stem cell transplantation (high dose chemotherapy with stem cell rescue), including chimeric antigen receptor modified T (CAR-T) cell therapy. In November 2018, the FDA ~~accepted~~granted fast track designation to selinexor for ~~filing~~the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. While the FDA previously agreed that the trial design and indication appear appropriate for accelerated approval, they reiterated to us in their feedback that the availability of accelerated approval will depend on the trial results and available therapies at the time of regulatory action. The FDA also has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach and, for DLBCL, recommended two randomized trials that isolate the treatment effect of selinexor for a DLBCL indication. In addition, as we experienced with our NDA ~~and also granted our request for priority review~~based on the results of Part 2 of the ~~NDA and assigned an action date of April 6, 2019 under the Prescription Drug User Fee Act (PDUFA). In its acceptance letter,~~STORM study, the FDA ~~stated that it is currently planning to hold an advisory committee meeting to discuss this NDA.~~has noted tolerability and dose optimization as review matters. We also plan to submit a ~~Marketing Authorization Application~~MAA to the ~~European Medicines Agency in early 2019~~EMA with a request for conditional approval.

We ~~expect to providetop-line~~ ~~data from~~anticipate submitting the ~~SADAL study~~NDA by the end of ~~2018,top-line~~ ~~data from~~2019 and the ~~BOSTON study in 2019 andtop-line~~ ~~data from the Phase 3 portion~~MAA during 2020.

Table of the SEAL study by the end of 2019. We are also establishing the commercial infrastructure to support a potential launch of selinexor in the United States, and we intend to work with existing and potential partners to establish such commercial infrastructure outside the United States. To date, we have financed our operations principally through private placements of our preferred stock and convertible notes, proceeds from our initial public offering and~~follow-on~~ ~~offerings of common stock and cash generated from our business development activities.~~

Contents

As of September 30, ~~2018,~~2019, we had an accumulated deficit of ~~$615.5~~$824.7 million. We had net losses of ~~$48.1~~$41.4 million and ~~$30.6~~$48.1 million for the three months ended September 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and net losses of ~~$120.2~~$150.9 million and ~~$89.9~~$120.2 million for the nine months ended September 30, 2019 and 2018, ~~and 2017,~~ respectively. WeAs of September 30, 2019, we have ~~not~~ generated ~~any revenue to date~~$12.8 million in net sales from XPOVIO, which first became commercially available in the ~~sales of any drugs.~~

We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:

United States in July 2019.

~~continue our research and preclinical and clinical development of our drug candidates;~~

~~initiate additional clinical trials for our drug candidates;~~

~~seek marketing approvals for any of our drug candidates that successfully complete clinical trials;~~

~~establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain marketing approval;~~

~~maintain, expand and protect our intellectual property portfolio;~~

~~manufacture our drug candidates;~~

~~hire additional clinical, quality control and scientific personnel;~~

~~identify additional drug candidates;~~

~~acquire orin-license~~ ~~other drugs and technologies; and~~

add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our other operations as a public company.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES

We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as “critical” because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used, which would have resulted in different financial results.

There were no changes to the critical accounting policies we identified in the ~~2017~~2018 Form

10-K,

other than ~~the adoption of ASUNo. 2014-09,~~with respect to product revenue recognition, as described ~~further~~ in Note 1 to the Condensed Consolidated Financial ~~Statements.~~ Statements included under Part I, Item 1 of this Quarterly Report on Form

10-Q.

It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies disclosed in the ~~2017~~2018 Form ~~10-K.~~

10-K,

as well as in Note 1 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form

10-Q.

RESULTS OF OPERATIONS

Comparison of the Three Months Ended September 30, ~~2018~~2019 and September 30, ~~2017~~

   Three Months Ended
September 30,
   2018    2017    $ Change    % Change
   (in thousands)
License and other revenue
   $ 239    $ —      $ 239    N/A
Operating expenses:

Research and development
   36,427    25,237    11,190    44 %
General and administrative
   12,966    5,818    7,148    123 %








Loss from operations
   (49,154 )    (31,055 )    (18,099 )    58 %
Other income, net
   1,085    428    657    154 %








Loss before income taxes
   (48,069 )    (30,627 )    (17,442 )    57 %
Income tax provision
   (14 )    (13 )    (1 )    8 %








Net loss
   $ (48,083 )    $ (30,640 )    $ (17,443 )    57 %

~~License~~2018

Three Months Ended
September 30,

2019

2018

$ Change

% Change

(in
thousands)

Revenues:





















Product revenue, net
$
12,821
$
—
$
12,821

100
%
License and other revenue

328

239

89

37
%
Operating expenses:

Cost of sales

1,013

—

1,013

100
%
Research and development

26,270

36,427

(10,157
)
(28
)%
Selling, general and administrative

25,267

12,966

12,301

95
%

Loss from operations

(39,401
)
(49,154
)
9,753

(20
)%
Other (expense) income, net

(1,946
)
1,085

(3,031
)
(279
)%

Loss before income taxes

(41,347
)
(48,069
)
6,722

(14
)%
Income tax provision

(20
)
(14
)
(6
)
43
%

Net loss
$
(41,367
) $
(48,083
) $
6,716

(14
)%

Product revenue, net.
We began to record product revenue, net in the third quarter of 2019 following the approval of XPOVIO by the FDA in July 2019 and ~~Other Revenue.~~its subsequent commercial launch in the United States. We ~~recognized~~did not generate any revenue infrom product sales prior to the three months ended September 30, ~~2018 pursuant~~2019.

Cost of Sales.

Cost of sales includes the cost of producing and distributing inventories that are related to XPOVIO product revenue in the United States during the respective period (including salary-related and stock-based compensation expenses for employees involved with XPOVIO production and distribution) and third-party royalties payable on our ~~providing~~net product revenue for XPOVIO. We began capitalizing XPOVIO inventory costs during the third quarter of ~~additional clinical supply~~2019 subsequent to ~~Biogen MA Inc. (Biogen) under~~FDA approval, as our expectation is that such costs will be recoverable through commercialization of XPOVIO. Prior to the ~~Asset Purchase Agreement (APA) with Biogen~~capitalization of XPOVIO inventory costs, such costs were recorded as ~~well as grant revenue pursuant~~research and development expenses in the period incurred. During the three months ended September 30, 2019, we recorded $1.0 million of cost of sales, including $0.7 million related to ~~a government grant arrangement~~royalties. The cost of sales during the three months ended September 30, ~~2018.~~

2019 only reflects a portion of the costs related to the manufacturing of XPOVIO and related materials, since, prior to FDA approval, these costs were expensed. The manufacturing costs of XPOVIO

on-hand

upon FDA approval were approximately $2.8 million. At September 30, 2019, we have $2.7 million of this previously expensed XPOVIO and related material
on-hand.

Research and Development Expense.

Research and development expense ~~increased~~decreased approximately ~~$11.2~~$10.2 million to $26.3 million for the three months ended September 30, 2019 from approximately $36.4 million for the three months ended September 30, ~~2018 from approximately $25.2 million for the three months ended September 30, 2017.~~2018. The ~~increase~~decrease is primarily related to:

~~an increase~~

a decrease of ~~$4.0~~$4.8 million in personnel ~~costs, primarily due to increased headcount and related onboarding~~ costs;

~~an increase~~

Table of ~~$3.4 million in consulting and professional expense related to the preparation and submission~~Contents

a decrease of ~~our NDA filing;~~

~~an increase of $2.0 million in other miscellaneous research and development costs; and~~

~~an increase of $1.8~~$2.7 million in clinical trial costs, primarily related to the selinexor ~~program.~~

program;

a decrease of $1.8 million in consulting and professional costs;

a decrease of $0.6 million in miscellaneous costs; and

a decrease of $0.3 million in travel costs.

We expect our research and development ~~expenses~~expense to ~~continue to increase~~be relatively consistent for the ~~full year 2018~~final quarter of 2019 as compared ~~with~~to the ~~prior year~~third quarter of 2019 as we ~~continue~~moderate our spending on our development programs and clinical trials, ~~including the continued~~while continuing clinical development of selinexor in our lead indications with a focus on regulatory submissions for selinexor. On August 6, 2018, we announced the completion of the rolling submission of an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with penta-refractory multiple myeloma as a result of our positive outcome from the expanded cohort of the STORM study. On October 5, 2018, the FDA accepted for filing our NDA. We also plan to submit a Marketing Authorization Application to the European Medicines Agency in early 2019 with a request for conditional approval.

Selling, General and Administrative Expense.~~General~~

Selling,

eneral and administrative expense increased approximately ~~$7.1~~$12.3 million to $25.3 million for the three months ended September 30, 2019 from approximately $13.0 million for the three months ended September 30, ~~2018 from approximately $5.8 million for the three months ended September 30, 2017.~~2018. The increase is primarily related to:

an increase of ~~$2.5~~$7.5 million in personnel costs, primarily due to increased headcount and related onboarding ~~costs;~~

costs associated with building our commercial team in connection with the U.S. commercial launch of XPOVIO;

an increase of ~~$1.5~~$3.1 million in commercial related activities;

an increase of ~~$1.5~~$1.9 million in costs related to corporate training, travel and corporate events; and

an increase of $0.3 million in facility costs and information technology infrastructure costs; offset by

a decrease of $0.5 million in consulting and professional ~~costs;~~

costs.

~~an increase of $1.0 million in occupancy costs; and~~

~~an increase of $0.5 million in other administrative costs.~~

We expect our selling, general and administrative expenses to ~~increase in~~remain consistent for the ~~future in~~remainder of 2019 to support of our expanding operating and commercial activities, particularly following the accelerated approval of XPOVIO by the FDA in July 2019 and ~~operating activities.~~

commercial launch shortly thereafter.

Other Income (Expense), net.

Other (expense) income, net ~~increased approximately $0.7~~decreased from $1.1 million ~~to $1.1 million~~of other income, net for the three months ended September 30, 2018 ~~from approximately $0.4~~to $1.9 million of other expense, net for the three months ended September 30, ~~2017.~~2019. The ~~increase~~decrease is primarily due to ~~increased investment returns resulting from a general~~$3.1 million of interest expense related to the issuance of our 3.00% convertible senior notes due 2025 (Notes) in October 2018.

We expect interest expense to increase in ~~interest rates~~the fourth quarter of 2019 and ~~an increase in~~beyond, related to the issuance of our ~~investment balances as a result~~deferred royalty obligation.

Table of ~~thefollow-on~~ ~~offering in May 2018.~~

Contents

Comparison of the Nine ~~Months~~months Ended September 30, ~~2018~~2019 and September 30, ~~2017~~

   Nine Months Ended
September 30,
   2018    2017    $ Change    % Change
   (in thousands)
License and other revenue
   $ 30,130    $ 71    $ 30,059    N/A
Operating expenses:

Research and development
   122,482    72,440    50,042    69 %
General and administrative
   30,076    18,717    11,359    61 %








Loss from operations
   (122,428 )    (91,086 )    (31,342 )    34 %
Other income, net
   2,240    1,196    1,044    87 %








Loss before income taxes
   (120,188 )    (89,890 )    (30,298 )    34 %
Income tax provision
   (9 )    (54 )    45    (83 )%








Net loss
   $ (120,197 )    $ (89,944 )    $ (30,253 )    34 %

2018

Nine months Ended
September 30,

        2019

        2018

        $ Change

        % Change

(in thousands)

Revenues:

















Product revenue, net
$
12,821
$
—
$
12,821

100
%
License and other revenue

9,976

30,130

(20,154
)
(67
)%
Operating expenses:

Cost of sales

1,013

—

1,013

100
%

Research and development

90,761

122,482

(31,721
)
(26
)%
Selling, general and administrative

77,032

30,076

46,956

156
%

Loss from operations

(146,009
)
(122,428
)
(23,581
)
19
%
Other (expense) income, net

(4,896
)
2,240

(7,136
)
(319
)%

Loss before income taxes

(150,905
)
(120,188
)
(30,717
)
26
%
Income tax provision

(38
)
(9
)
(29
)
322
%

Net loss
$
(150,943
) $
(120,197
) $
(30,746
)
26
%

Product revenue, net.
We began to record product revenue, net in the third quarter of 2019 following the approval of XPOVIO by the FDA in July 2019 and its subsequent commercial launch in the United States. We did not generate any revenue from product sales prior to the three months ended September 30, 2019.

License and Other Revenue. ~~Revenue~~

During the nine months ended September 30, 2019, we recognized $9.4 million in revenue pursuant to a license arrangement with Antengene Therapeutics Limited, $0.2 million in revenue for clinical supply provided to various partners, as well as $0.3 million in revenue pursuant to a government grant arrangement. During the nine months ended September 30, 2018, ~~was $30.1~~we recognized $10.0 million ~~compared~~in revenue pursuant to ~~$0.1~~an asset purchase agreement with Biogen MA Inc. for the sale of

KPT-350

and $19.9 million in revenue primarily as a result of a license arrangement with Ono Pharmaceutical Co., Ltd.

Cost of Sales.

Cost of sales includes the cost of producing and distributing inventories that are related to XPOVIO product revenue in the United States during the respective period (including salary-related and stock-based compensation expenses for employees involved with XPOVIO production and distribution) and third-party royalties payable on our net product revenue for XPOVIO. We began capitalizing XPOVIO inventory costs during the third quarter of 2019 subsequent to FDA approval and our expectation that such costs will be recoverable through commercialization of XPOVIO. Prior to the capitalization of XPOVIO inventory costs, such costs were recorded as research and development expenses in the period incurred. During the nine months ended September 30, 2019, we recorded $1.0 million of cost of sales, including $0.7 million related to royalties. The cost of sales during the nine months ended September 30, 2019 only reflects a portion of the costs related to the manufacturing of XPOVIO and related materials, since, prior to FDA approval, these costs were expensed. The manufacturing costs of XPOVIO

on-hand

upon approval were approximately $2.8 million. At September 30, 2019, we have $2.7 million of this previously expensed XPOVIO and related material

on-hand.

Research and Development Expense.

Research and development expense decreased approximately $31.7 million to $90.8 million for the nine months ended September 30, 2017. We recognized revenue pursuant to the APA with Biogen, a license arrangement with Ono Pharmaceutical Co., Ltd. (Ono) and a government grant arrangement during the nine months ended September 30, 2018, in comparison to only recognizing revenue pursuant to a government grant during the nine months ended September 30, 2017.

~~Research and Development Expense.~~ ~~Research and development expense increased~~2019 from approximately ~~$50.0 million to~~ $122.5 million for the nine months ended September 30, ~~2018 from approximately $72.4 million for the nine months ended September 30, 2017.~~2018. The ~~increase~~decrease is primarily related to:

~~an increase~~

a decrease of ~~$21.6~~$15.3 million in clinical trial costs, primarily related to the selinexor program;

~~an increase~~

a decrease of ~~$11.2~~$9.2 million in consulting and professional ~~expense related to the preparation~~costs;

a decrease of $7.5 million in personnel costs; and ~~submission~~

a decrease of ~~our NDA filing;~~

$0.6 million in travel costs; offset by

an increase of ~~$9.0~~$0.9 million in facility costs and information technology infrastructure costs.

Selling, General and Administrative Expense.

Selling, general and administrative expense increased approximately $47.0 million to $77.0 million for the nine months ended September 30, 2019 from approximately $30.1 million for the nine months ended September 30, 2018. The increase is primarily related to:

an increase of $28.8 million in personnel costs, primarily due to increased headcount and related onboarding ~~costs;~~

costs associated with building our commercial team in preparation for and in connection with the U.S. commercial launch of XPOVIO;

Table of Contents

an increase of ~~$6.3~~$9.5 million in commercial related activities;

an increase of $5.7 million in costs related to corporate training, travel and corporate events;

an increase of $3.6 million in facility costs and information technology infrastructure costs; and

an increase of $0.2 million in consulting and professional costs; offset by

a decrease of $0.8 million in miscellaneous costs.

Other Income (Expense), net.

Other (expense) income, net decreased from $2.2 million of other ~~research and development costs; and~~

~~an increase of $2.0 million related to our obligation to pay a portion of upfront fees received from certain of our license agreements to a third party.~~

~~General and Administrative Expense.~~~~General and administrative expense increased approximately $11.4 million to $30.1 million~~income, net for the nine months ended September 30, 2018 ~~from approximately $18.7~~to $4.9 million of other expense, net for the nine months ended September 30, ~~2017.~~2019. The ~~increase is primarily related to:~~

~~an increase in consulting and professional costs of $3.7 million, primarily related to commercial readiness and compliance;~~

~~an increase of $3.1 million in personnel costs, primarily due to increased headcount and related onboarding costs;~~

~~an increase of $1.9 million in commercial related activities;~~

~~an increase of $1.5 million in occupancy costs; and~~

~~an increase of $1.1 million in other administrative costs.~~

~~Other Income, net.~~ Other income, net, increased approximately $1.0 million to $2.2 million for the nine months ended September 30, 2018 from approximately $1.2 million for the nine months ended September 30, 2017. The increasedecrease is primarily due to $9.2 million of interest expense related to the issuance of the Notes in October 2018, offset by a $2.1 million increase in interest income due to increased ~~investment~~ returns resulting from a general increase in interest rates and ~~an increase in our~~higher investment balances.

LIQUIDITY AND CAPITAL RESOURCES

Sources of Liquidity

During the third quarter of 2019, we began generating revenues from drug sales, as XPOVIO first became commercially available in the United States in July 2019. We have had limited revenues to date ~~we have not generated any material revenues. We~~from product sales and have financed our operations ~~to date~~ principally through private placements of our preferred stock, ~~and convertible notes,~~ proceeds from our initial public offering andfollow-on offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the Revenue Interest Agreement (as defined below), and cash generated from our business development activities.

~~As of~~

At September 30, ~~2018, we had $211.6~~2019, our principal source of liquidity was $269.6 million inof cash, cash equivalents and ~~short-~~investments. We have had recurring losses and ~~long-term investments compared to $175.9~~incurred a loss of $150.9 million for the nine months ended September 30, 2019. Net cash used in operations for the nine months ended September 30, 2019 was $151.3 million. We expect that cash, cash equivalents and ~~short-~~investments at September 30, 2019 will be sufficient to fund our current operating plans and ~~long-term investments~~capital expenditure requirements for at least twelve months from the date of issuance of the financial statements contained in this Quarterly Report on Form

10-Q,

during which time we plan to enhance and support the commercial infrastructure for the sale of XPOVIO in the United States that began in July 2019.

On September 14, 2019, we entered into a Revenue Interest Financing Agreement (the “Revenue Interest Agreement”) with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P (“HCR”). Pursuant to the Revenue Interest Agreement, HCR paid us $75.0 million (the “First Investment Amount”), less certain transaction expenses, at the initial closing, which occurred on September 27, 2019, as disclosed in Note 12 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of ~~December 31, 2017.~~

this Quarterly Report on Form 10-Q.

On October 16, 2018, we completed an offering of $150.0 million aggregate principal amount of ~~our 3.00% convertible senior notes due 2025 (the Notes).~~the Notes. In addition, on October 26, 2018, we issued an additional $22.5 million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the sale of the Notes was ~~approximately~~ $166.9 million, after deducting the initial purchasers’ discounts and commissions and ~~estimated~~actual offering expenses payable by us.

In August 2018, we entered into an open market sale agreement (Open Market Sale Agreement) with Jefferies LLC, as agent, relating to an~~“at-the-market”~~ ~~offering,~~ “at the market offering”, pursuant to which we may issue and sell shares of our common stock, having an aggregate offering price of up to $75.0 million. ~~To date there have been no sales pursuant to~~As of October 31, 2019, we had sold an aggregate of 1,634,451 shares under the Open Market Sale ~~Agreement.~~

Agreement, for net proceeds of approximately $14.6 million, all of which were sold during the third quarter of 2019.

On May 7, 2018, we completed a

follow-on

offering under our shelf registration statement onForm

S-3 ~~(File~~

(File No.

333-222726)

pursuant to which we issued an aggregate of 10,525,424 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $14.75 per share. We received aggregate net proceeds of approximately $145.7 million from the offering after deducting the underwriting discounts and commissions and other offering expenses.

~~On May 23,~~

During the years ended December 31, 2018 ~~(Antengene Effective Date)~~and 2017, we received $44.6 million in upfront payments under our arrangements with Anivive Lifesciences, Inc., ~~we entered into a License Agreement (Antengene Agreement) with~~Ono Pharmaceutical Co., Ltd., Biogen MA Inc., and Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (Antengene) and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People’s Republic of China, pursuant to which we ~~granted Antengene exclusive rights to develop and commercialize, at its own cost, selinexor, eltanexor andKPT-9274,~~ ~~each for the diagnosis, treatment and/or prevention of all human oncology indications (Oncology Field), as well as verdinexor for the diagnosis, treatment and/or prevention of certain humannon-oncology~~ ~~indications(Non-Oncology~~ Field). We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the Oncology Field in mainland China and Macau and licensed the development and commercial rights to Antengene for~~KPT-9274~~ ~~in the Oncology Field, as well as verdinexor in theNon-Oncology~~ Field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Under the terms of the Antengene Agreement, we received an upfront cash payment of $11.7 million and are also entitled to receive up to $105.0 million in milestone payments from Antengene if certain development goals are achieved and up to $45.0 million in milestone payments from Antengene if certain sales milestones are achieved. We are further eligible to receive tiered double-digit royalties based on future net sales of selinexor and eltanexor in China and Macau, and tiered single- to double-digit royalties based on future net sales of~~KPT-9274~~ ~~and verdinexor in the licensed territories. Antengene’s obligations under the Antengene Agreement have been guaranteed by Antengene Corporation Co. Ltd.~~

~~We are party to a research agreement with the Multiple Myeloma Research Foundation (MMRF). Under this research agreement, we are obligated to make certain payments to MMRF, including if weout-license~~ ~~selinexor. The terms of this research agreement do not apply to eltanexor,KPT-9274~~ or verdinexor. During the quarter ended September 30, 2018, we paid approximately $0.3 million of the Antengene upfront cash payment to MMRF, which reflects the amount owed to MMRF under the Antengene License Agreement transaction. In connection with the transaction pursuant to the license agreement with Ono (Ono License Agreement), we paid to MMRF approximately $2.0 million of the upfront cash payment from Ono in the year ended December 31, 2017. We will be obligated to pay MMRF a percentage of any milestone payments from Antengene and Ono and a~~mid-single-digit~~ percentage of any royalty payments from Antengene and Ono. Such payments are recorded within research and development expense in our condensed consolidated statement of operations. As of September 30, 2018, a maximum of $3.8 million in future obligations are remaining under the MMRF agreement.

~~On January 24, 2018, we entered into the APA with Biogen, pursuant to which Biogen acquired exclusive worldwide rights to develop and commercialize our oral SINE compoundKPT-350~~ ~~and certain related assets with an initial focus in amyotrophic lateral sclerosis (ALS). Under the terms of the APA, Biogen purchasedKPT-350~~ ~~and certain related assets and assumed certain related liabilities. We received aone-time~~ upfront payment of $10.0 million from Biogen and are eligible to receive additional payments of up to $207.0 million based on the achievement by Biogen of future specified development and commercial milestones. We are also eligible to receive tiered royalty payments that reach low double digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a~~country-by-country~~ ~~basis.~~

On October 11, 2017 (Ono Effective Date), we entered into the Ono License Agreement, pursuant to which we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (Ono Territory). Pursuant to the terms of the Ono License Agreement, we received an upfront payment of ¥2.5 billion (US$21.9 million on the date received), and could receive up to ¥10.15 billion (US$90.5 million at the exchange rate as of the Ono Effective Date) in milestone payments, if certain development goals ~~are achieved~~ and ~~up to ¥9.0 billion (US$80.2 million at the exchange rate as of the Ono Effective Date) in milestone payments if certain~~ sales milestones are achieved, as well as ~~a low double-digit royalty based~~royalties on future net sales of ~~selinexor~~the licensed and ~~eltanexor~~sold products in the ~~Ono Territory.~~

~~In December 2015, we entered into a sales agreement (as amended on November 7, 2016 and December 1, 2017, the Sales Agreement) with Cantor Fitzgerald & Co., as sales agent (Cantor), relating to an“at-the-market”~~ ~~offering, pursuant to which we issued and sold 9,172,159 shares~~territories under such arrangements.

Table of ~~our common stock for net proceeds of approximately $89.1 million. On August 2, 2018, we delivered written notice to Cantor terminating the Sales Agreement effective on August 12, 2018.~~

We expect that our cash, cash equivalents and short- and long-term investments as of September 30, 2018, totaling $211.6 million, in addition to the estimated $166.9 million of net proceeds that we raised in the private placement of the Notes in October 2018, will be sufficient to fund our current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements contained in this~~Form 10-Q~~ while we are establishing the commercial infrastructure for a potential launch of selinexor in the United States. Our need for additional funds thereafter may be partially offset by: (i) cash generated from sales of drugs if selinexor receives accelerated approval and we successfully commercialize selinexor in the United States and (ii) from potential future payments related to collaboration or license arrangements.

Contents

Cash Flows

The following table provides information regarding our cash flows:

   Nine Months Ended
September 30,
   2018    2017
   (in thousands)
Net cash used in operating activities
   $ (110,945 )    $ (68,179 )
Net cash (used in) provided by investing activities
   (4,554 )    20,009
Net cash provided by financing activities
   148,333    52,786
Effect of exchange rate changes
   (9 )    181




Net increase in cash, cash equivalents and restricted cash
   $ 32,825    $ 4,797

Nine months Ended
September 30,

2019

2018

(in thousands)
Net cash used in operating activities


$
(151,333
)





$
(110,945
)

Net cash provided by (used in) investing activities

111,969

(4,554
)
Net cash provided by financing activities

89,369

148,333

Effect of exchange rate changes

(26
)
(9
)

Net increase in cash, cash equivalents and restricted cash
$
49,979
$
32,825

Operating activities.

The net cash used in operating activities in both periods resulted primarily from our net losses adjusted for

non-cash

charges and changes in the components of working capital. The increase in cash used in operating activities during the nine months ended September 30, ~~2018,~~2019, compared to the nine months ended September 30, ~~2017,~~2018, was primarily driven by ~~an increase in~~ our ~~net~~increased loss due to an increase in our operating expenses and a decrease of approximately $9.1 million in deferred revenue, which was primarily attributable to recognizing $19.7 million of the upfront payment received under the Ono License Agreement in 2017, partially offset by the $11.7 million upfront payment received under the Antengene License Agreement in June 2018.

from operations during that period.

Investing activities.

The net cash ~~used in~~provided by (used in) investing activities during the nine months ended September 30, ~~2018,~~2019, compared to the nine months ended September 30, ~~2017,~~2018, primarily reflects an increase in maturity of investments of $108.1 million offset by a decrease in purchases of ~~investments and property and equipment of $23.6 million and $1.3 million, respectively.~~

$7.3 million.

Financing activities.

The net cash provided by financing activities for the nine months ended September 30, ~~2018,~~2019, compared to the nine months ended September 30, ~~2017,~~2018, reflects ~~an increase~~a decrease of ~~$95.5~~$59.0 million primarily related to the net proceeds of $73.7 million from the execution of the Revenue Interest Agreement with HCR in September 2019 and the net proceeds of $14.6 million from the sale of Open Market Shares under the Open Market Sale Agreement during the third quarter of 2019, compared to the net proceeds of $145.7 million from ourfollow-on offering in May ~~2018 as compared to net proceeds of $37.9 million from ourfollow-on~~ ~~offering in April 2017 and net proceeds of $14.4 million from the sale of shares of common stock in April 2017 as part of our“at-the-market”~~ ~~offering under the Sales Agreement.~~

2018.

Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to commercialize XPOVIO and continue the clinical trials of, and ~~assuming positive results of our clinical trials and based on regulatory feedback, if and when~~as we seek marketing approval for ~~selinexor and~~ our ~~other~~ drug candidates. In addition, ~~if we obtain marketing approval for any of our drug candidates,~~ we expect to

incur significant commercialization expenses related to ~~drug~~ sales, marketing, manufacturing and distribution of any of our drug candidates for which we obtain marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any

such drug. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or ~~future~~ commercialization efforts.

Our need for additional funds thereafter may be partially offset by: (i) cash generated from sales of drugs if selinexor receives accelerated approval and we successfully commercialize selinexor in the United States and (ii) from potential future payments related to collaboration or license arrangements. However, our future capital requirements will depend on many factors, including:

revenue generated from commercial sales of XPOVIO;

costs related to the ~~progress~~sales and ~~results~~marketing of ~~our current and planned clinical trials of selinexor;~~

XPOVIO;

~~the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;~~

the costs, timing and outcome of regulatory review of our drug candidates;

~~our ability to establish and maintain collaborations on favorable terms, if at all;~~

~~the success of any collaborations that we may enter into with third parties;~~

~~the extent to which we acquire orin-license~~ ~~other drugs and technologies;~~

the costs of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we ~~seek~~receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;

the amount of revenue ~~if any,~~ received from commercial sales of our drug candidates ~~should any~~for which we receive marketing approval;

the progress and results of our current and planned clinical trials of selinexor;

the scope, progress, results and costs of drug ~~candidates receive marketing approval;~~discovery, preclinical development, laboratory testing and

clinical trials for our other drug candidates;

our ability to establish and maintain collaborations on favorable terms, if at all;

the success of any collaborations that we may enter into with third parties;

the extent to which we acquire or

in-license

other drugs and technologies;

Table of Contents

the costs associated with legal activities, including litigation, arising in the course of business activities and our ability to prevail in any such legal disputes; and

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

Identifying potential drug candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to ~~complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales.~~complete. In addition, our drug candidates ~~if approved,~~for which we receive marketing approval may not achieve commercial success. Our ~~commercial revenues, if any, will be derived~~ability to become and remain profitable depends on our ability to generate revenue. While we began to generate revenue from the sales of ~~drugs that~~XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not ~~become commercially available in the near term or~~achieve profitability for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. ~~In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.~~

Contractual Obligations

As of September 30, ~~2018, there~~2019, we have contractual obligations under the Revenue Interest Agreement with HCR, as disclosed in Note 12 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no other material changes to our contractual obligations described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the ~~2017~~2018 Form ~~10-K,~~ ~~except as described below.~~

In February 2018 and June 2018, we executed separate amendments to the operating lease at our Newton, Massachusetts facility. In aggregate, these amendments increased our leased space by 52,335 square feet and extended the term of the lease from September 30, 2022 to September 30, 2025.

~~As of September 30, 2018, the total minimum future rent payments under the lease agreements are as follows (in thousands):~~

Remainder of 2018
   $ 433
2019
   2,983
2020
   3,208
2021
   3,277
2022
   3,447
2023
   3,718
Thereafter
   6,735


Total future minimum lease payments
   $ 23,801


10-K.

On October 16, 2018, we completed an offering of $150.0 million aggregate principal amount of Notes. In addition, on October 26, 2018, we issued an additional $22.5 million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes are our senior unsecured obligations and bear interest at a rate of 3.00% per year payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019. The Notes will mature on October 15, 2025, unless earlier converted, redeemed or repurchased in accordance with their terms. Upon conversion of the Notes, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of common stock, at our election (subject to, and in accordance with, the settlement provisions of the indenture).

OFF-BALANCE

SHEET ARRANGEMENTS

We did not have during the periods presented, and we do not currently have, any

off-balance

sheet arrangements, as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents, restricted cash and investments of ~~$212.3~~$270.3 million as of September 30, ~~2018.~~2019. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio.

We do not believe our cash, cash equivalents, restricted cash and investments have significant risk of default or illiquidity. While we believe our cash, cash equivalents and investments do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in securities at one or more financial institutions that are in excess of federally insured limits. ~~Give~~Given the potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits and investments.

We are also exposed to market risk related to ~~change~~changes in foreign currency exchange rates. We contract with contract research organizations and contract manufacturing organizations that are located in Canada and Europe, which are denominated in foreign currencies. We also contract with a number of clinical trial sites outside the United States, and our budgets for those studies are frequently denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (principal executive officer) and ~~Executive~~Senior Vice President, Chief Financial Officer and Treasurer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of September 30, ~~2018.~~2019. The term “disclosure controls and procedures,” as defined inRules

13a-15(e) ~~and15d-15(e)~~

and

15d-15(e)

under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to ~~the Company’s~~our management, including ~~its~~our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies ~~its~~our judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of

Table of Contents

September 30, ~~2018,~~2019, our Chief Executive Officer and our ~~Executive~~Senior Vice President, Chief Financial Officer and Treasurer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

During the fiscal quarter ended September 30, 2019, we began generating product revenue from the sale of XPOVIO in the United States. We consider the accounting for our net product revenue to be material to the results of operations for the three and nine months ended September 30, 2019, and believe that the additional internal controls and procedures related to the accounting for net product revenue under ASC 606,

Revenue from Contracts with Customers,

have a material effect on our internal control over financial reporting. No ~~change~~other changes in our internal control over financial reporting occurred during the fiscal quarter ended September 30, ~~2018~~2019 that ~~has~~have materially affected, or isare reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We were recently named as a defendant in securities class action litigation in the U.S. District Court for the District of Massachusetts. A complaint was filed on July 23, 2019, by the Allegheny County Employees’ Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. A second complaint was filed by Heather Mehdi on September 17, 2019, against the same defendants with the exception of the underwriters. The two complaints are related and we expect them to be consolidated by the court. Both complaints allege violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and seek unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys’ and expert fees; unspecified recessionary damages; and such equitable/injunctive relief or other relief as the court may deem just and proper. We have reviewed the allegations and believe they are without merit. We intend to defend vigorously against this litigation.

Item 1A. Risk Factors.

Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report onForm
10-Q
and in other documents that we file with the SEC, in evaluating ~~the Company~~us and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks ~~facing the Company.~~we face. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations.

Risks Related to the Discovery, Development and Commercialization of Our Drugs and Drug Candidates

We depend heavily on the success of ~~our lead drug candidate selinexor(KPT-330),~~ ~~which is currently in clinical trials. Our clinical trials of selinexor may not be successful.~~XPOVIO
®
(selinexor). If we are unable to successfully commercialize XPOVIO or successfully develop selinexor for additional indications, or if we experience significant delays in doing so, our business will be materially harmed.

We have invested a significant portion of our efforts and financial resources in the research and development of our lead drug candidate, selinexor. Our ability to generate revenues from the sale of drugs that treat cancer and other diseases in humans will depend heavily on the successful development, regulatory approval and ~~eventual~~ commercialization of selinexor.

~~We cannot commercialize drug candidates in the United States without first obtaining regulatory approval for the drug from~~ On July 3, 2019, the U.S. Food and Drug Administration, or ~~FDA; similarly, we cannot commercialize~~FDA, granted accelerated approval for XPOVIO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Our ability to generate product revenues will depend on our successful commercialization of XPOVIO and our obtaining additional marketing approvals for, and successfully commercializing, selinexor for additional indications.

The commercial success of XPOVIO and the successful clinical development of selinexor and our other drug candidates ~~outside~~will depend on several factors, including the following:

successful commercialization of XPOVIO in the United States, ~~without obtaining regulatory~~including establishing and maintaining sales, marketing and distribution capabilities for XPOVIO;

the consistency of any new data we collect and analyses we conduct with prior results, whether they support a favorable safety, efficacy and effectiveness profile of XPOVIO and any potential impact on our FDA accelerated approval ~~from similar regulatory authorities outside~~and/or FDA package insert for XPOVIO;

Table of Contents

our ability to comply with FDA post-marketing requirements and commitments, including through successfully conducting additional studies that confirm clinical efficacy, effectiveness and safety of XPOVIO and acceptance of the ~~United States. Even if selinexor or another drug candidate were to successfully obtain approval from~~same by the FDA and~~non-U.S.~~ ~~regulatory authorities, any~~ medical community since continued approval ~~might contain significant limitations related to use restrictions~~ for ~~specified age groups, warnings, precautions or contraindications, or~~this indication may be ~~subject~~contingent upon verification of a clinical benefit in confirmatory trials;

acceptance of XPOVIO and, if and when approved, our drug candidates by patients, the medical community and third-party payors;

obtaining and maintaining coverage, adequate pricing and adequate reimbursement by third-party payors, including government payors, for XPOVIO and our drug candidates;

successful completion of preclinical studies;

acceptance by the FDA of investigational new drug applications, or INDs, for our drug candidates prior to ~~burdensome post-approval study~~commencing clinical studies;

successful enrollment in, and completion of, clinical trials, including demonstration of a favorable risk-benefit ratio;

receipt of marketing approvals from applicable regulatory authorities;

establishing commercial manufacturing capabilities or ~~risk management requirements.~~ making arrangements with third-party manufacturers;

obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;

establishing sales, marketing, manufacturing and distribution capabilities to commercialize any drug candidates for which we may obtain marketing approval, whether alone or in collaboration with others;

launching commercial sales of any drug candidates for which we obtain marketing approval, whether alone or in collaboration with others;

effectively competing with other therapies;

maintaining an acceptable safety profile of the drugs following approval;

enforcing and defending intellectual property rights and claims; and

maintaining and growing an organization of scientists and business people, including collaborators, who can develop and commercialize our drug candidates.

If we ~~are unable to obtain regulatory approval for selinexor in~~do not achieve one or more ~~jurisdictions,~~of these factors in a timely manner or ~~any approval contains~~at all, we could experience significant ~~limitations, we may not be able to obtain sufficient funding~~delays or ~~generate sufficient revenue to continue the development, marketing and/or commercialization of selinexor or any other drug candidate that we may discover,in-license,~~ develop or acquire in the future. Furthermore, even if we obtain regulatory approval for selinexor, we will still need to develop a commercial organization, or collaborate with third parties, for the commercialization of selinexor, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we or our commercialization collaborators are unablean inability to successfully commercialize ~~selinexor, we may not be able to generate sufficient revenues to continue~~XPOVIO or our drug candidates, which would materially harm our business.

The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or
non-U.S.
regulatory authorities.

~~We currently have no drugs approved for sale and we cannot guarantee that we will ever have marketable drugs.~~

Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our drug candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early-stage clinical trials does not mean that future larger registration clinical trials will be successful because drug candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and

non-U.S.

regulatory authorities despite having progressed through early-stage clinical trials. Drug candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials, and interim results of a clinical trial are not necessarily indicative of final results. ~~For example, we releasedtop-line~~ results from the expansion of our Selinexor Treatment of Refractory Myeloma (STORM) study in April and September 2018. While we believe the results we have observed to date are positive, there can be no assurance that results that we believe to be positive will be viewed similarly by regulatory authorities or as sufficient to support a request for registration.

In addition, the design of a clinical trial can determine whether its results will support approval of a drug, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and conduct a clinical trial to support regulatory approval. Further, if our drug candidates are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.

In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same drug candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase 2, Phase 3 or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to market our drug candidates.

Table of Contents

Further, our drug candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or other registration trials. The FDA or

non-U.S.

regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a drug candidate even after providing a positive opinion on, or otherwise reviewing and providing comments or advice on, a protocol for a clinical trial that has the potential to result in approval by the FDA or another regulatory authority. In addition, any of these regulatory authorities may also approve a drug candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. Furthermore, the FDA or ~~other~~

non-U.S.

regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our drug candidates.

To date, we have had several discussions with the FDA and

non-U.S.

regulatory authorities regarding the design of our later phase clinical trials for selinexor, including the BOSTON, STORM, SADAL and SEAL ~~studies currently underway.~~studies. In July 2019, the FDA approved, under accelerated approval based on response rate from the STORM study, XPOVIO in combination with dexamethasone for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. We plan to seek additional regulatory approvals of selinexor in North America and Europe in each indication with respect to which such later phase clinical trial is being conducted and with respect to which we receive positive results that may support full or accelerated approval, as the case may be. On August 6, 2018, we announced the completion of the rolling submission of an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with penta-refractory multiple myeloma. On October 5, 2018, the FDA accepted for filing our NDA and also granted our request for priority review of the NDA and assigned an action date of April 6, 2019 under the Prescription Drug User Fee Act, or PDUFA. In its acceptance letter, the FDA stated that it is currently planning to hold an advisory committee meeting to discuss this NDA. We or our current or future partners may also seek such approvals in other geographies. We cannot be certain that we will commence additional later phase trials or complete ongoing later phase trials as anticipated. Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and well-controlled clinical studies, and, with respect to approval in the United States, to the satisfaction of the FDA, that the drug candidate is safe and effective for use for that target indication. There is no assurance that the FDA or

non-U.S.

regulatory authorities would consider our current and planned later phase clinical trials to be sufficient to serve as the basis for filing for approval or to gain approval of selinexor for any indication. The FDA and

non-U.S.

regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that selinexor is safe and effective. If we are required to conduct additional clinical trials of selinexor prior to approval, including additional earlier phase clinical trials that may be required prior to commencing any later phase clinical trials, or additional clinical trials following completion of our current and planned later phase clinical trials, we will need substantial additional funds, and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.

The results to date in preclinical and early clinical studies conducted by us or our academic collaborators and in Phase 1 and Phase 2 clinical trials that we are currently conducting include the response of tumors to selinexor. We expect that in any later phase clinical trial where patients are randomized to receive either selinexor on the one hand, or standard of care, supportive care or placebo on the other hand, the primary endpoint will be either progression free survival, meaning the length of time on treatment until objective tumor progression, or overall survival, while the primary endpoint in any later phase clinical trial that is not similarly randomized may be different. For example, the primary endpoint of our Phase 2/3 SEAL study, the clinical trial of selinexor in patients with dedifferentiated liposarcoma, and a primary endpoint of our Phase 3 BOSTON study, the clinical trial of selinexor in combination with Velcade (bortezomib) and dexamethasone in patients with multiple myeloma, is progression free survival. In some instances, the FDA and other regulatory bodies have accepted overall response rate as a surrogate for a clinical benefit and have granted regulatory approvals based on this or other surrogate endpoints. Overall response rate is defined as the portion of patients with tumor size reduction of a predefined amount for a minimum time period. For some types of cancer, we may use overall response rate as a primary endpoint, as we ~~are doing~~did in our SADAL study and our STORM study. These clinical trials will not be randomized against control arms and the primary endpoints of these trials are overall response rate. If selinexor does not demonstrate sufficient overall response rates in these indications, or any other indication for which a clinical trial has overall response rate as a primary endpoint, or if the FDA or

non-U.S.

regulatory authorities do not deem overall response rate a sufficient endpoint, or deem a positive overall response rate to be insufficient, it will likely not be approved for that indication based on the applicable study.

~~We are early~~ With respect to the STORM and SADAL studies, the FDA has reiterated to us that it recommends, in ~~our development efforts~~general, a randomized trial with a limited number of drug candidates in human clinical development. If we are unable to successfully develop and commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed.

~~We are early in our development efforts and have four drug candidates, selinexor, verdinexor, eltanexor andKPT-9274,~~ ~~in clinical development for treatment of human diseases. The success of these and any of our other drug candidates will depend on several factors, including the following:~~

~~successful completion of preclinical studies;~~

~~acceptance by the FDA of investigational new drug applications, or INDs, for our drug candidates prior to commencing clinical studies;~~

~~successful enrollment in, and completion of, clinical trials, including demonstration of a favorable risk-benefit ratio;~~

~~receipt of marketing approvals from applicable regulatory authorities;~~

~~establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;~~

~~obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;~~

~~establishing sales, marketing, manufacturing and distribution capabilities to commercialize any drugs for which we may obtain marketing approval;~~

~~launching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others;~~

~~acceptance of the drugs, if and when approved, by patients, the medical community and third-party payors;~~

~~effectively competing with other therapies;~~

~~obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for any approved drugs;~~

~~maintaining~~progression-free survival endpoint as an ~~acceptable safety profile of the drugs following approval;~~

initial registration approach.

~~enforcing and defending intellectual property rights and claims; and~~

~~maintaining and growing an organization of scientists and business people, including collaborators, who can develop and commercialize our drug candidates.~~

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm our business.

Our approach to the discovery and development of drug candidates that target Exportin 1, or XPO1, is unproven, and we do not know whether we will be able to develop any drugs of commercial value. If selinexor is unsuccessful in proving that drug candidates targeting XPO1 have commercial value or experiences significant delays in doing so, our business may be materially harmed.

Our SINE compounds inhibit the nuclear export protein XPO1. We believe that no currently approved cancer treatments are selectively targeting the restoration and increase in the levels of multiple tumor suppressor proteins in the nucleus. Despite promising results to date in preclinical studies of selinexor that we have conducted and in Phase 1 and Phase 2 clinical trials of selinexor conducted by us or our academic collaborators, we may not succeed in demonstrating safety and efficacy of SINE compounds in our current and future human clinical trials. Any drug candidates that we develop may not effectively prevent the exportation of tumor suppressor and/or growth regulatory proteins from the nucleus in humans with a particular form of cancer. If selinexor is unsuccessful in supporting the hypothesis that drug candidates targeting the regulation of intracellular transport of XPO1 have commercial value or experiences significant delays in doing so, our business may be materially harmed and we may not be able to generate sufficient revenues to continue our business.

We may not be successful in our efforts to identify or discover additional potential drug candidates.

Part of our strategy involves identifying and developing drug candidates to build a pipeline of novel drug candidates. Our drug discovery efforts may not be successful in identifying compounds that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including:

the research methodology used may not be successful in identifying potential drug candidates;

Table of Contents

potential drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; or

potential drug candidates may not be effective in treating their targeted diseases.

Research programs to identify new drug candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful.

If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain revenues from sale of drugs in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.

Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of ~~our~~such drug candidates.

Before obtaining marketing approval from regulatory authorities for the sale of our drug candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later stage clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, certain data from our Phase 1 and Phase 2 clinical trials of selinexor to date are based on unaudited data provided by our clinical trial investigators. An audit of this data may change the conclusions drawn from this unaudited data provided by our clinical trial investigators indicating less promising results than we currently anticipate. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their ~~drugs.~~

drug candidates. Furthermore, the failure of any drug candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other drug candidates and/or cause the FDA or other regulatory authorities to require additional testing before any of our drug candidates are approved.

We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our drug candidates, including:

regulatory authorities or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;

feedback from regulatory authorities that requires us to modify the design of our clinical trials;

we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations;

clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, suspend ongoing clinical trials or abandon drug development programs;

the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;

our third-party contractors, including those manufacturing our drug candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

we or our investigators might have to suspend or terminate clinical trials of our drug candidates for various reasons, including

non-compliance

with regulatory requirements, a finding that our drug candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;

regulators may recommend or require us to perform additional or unanticipated clinical trials to obtain approval;

regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate;

the cost of clinical trials of our drug candidates may be greater than we anticipate;

the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;

Table of Contents

regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate; and

any partners and collaborators that help conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.

If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

be delayed in obtaining marketing approval for our drug candidates;

not obtain marketing approval at all;

obtain marketing approval in some countries and not in others;

obtain approval for indications or patient populations that are not as broad as intended or desired;

obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;

be subject to additional post-marketing testing requirements; or

have the drug removed from the market after obtaining marketing approval.

Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates, allow our competitors to bring drugs to market before we do or impair our ability to successfully commercialize our drug candidates, which would harm our business and results of operations.

In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of regulatory approval of our drug candidates.

If we experience delays or difficulties in the enrollment of patients in clinical trials, or we are otherwise delayed in our ability to conduct clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In addition, some of our competitors may have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ drug candidates.

Patient enrollment is affected by other factors, including:

severity of the disease under investigation;

availability and efficacy of approved drugs for the disease under investigation;

patient eligibility criteria for the study in question;

competing drugs in clinical development;

perceived risks and benefits of the drug candidate under study;

restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;

efforts to facilitate timely enrollment in clinical trials;

patient referral practices of physicians;

the ability to monitor patients adequately during and after treatment; and

proximity and availability of clinical trial sites for prospective patients.

In addition, patient enrollment may be affected by future regulatory actions, such as Form 483 observations or the partial clinical hold we were subject to previously. In February 2017, following the conclusion of a joint inspection conducted by the FDA and Danish Medicines Agency at our corporate headquarters, the FDA issued a Form 483 noting certain deficiencies in procedures and documentation that were identified in our selinexor development program. We implemented corrective actions, preventative actions and other initiatives directed at resolving the deficiencies identified in the Form 483 observations and provided the FDA with our responses to the Form 483 observations in February 2017.

Table of Contents

In addition, in March 2017, the FDA notified us that it had placed the clinical trials under our IND for selinexor on partial clinical hold, which is an order by the FDA to delay or suspend part of a sponsor’s clinical work requested under its IND as well as investigator-sponsored trials. The partial clinical hold was due to incomplete information in the existing version of the investigator’s brochure, including an incomplete list of serious adverse events, or SAEs, associated with selinexor, and not as a result of any new

information regarding the safety profile of selinexor. The partial clinical holds on the clinical trials of selinexor were lifted by the FDA Division of Hematology Products (effective March 30, 2017), Division of Oncology Products 1 (effective April 5, 2017) and Division of Oncology Products 2 (effective March 31, 2017). However, if in the future we are delayed in addressing, or unable to address, any concerns of the FDA or other regulators, we could be delayed or prevented from enrolling patients in our clinical trials.

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, ~~or may~~could require us to abandon one or more clinical trials ~~altogether.~~altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.

If serious adverse or unacceptable side effects are identified during the development of our drug candidates or we observe limited efficacy of our drug candidates, we may need to abandon or limit the development of one or more of our drug ~~candidates.~~

candidates or it could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.

Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. ~~It is impossible to predict when~~If XPOVIO or if any of ~~our drug candidates will prove effective or safe in humans or will receive marketing approval. If~~ our drug candidates are associated with undesirable side effects or have characteristics that are unexpected in clinical trials or following approval and/or commercialization, we may need to abandon their development or limit development or marketing to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, we have modified our informed consent form and advised patients already enrolled in our clinical trials of the potential for worsening of

pre-existing

cataracts as a result of treatment with selinexor. ~~Also, even though selinexor has generally been well-tolerated by patients~~Adverse events, or AEs, in our clinical trials to date inhave been generally predictable and manageable, although some ~~cases there were adverse events, or AEs, some of which were serious.~~patients have experienced more serious AEs. The most common drug-related AEs were gastrointestinal, such as nausea, anorexia, diarrhea and vomiting, and fatigue. These side effects were generally mild or moderate in severity. The most common AEs that were Grade 3 or Grade 4, meaning they were more than mild or moderate in severity, were thrombocytopenia, or low count of platelets in the blood, and neutropenia, or low neutrophil counts. ~~A small percentage~~To date, the most common AEs have been managed with supportive care and dose modifications. However, a number of patients have withdrawn from our clinical trials as a result of AEs. For example, amongst the 202 patients enrolled in Parts 1 and 2 of the STORM study who were treated with selinexor in combination with dexamethasone, the most common AEs (incidence

≥

20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections. The treatment discontinuation rate due to AEs was 27%; 53% of patients had a reduction in the selinexor dose, and 65.3% had the dose of selinexor interrupted. In this group of patients, the most frequent AEs requiring permanent discontinuation in 4% or greater of patients who received selinexor included fatigue, nausea, and thrombocytopenia. Similarly, in the SADAL study, as of April 3, 2019, among the 127 patients included in the safety analysis, the treatment discontinuation rate due to AEs was 13.5%; 49.6% of patients had a reduction in the selinexor dose, and 90.6% had the dose of selinexor interrupted or withheld with the most common AEs (incidence

≥

20%) being thrombocytopenia, nausea, fatigue, anemia, anorexia, diarrhea, constipation, weight loss, neutropenia, vomiting, pyrexia and asthenia. A small percentage of patients across our clinical trials have experienced SAEs deemed by us and the clinical investigator to be related to selinexor. SAEs generally refer to AEs that result in death, are life threatening, require hospitalization or prolonging of hospitalization, or cause a significant and permanent disruption of normal life functions, congenital anomalies or birth defects, or require intervention to prevent such an outcome.

~~As a result of these~~

These AEs and the resulting dose modification and/or ~~further~~treatment discontinuation rates or safety or toxicity issues that we may experience in our clinical trials in the future ~~we may not receive~~could result in a more restrictive label for any drug candidates approved for marketing or could result in the delay or denial of approval to market any drug candidates by the FDA or comparable foreign regulatory authorities, which could prevent us from ever generating revenue from the sale of drugs or achieving profitability. Results of our trials could reveal an unacceptably high severity and prevalence of side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our drug candidates for any or all targeted indications. Many compounds that initially showed promise in early-stage trials for treating cancer or other diseases have later been found to cause side effects that prevented further development of the compound.

If such an event occurs after any of our drug candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:

regulatory authorities may withdraw the approval of such drug;

Table of Contents

regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;
regulatory authorities may require one or more post-marketing studies;
regulatory authorities may withdraw the approval of such drug;
we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;
we could be sued and held liable for harm caused to patients; and
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the affected drug candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenues from the sale of our drugs and harm our business and results of operations.

The FDA or
non-U.S.
regulatory authorities may disagree with our and/or our clinical trial investigators’ interpretation of data from clinical trials in determining if serious adverse or unacceptable side effects are drug-related.

We, and our clinical trial investigators, currently determine if serious adverse or unacceptable side effects are drug-related. The FDA or

non-U.S.

regulatory authorities may disagree with our or our clinical trial investigators’ interpretation of data from clinical trials and the conclusion by us or our clinical trial investigators that a serious adverse effect or unacceptable side effect was not drug-related. The FDA or

non-U.S.

regulatory authorities may require more information, including additional preclinical or clinical data to support approval, which may cause us to incur additional expenses, delay or prevent the approval of one of our drug candidates, and/or delay or cause us to change our commercialization plans, or we may decide to abandon the development or commercialization of the drug candidate altogether.

We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially-viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.

~~Even if~~

XPOVIO or any of our drug candidates that receives marketing approval ~~such drug~~ may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.

XPOVIO or any of our drug candidates receives marketing approval it may ~~nonetheless~~ fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Efforts to educate the medical community and third-party payors on the benefits of our drug candidates will require significant resources and may not be successful. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and doctors may continue to rely on these treatments. If XPOVIO or our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not become profitable. The degree of market acceptance of XPOVIO and our drug candidates, if approved for commercial sale, will depend on a number of factors, including:

efficacy and potential advantages compared to alternative treatments;

the ability to offer our drugs for sale at competitive prices;

convenience and ease of administration compared to alternative treatments;

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

the strength of marketing and distribution support;

the timing of market introduction of competitive products;

sufficient third-party coverage or reimbursement;

effectiveness of our sales and marketing efforts;

Table of Contents

adverse publicity about our drugs or favorable publicity about competitive products;

the prevalence and severity of any side effects;

any restrictions on the use of our drugs together with other medications; and

inability of certain types of patients to take our drugs.

Our estimates of the potential market opportunities for XPOVIO and our drug candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If inany of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the ~~future,~~actual market for XPOVIO, selinexor or any other drug candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability.

If we are unable to establish and maintain sales, marketing and ~~marketing~~distribution capabilities or maintain current agreements or enter into additional sales, marketing and distribution agreements with third parties, ~~to sell and market our drug candidates,~~ we may not be successful in commercializing XPOVIO or any of our drug candidates that we may develop if and when they are approved.

We are in the process of establishing and maintaining a sales and marketing infrastructure for XPOVIO, our first product, and our company ~~has~~does not ~~previously sold~~have any prior experience in the sales, marketing or ~~marketed~~distribution of pharmaceutical drugs. To achieve commercial success for any approved drug for which sales and marketing is not the responsibility of any strategic collaborator that we have or may have in the future, we must either develop a sales, marketing and ~~marketing~~distribution organization or outsource these functions to other third parties. In the future, we may choose to build a sales, marketing and ~~marketing~~distribution infrastructure to market or

co-promote

one or more of our drug candidates, if and when they are approved, or enter into additional collaborations with respect to the sale, marketing and ~~marketing~~distribution of our drug candidates. We ~~are currently establishing~~intend to work with existing and potential partners to establish the commercial infrastructure to support a potential launch of selinexor ~~in the United States, and we intend to work with existing and potential partners to establish such commercial infrastructure~~ outside the United States.

There are risks involved with both establishing and maintaining our own sales, marketing and ~~marketing~~distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a drug candidate. Further, we may underestimate the size of the sales force required for a successful product launch and may need to expand our sales force earlier and at a higher cost than we anticipated. If the commercial launch of aany of our drug ~~candidate~~candidates for which we ~~recruit~~establish a ~~sales force and establish marketing capabilities~~commercial infrastructure is delayed or does not occur for any reason, including if we do not receive marketing approval on the timeframe we expect, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

Factors that may inhibit our efforts to commercialize ~~our drugs~~XPOVIO or any drug candidates for which we receive marketing approval on our own include:

our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;

the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;

the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug lines;

unforeseen costs and expenses associated with creating an independent sales, marketing and ~~marketing~~distribution organization; and

inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.

Entering into arrangements with third parties to perform sales and marketing services may result in lower revenues from the sale of drug or the profitability of these revenues to us than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in maintaining current arrangements or entering into additional arrangements with third parties to sell, market and ~~market~~distribute XPOVIO or any of our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drugs effectively. If we do not establish sales, marketing and ~~marketing~~distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing XPOVIO or any of our drug ~~candidates.~~

candidates for which we obtain marketing approval.

Table of Contents

We have a limited number of engagements with specialty pharmacies and specialty distributors. The specialty pharmacies sell XPOVIO directly to patients. The specialty distributors sell XPOVIO to healthcare entities who then resell XPOVIO to patients. While we have entered into agreements with each of these pharmacies and distributors to distribute XPOVIO in the United States, they may not perform as agreed or they may terminate their agreements with us. Also, we may need to enter into agreements with additional pharmacies or distributors, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of specialty pharmacies and specialty distributors, we would be exposed to substantial distribution risk.

We may not receive royalty or milestone revenue under our license agreements for several years, or at all.

Our license agreements provide for payments on achievement of development and/or commercialization milestones and for royalties on product sales. However, because ~~none of our drug candidates have been approved for commercial sale, our drug candidates are at early stages of development and~~ drug development entails a high risk of failure, we may never realize any material portion of the milestone revenue provided in our license agreements and we do not expect to receive any royalty revenue for several years, if at all.

We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.

The discovery, development and commercialization of new drugs is highly competitive. We face competition with respect to XPOVIO and our ~~current~~ drug candidates and will face competition with respect to any drug candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs for the treatment of cancer and the other disease indications for which we are developing our drug candidates, although we believe that to date, none of these competitive drugs and therapies currently in development are based on scientific approaches that are the same as our approach. Potential competitors also include academic institutions and governmental agencies and public and private research institutions.

We are initially focused on developing our current drug candidates for the treatment of cancer. There are a variety of available therapies marketed for cancer. In many cases, cancer drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic drugs. We expect that ifany of our drug candidates that are approved ~~they~~ will be priced at a significant premium over competitive generic drugs. This may make it difficult for us to achieve our business strategy of using our drug candidates in combination with existing therapies or replacing existing therapies with our drug candidates.

Our commercial opportunity could be reduced or eliminated if our competitors ~~may~~ develop and commercialize drugs that are more effective, safer, more convenient or less costly than any that we are developing or that would render our drug candidates obsolete or

non-competitive.

Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or preventing us from entering into a particular indication at all.

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.

Even if we are able to effectively commercialize XPOVIO or any drug ~~candidates,~~candidate that we may develop, the drugs may not receive coverage or may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, all of which would harm our business.

The legislation and regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or drug licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. In the United States, approval and reimbursement decisions are not linked directly, but there is increasing scrutiny from the Congress and regulatory authorities of the pricing of pharmaceutical products. As a result, we might obtain marketing approval for a drug in a particular

Table of Contents

country, but then be subject to price regulations that delay our commercial launch of the drug, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval.

~~Significant uncertainty exists as~~

Our ability to ~~the coverage and reimbursement status~~effectively commercialize XPOVIO or any of our product candidates ~~for which~~that we ~~seek regulatory approval. Our ability to commercialize any drugs~~may develop successfully will depend, in part, on the extent to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Obtaining and maintaining adequate reimbursement for XPOVIO and any of our product candidates, if approved, may be difficult. Moreover, the process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for our products ~~if they are approved,~~ by third-party payors.

A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek, with respect to an approved product, additional clinical evidence that goes beyond the data required to obtain marketing approval. They may require such evidence to demonstrate clinical benefits and value in specific patient populations or they may call for costly pharmaceutical studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies before covering our products. Accordingly, we cannot be sure that reimbursement will be available for XPOVIO and any drug candidate that we commercialize and, if reimbursement is available, we cannot be sure as to the level of reimbursement and whether it will be adequate. Coverage and reimbursement may impact the demand for, or the price of, XPOVIO or any drug candidate for which we obtain marketing approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize XPOVIO or any drug candidate for which we obtain marketing approval.

There may be significant delays in obtaining reimbursement for newly-approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable regulatory authorities outside of the United States. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.

Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and to limit commercialization of XPOVIO and any other drugs that we may develop.

We face an inherent risk of product liability exposure related to the testing of our drug candidates in human clinical ~~trials and will~~trials. We face an even greater risk ifas we ~~commercially sell~~commercialize XPOVIO or any other drugs that we may develop. For example, we may be sued if any drug we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against claims that our drug candidates or drugs caused injuries, we will incur substantial ~~liabilities.~~liabilities or be required to limit commercialization of our drug candidates. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for XPOVIO and any ~~drug candidates or~~other drugs that we may develop;

injury to our reputation and significant negative media attention;

withdrawal of clinical trial participants;

initiation of investigations by regulators;

product recalls, withdrawals or labeling, marketing or promotional restrictions;

Table of Contents

significant costs to defend the related litigation;

substantial monetary awards to trial participants or patients;

loss of revenue;

reduced resources of our management to pursue our business strategy; and

the inability to successfully commercialize XPOVIO and any other drugs that we may develop.

We currently hold clinical trial and general product liability insurance coverage, but that coverage may not be adequate to cover any and all liabilities that we may incur. ~~We would need to increase our insurance coverage when we begin the commercialization of our drug candidates, if ever.~~ Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

The business that we conduct outside the United States may be adversely affected by international risk and uncertainties.

Although our operations are based in the United States, we conduct business outside the United States and expect to continue to do so in the future. For instance, many of the sites at which our clinical trials are being conducted are located outside the United States. In addition, we plan to seek approvals to sell our products in foreign countries. Any business that we conduct outside the United States will be subject to additional risks that may materially adversely affect our ability to conduct business in international markets, including:

potentially reduced protection for intellectual property rights;

the potential for

so-called

parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;

unexpected changes in tariffs, trade barriers and regulatory requirements;

economic weakness, including inflation, volatility in currency exchange rates or political instability in particular foreign economies and markets;

workforce uncertainty in countries where labor unrest is more common than in the United States;

production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad;

business interruptions resulting from

geo-political

actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and fires; and

failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act, or FCPA.

Risks Related to Our Financial Position, Convertible Senior Notes, Revenue Interest Financing Agreement and Need for Additional Capital

We have incurred significant losses since inception. We expect to continue to incur losses in the future and may never achieve or maintain profitability.

Since inception, we have incurred significant operating losses. Our net loss was ~~$120.2~~$150.9 million for the nine months ended September 30, ~~2018.~~2019. As of September 30, ~~2018,~~2019, we had an accumulated deficit of ~~$615.5~~$824.7 million. WeAs we only recently launched our first

FDA-approved

product, XPOVIO, in July 2019, we have ~~not generated any revenue~~had limited revenues to date from product sales ~~of any drugs~~ and have financed our operations to date principally through private placements of our preferred stock, ~~and convertible notes,~~ proceeds from our initial public offering and

follow-on

offerings of common stock, issuance of convertible debt, proceeds from a revenue interest financing and cash generated from our business development activities. We have devoted substantially all of our efforts to research and ~~development. Our~~development, including preclinical studies and clinical trials, pursuing regulatory approvals and engaging in activities to commercially launch XPOVIO for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Other than the FDA’s accelerated approval of XPOVIO, our lead drug candidate, oral selinexor (for indications not yet approved), as well as verdinexor, eltanexor and

KPT-9274,

are in clinical development. ~~Even if~~Although we ~~are able~~expect to ~~commercialize one~~continue to generate revenue from sales of ~~our drug candidates for~~XPOVIO, there can be no assurance as to the ~~treatment~~amount or timing of ~~human disease in the near future,~~any such revenue, and we expect to continue to incur significant expenses and operating losses. The net losses we incur may fluctuate significantly from quarter to quarter.

Table of Contents

We anticipate that our expenses will continue to increase substantially as compared to prior periods as we continue to commercialize XPOVIO in the Unites States and engage in activities to prepare for the potential commercialization of additional indications for selinexor and the potential approval of our other drug candidates, including due to the impact of increased headcount, to support our clinical and commercialization activities, expanded infrastructure and increased insurance premiums.

We anticipate that our expenses will increase substantially if and as we:

continue to commercialize XPOVIO in the United States and seek regulatory approval for XPOVIO outside of the United States;

continue to grow our sales, marketing and distribution infrastructure during the commercialization of XPOVIO and any drug candidates for which we may obtain marketing approval, prior to or upon receiving marketing approval;

continue our research and preclinical and clinical development of our drug candidates;

initiate additional clinical trials for our drug candidates;

seek marketing approvals for any of our drug candidates that successfully complete clinical trials;

~~establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain marketing approval;~~

maintain, expand and protect our intellectual property portfolio;

manufacture our drug candidates;

hire additional clinical, quality control, scientific, commercial and ~~scientific~~management personnel;

identify additional drug candidates;

acquire or

in-license

other drugs and technologies; ~~and~~

add operational, financial and management information systems and personnel, including personnel to support our drug development, any ~~future~~ commercialization efforts and our other operations as a public ~~company.~~

company; and

increase our product liability insurance coverage as we initiate and expand our commercialization efforts.

Our ability to become and remain profitable ~~we must develop and eventually~~depends on our ability to commercialize a drug or drugs with significant market potential, either on our own or with a collaborator. While we began to generate revenue from the sales of XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not achieve profitability for several years, if at all. This will require us to be successful in a range of challenging activities, including:

successful launching of XPOVIO, including by further developing our sales force, marketing and distribution capabilities;

achieving an adequate level of market acceptance and obtaining and maintaining coverage and adequate reimbursement from third-party payors for XPOVIO and any other drugs we commercialize;

completing preclinical studies and clinical trials of our drug ~~candidates,~~ candidates;

obtaining marketing approval for these drug ~~candidates,~~ candidates;

manufacturing at commercial scale, marketing, selling and ~~selling those drugs~~distributing XPOVIO or any drug candidates for which we may obtain marketing ~~approval~~approval;

maintaining regulatory and marketing approvals for XPOVIO and for any drug candidates for which we obtain marketing approval;

establishing and managing any collaborations for the development, marketing and/or commercialization of our drug candidates;

hiring and building a full commercial organization required for the marketing, selling and distribution for those drugs for which we obtain marketing approval; and

obtaining, maintaining and protecting our intellectual property rights.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase if we are required by the FDA or other regulatory authorities to perform clinical trials and

non-clinical

studies in addition to those that have been conducted or are currently expected, or if there are any delays in the development of any of our drug candidates or the manufacture of any of our drug candidates.

Table of Contents

XPOVIO is our only product that has been approved for sale and it has only been approved in the United States for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Our ability to become and remain profitable will depend, in part, on the timing and success of commercial sales of XPOVIO, which we commercially launched in the United States in July 2019. However, the successful commercialization of XPOVIO in the United States is subject to many risks. We are currently undertaking our first commercial launch with XPOVIO, and we may not be able to do so successfully. There are numerous examples of unsuccessful product launches and failures to meet expectations of market potential, including by pharmaceutical companies with more experience and resources than us. We do not anticipate our revenue from sales of XPOVIO alone will be sufficient for us to become profitable for several years, if at all.

We may never succeed in these activities and ~~even if we do,~~ may never generate revenues that are significant or large enough to achieve profitability. IfEven if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.

The nature and length of our operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.

We were incorporated in 2008 and commenced operations in 2009. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our platform, identifying potential drug candidates, ~~and~~ conducting preclinical studies and early-phase and later-phase clinical trials of our drug ~~candidates. Our lead drug candidate is currently~~candidates and establishing a commercial infrastructure to launch XPOVIO. We only recently launched XPOVIO and are still in ~~multiple Phase 2~~the process of executing our commercial launch plan and, ~~Phase 3 clinical trials and all of our other drug candidates for the treatment of human disease are in early clinical development. We~~to date, have not yet demonstrated our ability to successfully complete any late-phase clinical trials in humans, including large-scale clinical trials, obtain marketing approvals, manufacture a commercial scale drug, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful drug commercialization. Typically, it takes about six to ten years to develop one new druggenerated significant revenue from the ~~time it is in Phase 1 clinical trials to when it is commercially available for treating patients.~~sale of XPOVIO. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, as a business with a short operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance.

We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and drug development programs or commercialization efforts.

We expect our expenses to increase in connection with our ongoing activities, particularly as we commercialize XPOVIO (selinexor) and continue the clinical trials of, and seek marketing approval and prepare for commercialization of, selinexor in additional indications and our other drug candidates. ~~In addition, if~~Our expenses have increased as we have begun commercializing XPOVIO, including costs associated with our sales force and increased marketing and distribution capabilities. If we obtain marketing approval for any ~~of our~~ drug candidates that we develop, we expect to incur significant additional commercialization expenses ~~related to~~for such drug ~~sales, marketing, manufacturing and distribution~~candidate to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such ~~drug.~~drug candidate. Furthermore, we will continue to incur additional costs associated with operating as a public ~~company.~~company, hiring additional personnel and expanding our facilities. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and drug development programs or any current or future commercialization efforts.

We expect that our existing cash, cash equivalents and ~~short- and long-term~~ investments ~~in addition to the net proceeds we raised in the private placement of our 3.00% Convertible Senior Notes due 2025, or the Notes, in October 2018,~~ will enable us to fund our current operating and capital expenditure plans for at least twelve months from the date of issuance of the financial statements contained in thisForm ~~10-Q~~ ~~while we are establishing the commercial infrastructure for a potential launch of selinexor in the United States.~~

10-Q.

Our future capital requirements will depend on many factors, including:

our ability to successfully commercialize and sell XPOVIO in the United States;

the cost of, and our ability to expand and maintain, the commercial infrastructure required to support the commercialization of XPOVIO and any other drug for which we receive marketing approval, including product sales, medical affairs, marketing and distribution;

the progress and results of our current and planned clinical trials of selinexor;

the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;

Table of Contents

the costs, timing and outcome of regulatory review of our drug ~~candidates;~~

candidates, including whether any additional clinical trials or other activities are required for approval or label expansion;

our ability to establish and maintain collaborations on favorable ~~terms, if at all;~~

terms;

the success of any collaborations that we have entered into and may enter into with third parties;

the extent to which we acquire or

in-license

other drugs and technologies;

the costs of ~~future~~ commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we receive marketing approval, and

pre-commercialization

costs for our drug candidates incurred prior to receiving any such marketing approval, including the ~~extent that such~~costs and timing of establishing product sales, marketing, manufacturing and distribution capabilities that are not the responsibility of any collaborator that we may have at such time;

the amount of revenue, if any, received from commercial sales of our drug candidates, ~~should~~assuming receipt of marketing approval;

the terms and timing of any ~~of our drug candidates receive~~future collaborations, partnerships, licensing, marketing, ~~approval;~~distribution or other arrangements that we may establish; and

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

Identifying potential drug candidates, ~~and~~ conducting preclinical studies and clinical trials, ~~is a~~seeking marketing approvals and commercializing products are time-consuming, expensive and uncertain ~~process~~processes that ~~takes~~take years to ~~complete, and~~complete. Although we commercially launched XPOVIO in July 2019, we do not anticipate that our revenue from product sales of XPOVIO will be sufficient for us to become profitable for several years, if at all. In addition, we may never generate the necessary data or results required to obtain marketing approval ~~and achieve drug sales. In addition,~~of our drug candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for at least one, or possibly many years, if at all.candidates. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.

~~Raising~~ Adequate additional ~~capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates.~~

Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through further collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be ~~favorable~~available to ~~us.~~us on acceptable terms, or at all. If weadequate funds are ~~unable~~not available to ~~raise additional funds through equity or debt financings when needed,~~us on a timely basis, we may be required to delay, limit, reduce or terminate ~~our research and drug~~ development activities for one or ~~commercialization efforts or grant rights to develop and market~~more of our drug candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize XPOVIO or our drug candidates for which we ~~would otherwise prefer to develop and market ourselves.~~

obtain marketing approval.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

Global credit and financial markets have experienced extreme disruptions over some of the past several years. Such disruptions have resulted, and could in the future result, in diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that any deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be compromised by economic downturns, a volatile business environment and unpredictable and unstable market conditions. If the equity and credit markets deteriorate, it may make any necessary equity or debt financing more difficult to secure, more costly or more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could harm our growth strategy, financial performance and stock price and could require us to delay or abandon plans with respect to our business, including clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers or other third parties with which we conduct business may not survive difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.

Our indebtedness could limit cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the Notes.

We incurred $172.5 million of indebtedness as a result of the sale of the ~~Notes.~~Notes and $75.0 million as a result of the initial closing pursuant to the Revenue Interest Financing Agreement, or Revenue Interest Agreement, that we entered into with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P., or HCR, on September 14, 2019. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:

increasing our vulnerability to adverse economic and industry conditions;

limiting our ability to obtain additional financing;

Table of Contents

requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;

limiting our flexibility to plan for, or react to, changes in our business;

diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the Notes; and

placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.

Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the Notes, and our cash needs may increase in the future.

Servicing the Notes will require a significant amount of cash, and we may not have sufficient cash flow from our business to make payments on our indebtedness.

Our ability to pay the principal of or interest and additional interest, if any, on the Notes or to make cash payments in connection with any conversion of the Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service the Notes or other future indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional debt financing or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Notes or other future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Notes.

We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash, to repurchase the Notes for cash upon a fundamental change, to pay the redemption price for any Notes we redeem or to refinance the Notes, and any future debt we incur may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.

Holders may require us to repurchase their Notes following a fundamental change at a cash repurchase price generally equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest and additional interest, if any. In addition, upon conversion, unless we elect to deliver solely shares of our common stock to settle conversions (other than paying cash in lieu of delivering any fractional share), we must satisfy the conversion in cash. We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the Notes, pay cash amounts due upon conversion or redemption of the Notes or refinance the Notes. In addition, our ability to repurchase the Notes, to pay cash upon conversion or redemption of the Notes or to refinance the Notes may be limited by law, regulatory authority or agreements governing any future indebtedness that we may incur. Our failure to repurchase notes at a time when the repurchase is required by the indenture governing the Notes or to pay cash upon conversion of the Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness, if any. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreements. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or to pay cash upon conversion of the Notes.

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal amount of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.

In May 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. APB

14-1,

Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement),

which has subsequently been codified as Accounting Standards Codification

470-20,

Debt with Conversion and Other Options, orASC

470-20.

UnderASC

470-20,

an entity must separately account for the liability and equity components of the convertible debt instruments (such as the Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest

Table of Contents

cost. The effect ofASC

470-20

on the accounting for the Notes is that the equity component is required to be included in the additional

paid-in

capital section of stockholders’ equity on our consolidated balance sheet at the issuance date, and the value of the equity component would be treated as debt discount for purposes of accounting for the debt component of the Notes. As a result, we will be required to record a greater amount of

non-cash

interest expense as a result of the amortization of the discounted carrying value of the Notes to their face amount over the term of the Notes. We will report a larger net loss in our financial results becauseASC

470-20

will require interest to include both the amortization of the debt discount and the instrument’s coupon interest rate, which could adversely affect our future financial results, the market price of our common stock and the trading price of the Notes.

In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently eligible to be accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. If we are unable to use the treasury stock method in accounting for the shares issuable upon conversion of the Notes, then our diluted earnings per share would be adversely affected.

Furthermore, if any of the conditions to the convertibility of the Notes is satisfied, then we may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability. This reclassification could be required even if no holders convert their Notes and could materially reduce our reported working capital.

Our Revenue Interest Agreement with HCR contains various covenants and other provisions, which, if violated, could result in the acceleration of payments due under such agreement.

On September 14, 2019, we entered into the Revenue Interest Agreement with HCR. Pursuant to the Revenue Interest Agreement, we are required to comply with various covenants relating to the conduct of our business and the commercialization of XPOVIO. In addition, the Revenue Interest Agreement includes customary events of default upon the occurrence of enumerated events, including

non-payment

of revenue interests, failure to perform certain covenants and the occurrence of insolvency proceedings, specified judgments, specified cross-defaults or specified revocations, withdrawals or cancellations of regulatory approval for XPOVIO. Upon the occurrence of an event of default, HCR may accelerate payments due under the Revenue Interest Agreement up to $138.8 million, less the aggregate of all of the payments made to date. Upon the occurrence of specified material adverse events or the material breach of specified representations and warranties, which will not be considered events of default, HCR may elect to terminate the Revenue Interest Agreement and require us to make payments necessary for HCR to receive $75 million, less the aggregate of all of the payments made to date, plus a specified annual rate of return. In the event that we are unable to make such payment, then HCR may be able to foreclose on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO. Any such foreclosure remedy would significantly and adversely affect us and could result in us losing our interest in such assets.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates.

Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, during the term of the Revenue Interest Agreement, we cannot make any voluntary or optional cash payment or prepayment on our existing convertible debt and cannot enter into any new debt without the consent of HCR.

Table of Contents

Risks Related to Our Dependence on Third Parties

We depend on third parties for certain aspects of the development, marketing and/or commercialization of our drug candidates and plan to enter into additional collaborations. If those collaborations are not successful, we may not be able to capitalize on the market potential of these drug candidates.

We intend to maintain our existing collaborations and will continue to seek additional third-party collaborators for certain aspects of the development, marketing and/or commercialization of our drug candidates. For example, we have entered into license arrangements with Ono Pharmaceutical Co., Ltd. and Antengene Therapeutics Limited, and plan to continue to seek to enter into additional license relationships, for marketing and commercialization of selinexor for other geographies outside the United States. In addition, we intend to seek one or more collaborators to aid in the further development, marketing and/or commercialization of our other SINE compounds for indications outside of oncology. Our likely collaborators for any collaboration arrangements include large and

mid-size

pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In connection with any such arrangements with third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development, marketing and/or commercialization of our drug candidates. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements.

Collaborations involving our drug candidates pose the following risks to us:

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;

collaborators may not perform their obligations as expected or in compliance with applicable regulatory requirements;

collaborators may not pursue development, marketing and/or commercialization of our drug candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;

collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;

collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs or drug candidates if the collaborators believe that competitive drugs are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;

disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;

collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our drugs or drug candidates or that result in costly litigation or arbitration that diverts management’s attention and resources of our company;

we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;

collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable drug candidates;

collaborators may learn about our discoveries and use this knowledge to compete with us in the future; and

the number and type of our collaborations could adversely affect our attractiveness to collaborators or acquirers.

Table of Contents

Collaboration agreements may not lead to development or commercialization of drug candidates in the most efficient manner, or at all. If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report onForm

10-Q

also apply to the activities of our collaborators.

If we are unable to establish and maintain our agreements with third parties to distribute XPOVIO to patients, our results of operations and business could be adversely affected.

We rely on third parties to commercially distribute XPOVIO to patients. For example, we have contracted with a limited number of specialty pharmacies and specialty distributors to sell and distribute XPOVIO. The use of specialty pharmacies and specialty distributors involves certain risks, including, but not limited to, risks that these organizations will:

not provide us accurate or timely information regarding their inventories, the number of patients who are using XPOVIO or serious adverse reactions, events and/or product complaints regarding XPOVIO;

not effectively sell or support XPOVIO or communicate publicly concerning XPOVIO in a manner that is contrary to FDA rules and regulations;

reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support XPOVIO;

not devote the resources necessary to sell XPOVIO in the volumes and within the time frames that we expect;

be unable to satisfy financial obligations to us or others; or

cease operations.

Any such events may result in decreased product sales and lower product revenue, which would harm our results of operations and business.

If we are not able to maintain our existing collaborations or establish additional collaborations as we currently plan, we may have to alter our development and commercialization ~~plans.~~

plans and our business could be adversely affected.

Our drug development programs and the ~~potential~~ commercialization of our drug candidates for which we receive marketing approval will require substantial additional cash to fund expenses. As noted above, we expect to maintain our existing collaborations and collaborate with additional pharmaceutical and biotechnology companies for the development ~~and/~~of our drug candidates and the commercialization of our drugs or the potential commercialization of our drug candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside of the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate.

We may also be restricted under then-existing collaboration agreements from entering into future agreements on certain terms with potential collaborators.

Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.

Table of Contents

We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such drug candidate, reduce or delay its development program or one or more of our other development programs, delay ~~its potential~~the commercialization of a drug or a drug candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate revenue from sales of drugs.

We rely on some third parties as we conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.

We rely on some third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, as we conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our drug development activities.

Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The European Medicines Agency, or EMA, also requires us to comply with comparable standards. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or any of the third parties that we rely on in connection with our clinical trials fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements.

We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates.

In such an event, our financial results and the commercial prospects for our drug candidates could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.

We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay clinical development or marketing approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue from sales of drugs.

We rely on third parties to conduct investigator-sponsored clinical trials of selinexor and our other drug candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our ability to obtain regulatory approval for selinexor and our other drug candidates.

We rely on academic and private

non-academic

institutions to conduct and sponsor clinical trials relating to selinexor and our other drug candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or

non-U.S.

regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.

Such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we do not have control over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our drug candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our drug candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.

Table of Contents

Additionally, the FDA or

non-U.S.

regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA or ~~other~~

non-U.S.

regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.

We contract with third parties for the manufacture of our drug candidates for preclinical studies and clinical trials and expect to continue to do so in connection with the commercialization of XPOVIO and for clinical trials and ~~ultimately for commercialization.~~commercialization of any drug candidates that we develop and commercialize. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not have any manufacturing facilities or personnel. We do not currently have nor do we plan to build internal infrastructure or capability to manufacture XPOVIO or our drug candidates for use in the conduct of our clinical trials or for commercial supply. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our drug candidates for preclinical studies and clinical trials under the guidance of members of our organization. We have engaged third-party manufacturers for drug substance and drug product services. We do not have a long term supply agreement with any of these third-party manufacturers, and we purchase our required drug supplies on a purchase order basis.

We currently rely, and expect to continue to rely, on third-party manufacturers or third-party collaborators for the manufacture of ~~our drug candidates for clinical trials and ultimately for~~ commercial ~~supply~~quantities of any ~~of these~~ drug ~~candidates for which~~candidate that we ~~or any of our collaborators obtain~~commercialize following marketing approval. ~~We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance~~Reliance on third-party manufacturers entails ~~additional~~ risks, including:

reliance on the third party for regulatory compliance and quality assurance;

the possible breach of the manufacturing agreement by the third party;

the possible failure of the third party to manufacture our drugs or drug ~~candidate~~candidates according to our schedule, or at all, including if the third-party manufacturer gives greater priority to the supply of other drugs over our drugs and drug candidates, or otherwise does not satisfactorily perform according to the terms of the manufacturing agreement;

equipment malfunctions, power outages or other general disruptions experienced by our third-party manufacturers to their respective operations and other general problems with a multi-step manufacturing process;

the possible misappropriation or disclosure by the third party or others of our proprietary information, including our trade secrets and

know-how;

and

the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

We have engaged a third-party contract manufacturer for the commercial production of XPOVIO and intend to do the same for any drug candidate that is approved by any regulatory agency. This process is difficult and time consuming and we may face competition for access to manufacturing facilities, as there are a limited number of contract manufacturers operating under current Good Manufacturing Practices, or cGMPs, that are capable of manufacturing our drug candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization.

Third-party manufacturers may not be able to comply with ~~current Good Manufacturing Practices, or~~ cGMP regulations or similar regulatory requirements outside of the United States. ~~As with all~~Facilities used by our third-party manufacturers must be inspected by the FDA after we submit an NDA and before potential approval of the drug ~~manufacturing, our failure, or the failure~~candidate. Similar regulations apply to manufacturers of our drug candidates for use or sale in foreign countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our drug candidates. If our manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable drug candidate as alternative qualified manufacturing facilities may not be available on a timely basis or at all. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable ~~regulations~~cGMPs or other regulatory requirements could result in sanctions being imposed on us or the contract manufacturer, including fines, injunctions, civil penalties, delays, ~~suspension~~suspensions or ~~withdrawal~~withdrawals of approvals, ~~license revocation, seizures or recalls~~operating restrictions,

Table of ~~drug candidates or drugs, operating restrictions~~Contents

interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our ~~drugs~~drug candidates and ~~harm~~have a material adverse impact on our business, financial condition and results of operations.

Any drugs that we may develop may compete with other drug candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or ~~marketing approval.~~commercialization. If our current contract manufacturers cannot perform as agreed, we may be required to replace those manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our drug candidates or drugs, we may incur added costs and delays in identifying and qualifying any such replacement.

Our current and anticipated future dependence upon others for the manufacture of ~~our~~XPOVIO or any drug candidates ~~or drugs~~that we develop may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.

Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters

Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. As a result, we cannot predict when or if we or any of our collaborators will obtain marketing approval to commercialize a drug candidate.

The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We are not permitted to market our drug candidates in the United States or in other countries until we or any of our collaborators receive approval of ~~a New Drug Application, or~~an NDA from the FDA or marketing approval from applicable regulatory authorities outside of the United States. ~~Our drug candidates are~~In July 2019, the FDA approved XPOVIO

(selinexor) in ~~early stages~~combination with dexamethasone for the treatment of ~~development~~adult patients with RRMM who have received at least four prior therapies and ~~are subject~~whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON study evaluating selinexor in combination with Velcade

(bortezomib) and

low-dose

dexamethasone will serve as the confirmatory trial. In addition, we submitted a Marketing Authorization Application (MAA) to the ~~risks of failure~~

~~inherent~~European Medicines Agency (EMA) in ~~drug development. On August 6, 2018, we announced the completion of the rolling submission of an NDA to the FDA~~January 2019 with a request for ~~accelerated~~conditional approval ~~for~~of selinexor as a ~~new~~ treatment for patients with ~~penta-refractory~~heavily pretreated multiple ~~myeloma. On October 5, 2018,~~myeloma based on the results of the STORM study. During March 2019, the EMA had inspectors conduct a Good Clinical Practices (GCP) inspection at our headquarters, which was also attended by the FDA, ~~accepted for filing our NDA, granted our request for priority review and assigned an action date~~as well as inspections of ~~April 6, 2019 under~~two clinical sites that participated in Part 2 of the ~~PDUFA. In its acceptance letter,~~STORM study. While we did not receive any findings from the FDA, ~~stated~~in May 2019, the EMA inspectors provided us a written inspection report seeking our responses to various questions and findings. We promptly addressed the questions and findings in the inspection report and submitted proposals to the EMA’s Committee for Medicinal Products for Human Use (CHMP). In September 2019, we received the Day 180 List of Outstanding Issues from CHMP, which identified two issues requiring resolution. First, CHMP requested that ~~it is~~we reconfirm the IRC adjudicated response rate to justify a positive benefit-risk assessment and, second, CHMP requested that we address the findings from the GCP inspection and our corrective measures taken to justify that the clinical trial data are of sufficient quality to support a benefit-risk assessment. We are currently ~~planning~~working with CHMP to ~~hold an advisory committee meeting~~address both topics and expect to ~~discuss this NDA.~~receive a decision on the application in early 2020. We have not submitted any other application for, or received any marketing approval of, any of our drug candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.

The process of obtaining marketing approvals, both in the United States and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved.

In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval we or any of our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.

Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any of our collaborators to generate revenue from the particular drug candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.

Table of Contents

Since XPOVIO received accelerated approval by the FDA, we must still comply with post-approval development and regulatory requirements to maintain that approval and, if we fail to do so, FDA could withdraw its approval of XPOVIO, which would lead to substantially lower revenues.
For drugs granted accelerated approval, the FDA typically requires post-marketing confirmatory trials to evaluate the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence. As a condition of the accelerated approval of XPOVIO, we are required to (i) complete and submit a final report with full datasets from the BOSTON study following completion of the study, (ii) conduct a randomized phase 2 clinical trial of selinexor plus dexamethasone with two different doses of selinexor that are lower than 80 mg on days 1 and 3 of each week, in a similar patient population for which XPOVIO is indicated (which we plan to conduct outside the United States), (iii) conduct a hepatic impairment trial with selinexor in patients with cancer and (iv) conduct a drug interaction trial with selinexor in patients to evaluate the effect of
co-administration
of a strong CYP3A4 inhibitor on the pharmacokinetics of selinexor.
The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. Similar risks to those described above are also applicable to any application that we have submitted or may submit to the EMA to support conditional approval of selinexor to treat heavily pretreated multiple myeloma, relapsed/refractory DLBCL, or any other cancer indication.
There can be no assurance that the BOSTON study conducted as part of our post-marketing obligations will confirm that the surrogate marker used for accelerated approval of XPOVIO will eventually show an adequate correlation with clinical outcomes. If the BOSTON study fails to show such adequate correlation, we may not be able to maintain our previously granted marketing approval of XPOVIO.

Our failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in foreign jurisdictions.

In order to market and sell our drugs in the European Union and many other jurisdictions, we and our current or future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. We and our collaborators may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.

However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.

Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On March 29, 2017, the ~~country~~United Kingdom formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom had a period of a maximum of two years from the date of its formal notification to negotiate the terms of its withdrawal from, and future relationship with, the European Union. If no formal withdrawal agreement can be reached between the United Kingdom and the European Union, then it is expected that the United Kingdom’s membership of the European Union would automatically terminate on the deadline, which was initially March 29, 2019. That deadline has been extended to October 31, 2019 to allow the parties to negotiate a withdrawal agreement, which has proven to be extremely difficult to date. Discussions between the United Kingdom and the European Union will continue to focus on withdrawal issues and transition agreements. However, limited progress to date in these negotiations and ongoing uncertainty within the United Kingdom Government and Parliament sustains the possibility of the United Kingdom leaving the European Union without a withdrawal agreement and associated transition period in place, which is likely to cause significant market and economic disruption.

Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the ~~referendum~~withdrawal could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business.

Table of Contents

We may seek approval from the FDA or comparable
non-U.S.
regulatory authorities to use accelerated development pathways for our product candidates, including for selinexor in ~~multiple myeloma and~~ diffuse large
B-cell
lymphoma. If we are not able to use such pathways, we may be required to conduct additional clinical trials beyond those that we contemplate and that would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we receive them at all. In addition, even if we are able to use an accelerated approval pathway, it may not lead to expedited approval of our product candidates, or approval at all.

Under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically

meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective.

Prior to seeking such accelerated approval, we will continue to seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval.

We are using the data from our expanded STORM study to support a request that the FDA consider granting accelerated approval for selinexor as a new treatment for patients with penta-refractory multiple myeloma. On August 6, 2018, we announced the completion of the rolling submission of an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with penta-refractory multiple myeloma. On October 5, 2018, the FDA accepted for filing our NDA and also granted our request for priority review and assigned an action date of April 6, 2019 under the PDUFA. However, the FDA has reiterated to us in its feedback that accelerated approval is available only for drugs that provide a meaningful therapeutic benefit over existing treatments at the time of consideration of the application for accelerated approval. Any approved therapies showing activity in patients with penta-refractory multiple myeloma that may exist at the time the FDA acts on any request we may make for accelerated approval could cause the FDA to deny our request. In addition, the FDA has indicated that additional therapies may receive full approval in multiple myeloma prior to the FDA taking action on our accelerated approval submission, which could mean that, at the time the FDA takes action on our accelerated approval submission, treatment of the penta-refractory group is no longer considered an unmet medical need or a patient population that has exhausted available therapies. The FDA has recommended that we plan for regular approval based on a randomized trial for the evaluation of safety and efficacy of selinexor for the treatment of multiple myeloma, and has previously indicated to us its preference for studies that isolate the effects of individual drugs. Although we believe that the STORM study design and the expansion in the penta-refractory patient group present an opportunity for us to request that the FDA grant accelerated approval, there can be no assurance that the FDA will grant such approval, whether on an accelerated basis, or at all.

~~Similarly, assuming positive results from our SADAL study and remaining unmet medical need, we~~ intend to use the data from the SADAL study to support aan NDA request that the FDA consider granting accelerated approval for selinexor in relapsed and/or refractory diffuse large

B-cell

lymphoma, or ~~DLBCL.~~DLBCL, and work with the FDA to determine the appropriate timeline for the submission of the NDA. In November 2018, the FDA granted fast track designation to selinexor for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. While the FDA agreed that the ~~current~~ trial design and indication appear appropriate for accelerated approval, they reiterated to us in their feedback that the availability of accelerated approval will depend on the trial results and available therapies at the time of regulatory action. The FDA also has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach and, for DLBCL, recommended two randomized trials that isolate the treatment effect of selinexor for a DLBCL indication. In addition, as we experienced with our NDA based on the results of Part 2 of the STORM study, the FDA has noted tolerability and dose optimization as review matters. Although we believe that our SADAL study presents an opportunity for us to request that the FDA grant accelerated approval for selinexor in relapsed and/or refractory DLBCL, ~~if data from our SADAL study support such an application,~~ there can be no assurance that the FDA will grant such approval, whether on an accelerated basis, or at all.

There can also be no assurance that the FDA will agree with our surrogate endpoints or intermediate clinical endpoints, or that we will decide to pursue or submit any additional NDAs for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.

Moreover, for drugs granted accelerated approval, the FDA typically requires post-marketing confirmatory trials to evaluate the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence. The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. Similar risks to those described above are also applicable to any application that we may submit to the EMA to support conditional approval of selinexor to treat penta-refractory multiple myeloma, relapsed/refractory diffuse large~~B-cell~~ ~~lymphoma, or any other cancer indication.~~

A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period ~~for~~until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

A fast track designation or breakthrough therapy status by the FDA is not assured and, in any event, may not actually lead to a faster development or regulatory review or approval process and, moreover, would not assure FDA approval of our product candidates.

We may be eligible for fast track designation or breakthrough therapy status for product candidates that we develop. If a product is intended for the treatment of a serious or life-threatening disease or condition and the product demonstrates the potential to address unmet medical needs for this disease or condition, the product sponsor may apply for FDA fast track designation. Additionally, a product candidate may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may

Table of Contents

demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for such designation or status, the FDA could decide not to grant it. Moreover, even if we do receive such a designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that our product candidate will be approved by the FDA.

In April 2018, the FDA granted fast track designation to selinexor for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy that include regimens comprised of an alkylating agent, a glucocorticoid, Velcade^{®
(bortezomib), Kyprolis^{®
(carfilzomib), Revlimid^{®
(lenalidomide), Pomalyst^{®
(pomalidomide) and Darzalex^{®
(daratumumab) and whose disease is refractory to at least one proteasome inhibitor (Velcade or Kyprolis), one immunomodulatory agent (Revlimid or Pomalyst), glucocorticoids and to Darzalex, as well as to the most recent therapy. In addition, in November 2018, the FDA granted fast track designation to selinexor for the treatment of patients withthat have relapsed and/or refractory DLBCL who have receivedafter at least two prior multi-agent therapies and who are not eligibleineligible for transplantation, including high dose chemotherapy with stem cell rescue or chimeric antigen receptor T-Cell (CAR-T) therapy.rescue. However, even with these fast track designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that selinexor will be approved by the FDA.FDA for additional indications. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.}}}}}

Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidate.

If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the FDA’s goal to review an application is six months, rather than the standard review period of ten months. On August 6, 2018, we announced the completion of the rolling submission of an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with penta-refractory multiple myeloma. On October 5, 2018, the FDA accepted for filing our NDA and granted our request for priority review and assigned an action date of April 6, 2019 under the PDUFA. In addition, we may request priority review in the future for our product candidates in other indications. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. For example, in connection with our NDA for XPOVIO, in March 2019, the FDA extended the Prescription Drug User Fee Act (PDUFA) action date by three months following our submission of additional, existing clinical information as an amendment to the NDA, which resulted in a nine-month review cycle. Receiving priority review from the FDA does not guarantee approval within the

six-month

review cycle or thereafter.

We may not be able to obtain orphan drug exclusivity for our product candidates.

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States.

Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.

Even if we obtain orphan drug exclusivity from the FDA for a product, as we have for XPOVIO as a treatment for patients with heavily pretreated multiple myeloma and selinexor in acute myeloid leukemia ~~DLBCL~~ and ~~multiple myeloma,~~DLBCL, that exclusivity may not effectively protect the product from competition because different products

can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA’s

pre-existing

regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.

Table of Contents

Even if we or any of our collaborators obtain marketing approvals for our drug candidates, the terms of approvals and ongoing regulation of our drugs may limit how we, or they, manufacture and market our drugs, which could materially impair our ability to generate revenue.

Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive regulation. We and our collaborators must therefore comply with requirements concerning advertising and promotion for XPOVIO or for any of our drug candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug’s approved labeling. Thus, we and our collaborators may not be able to promote any drugs we develop for indications or uses for which they are not approved.

In addition, manufacturers of approved drugs and those manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.

Accordingly, assuming we or our current or future collaborators receive marketing approval for one or more of our drug candidates, we, and our collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.

If we and our collaborators are not able to comply with post-approval regulatory requirements, we and our collaborators could have the marketing approvals for our drugs withdrawn by regulatory authorities, and our or our collaborators’ ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.

~~Any~~

XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market, and we and our collaborators may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our drugs following approval.

~~Any~~

XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, which could include requirements for a restricted distribution system.

The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a drug. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding

off-label

use, and if we or our collaborators do not market any of our drug candidates for which we, or

they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for

off-label

marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.

In addition, later discovery of previously unknown AEs or other problems with our drugs or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:

litigation involving patients taking our drug;

restrictions on such drugs, manufacturers or manufacturing processes;

restrictions on the labeling or marketing of a drug;

Table of Contents

restrictions on drug distribution or use;

requirements to conduct post-marketing studies or clinical trials;

warning letters or untitled letters;

withdrawal of the drugs from the market;

refusal to approve pending applications or supplements to approved applications that we submit;

recall of drugs;

fines, restitution or disgorgement of profits or revenues;

suspension or withdrawal of marketing approvals;

damage to relationships with any potential collaborators;

unfavorable press coverage and damage to our reputation;

refusal to permit the import or export of drugs;

drug seizure; or

injunctions or the imposition of civil or criminal penalties.

Under the Cures Act and the Trump Administration’s regulatory reform initiatives, the FDA’s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue.

In December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump Administration may impact our business and industry. Namely, the Trump Administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-resourced FDA could result in delays in the FDA’s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. In January 2017, President Trump issued an executive order, applicable to all executive agencies including the FDA, which requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the

“two-for-one”

provisions. This executive order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the executive order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB in February 2017, the administration indicates that the

“two-for-one”

provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a “Regulatory

Reform Officer” and establish a “Regulatory Reform Task Force” to implement the

two-for-one

provisions and other previously issued executive orders relating to the review of federal regulations. It is difficult to predict how these various requirements will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.

Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our drug candidates and affect the prices we, or they, may obtain.

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or

Table of Contents

commercialize XPOVIO or any ~~drugs~~drug candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved drugs.

Among the provisions of the Patient Protection and Affordable Care Act, or ACA, of potential importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our drug candidates that are approved for sale, are the following:

an annual,

non-deductible

fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;

an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;

expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;

a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% starting January 1, 2019)

point-of-sale

discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer’s outpatient drugs to be covered under Medicare Part D;

extension of manufacturers’ Medicaid rebate liability;

expansion of eligibility criteria for Medicaid programs;

expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;

new requirements to report certain financial arrangements with physicians and teaching hospitals;

a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.

Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for XPOVIO and for any of our product candidates for which we may obtain regulatory approval or the frequency with which XPOVIO or any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.

We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for XPOVIO or any other approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.

~~Since enactment~~

Some of the provisions of the ACA have yet to be implemented, and there have been ~~numerous legal challenges~~judicial and Congressional ~~actions~~challenges to certain aspects of the ACA, as well as recent efforts by the Trump Administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Congress has considered legislation that would repeal or repeal and replace ~~provisions~~all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. ~~For example, with the December 2017 enactment of the~~The Tax Cuts and Jobs Act of 2017, ~~Congress repealed~~or the Tax Act, includes a provision repealing, effective January 1, 2019, the

tax-based

shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual ~~mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will~~

become effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Additionally, onmandate”. On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain

ACA-mandated

fees, including the

so-called ~~“Cadillac”~~

“Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers

Table of Contents

based on market share, and the medical device excise tax on

non-exempt

medical devices. ~~Further, the~~The Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January 1, 2019, to ~~increase from 50 percent to 70 percent thepoint-of-sale~~ ~~discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to~~ close the coverage gap in most Medicare drug plans, commonly referred to as the “donut ~~hole.” Further, each chamber~~hole”. In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the ~~Congress has put forth multiple bills designed~~method CMS uses to ~~repeal or repeal and replace portions~~determine this risk adjustment. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the ACA. Although none of these measures has been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. The Congress will likely consider other legislation to replace elementsindividual mandate is an inseverable feature of the ACA, ~~during~~and therefore, because it was repealed as part of the ~~next Congressional session.~~

Tax Act, the remaining provisions of the ACA are invalid as well. The Trump Administration has recently represented to the Court of Appeals considering this judgment that it does not oppose the lower court’s ruling. On July 10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. In those arguments, the Trump Administration argued in support of upholding the lower court decision. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.

The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA. In January 2017, President Trump signed an executive order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second executive order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the ACA exchanges. At the same time, the Trump Administration announced that it will discontinue the payment of cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain. Further, in July 2018 following a federal district court decision from New Mexico, the Administration announced that it would be freezing payments to insurers under the ACA to cover sicker patients until it or Congress can address the appropriate methodology for calculating and making such payments. It remains to be seen how this action will affect the implementation of the ACA.

We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provisions. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from XPOVIO or from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.

Further, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for

low-income

patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.

~~In addition,~~

Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May 11, 2018, the ~~Administration~~current administration issued a plan to lower drug prices. Under this blueprint for action, the ~~Administration~~current administration indicated that the Department of Health and Human Services, or HHS, ~~will:~~will take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect ~~monopolies;~~monopolies, advance biosimilars and generics to boost price ~~competition;~~competition, evaluate the inclusion of prices in drug makers’ ads to enhance price ~~competition;~~competition, speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug ~~makers;~~makers, avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and ~~Medicaid;~~Medicaid, work to give Medicare Part D plan sponsors more negotiation power with drug ~~makers;~~makers, examine which Medicare Part B ~~drugs~~drug prices could be negotiated ~~for a lower price~~ by Medicare Part D plans, ~~and improving~~improve the design of the Medicare Part B Competitive Acquisition ~~Program;~~Program, update Medicare’s drug-pricing dashboard to increase ~~transparency;~~transparency, prohibit Medicare Part D contracts that include “gag rules” that prevent pharmacists from informing patients when they could pay less

out-of-pocket

by not using ~~insurance;~~ insurance,

Table of Contents

and require that Medicare Part D plan members be provided with an annual statement of plan payments,

out-of-pocket

spending, and drug price increases.

More recently, on January 31, 2019, the HHS Office of Inspector General proposed modifications to the federal anti-kickback statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations.

At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on

certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.

Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us and any collaborators to more stringent drug labeling and post-marketing testing and other requirements.

Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Healthcare providers, physicians and third party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:

Anti-Kickback Statute

—the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

Table of Contents

False Claims Act

—the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant

per-claim

penalties, currently set at $5,500 to $11,000 per false claim;

HIPAA

—the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;

Transparency Requirements

—federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and

Analogous State and Foreign Laws

—analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions.

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not

pre-empted

by HIPAA, thus complicating compliance efforts.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.

Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.

The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data ~~including personal health data, of~~regarding individuals in the European Union, including personal health data, is ~~governed by~~subject to the EU General Data Protection Regulation, or ~~GDPR.~~the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR ~~became effective on May 25, 2018. It~~is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating ~~to:~~to processing health and other sensitive ~~data;~~data, obtaining consent of ~~individuals;~~the individuals to whom the personal data relates, providing ~~notice~~information to individuals regarding data processing ~~activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; and~~activities, implementing safeguards to protect the security and confidentiality of personal ~~data.~~data, providing notification of data breaches, and taking certain

Table of Contents

measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. ~~Failure~~The GDPR also permits data protection authorities to ~~comply with the requirements~~require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, ~~may result in fines~~which can be up to four percent of ~~up to~~global revenues or 20 million Euros, ~~or four percent of annual global revenues,~~ whichever is ~~greater. The GDPR~~greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for ~~damages.~~damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.

Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR’s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR ~~increases~~and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our ~~responsibility and potential liability in relation to personal data that we process, and we may be required~~clinical trials, could require us to change our business practices orand put in place additional compliance mechanisms, ~~ensuring compliance with the GDPR. This~~ may ~~be onerous~~interrupt or delay our development, regulatory and ~~adversely affect~~commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of ~~operations,~~operations.

Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and ~~prospects,~~a wide range of enforcement agencies at both the state and ~~despite our efforts, there~~ federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act—which goes into effect in 2020—is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain information collected as part of a ~~risk that we may be~~clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines ~~litigation,~~ and ~~reputational~~penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm ~~in connection with~~ our ~~European activities.~~

reputation and our business.

Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including
non-compliance
with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.

We are exposed to the risk of ~~employee~~ fraud or other misconduct ~~including~~by our employees, independent contractors, consultants and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, ~~we have established,~~ comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of

non-U.S.

jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or ~~regulations.~~codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.

Table of Contents

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain drug candidates outside of the United States and require us to develop and implement costly compliance programs.

We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring ~~the company~~us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The Securities and Exchange Commission, or SEC, is involved with enforcement of the books and records provisions of the FCPA.

Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain

non-U.S.

nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States, has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

Table of Contents

Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of drugs, if any.

In some countries, including the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we or our existing and future collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including in recent months, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our drug candidates and other discoveries, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drugs and other discoveries similar or identical to ours, and our ability to successfully commercialize our drug candidates and other discoveries may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary drug candidates and other discoveries. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel drug candidates and other discoveries that are important to our business. To date, 4969 patents have issued that relate to XPO1 inhibitors, including composition of matter patents for selinexor, verdinexor and eltanexor in the United States, and their use in targeted therapeutics. In addition, ~~four~~11 patents have issued that relate to our PAK4/NAMPT ~~inhibitor,KPT-9274,~~inhibitors, including atwo composition of matter ~~patent~~ patents for

KPT-9274

in the United States and its use in targeted therapeutics. We cannot be certain that any other patents will issue with claims that cover any of our key drug candidates or other discoveries or drug candidates.

The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our drug candidates or other discoveries, or which effectively prevent others from commercializing competitive drugs and discoveries. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.

The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, in some foreign jurisdictions, our ability to secure patents based on our filings in the United States may depend, in part, on our ability to timely obtain assignment of rights to the invention from the employees and consultants who invented the technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.

Table of Contents

Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside of the United States, the first to file a patent application is entitled to the patent. In March 2013, the United States transitioned to a

first-inventor-to-file

system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, revocation, reexamination, or post-grant or

inter partes

review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our discoveries or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights.

Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative discoveries or drugs in a

non-infringing

manner.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical discoveries and drugs, or limit the duration of the patent protection of our discoveries and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors or commercial supply companies or others may infringe our patents and other intellectual property rights. For example, we are aware of third parties selling a version of our lead product candidate for research purposes, which may infringe our intellectual property rights. To counter such infringement, we may advise such companies of our intellectual property rights, including, in some cases, intellectual property rights that provide protection for our lead product candidates, and demand that they stop infringing those rights. Such demand may provide such companies the opportunity to challenge the validity of certain of our intellectual property rights, or the opportunity to seek a finding that their activities do not infringe our intellectual property rights. We may also be required to file infringement actions, which can be expensive and time-consuming. In an infringement proceeding, a defendant may assert and a court may agree with a defendant that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the intellectual property at issue. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of any current and future collaborators to develop, manufacture, market and sell XPOVIO and our drug candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and technology, including interference proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. No litigation asserting such infringement claims is currently pending against us, and we have not been found by a court of competent jurisdiction to have infringed a third party’s intellectual property rights. If we are found to infringe or think there is a risk we may be found to infringe, a third party’s intellectual property rights, we could be required or choose to obtain a license from such third party to continue developing, marketing and ~~marketing~~selling our drugs, drug candidates and ~~using our~~ technology. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be

non-exclusive,

thereby giving our competitors access to the same intellectual property licensed to us. We could be forced, including by court order, to cease commercializing the infringing intellectual property or drug or to cease using the infringing technology. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

Table of Contents

We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or

know-how

of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
non-compliance
with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the United States Patent and Trademark Office, or USPTO, and various foreign patent offices at various points over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with such provisions, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which

non-compliance

can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.

If we do not successfully extend the term of patents covering our drug candidates under the Hatch-Waxman Amendments and similar foreign legislation, our business may be materially harmed.

Depending upon the timing, duration and conditions of FDA marketing approval, if any, of our drug candidates, one or more of our U.S. patents may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for one patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. The total patent term, including the extension period, may not exceed 14 years following FDA approval. Accordingly, the length of the extension, or the ability to even obtain an extension, depends on many factors.

In the United States, only a single patent can be extended for each qualifying FDA approval, and any patent can be extended only once and only for a single product. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Because both selinexor and verdinexor are protected by a single family of patents and applications, we may not be able to secure patent term extensions for both of these drug candidates in all jurisdictions where these drug candidates are approved, if ever.

If we are unable to obtain a patent term extension for a drug candidate or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that drug candidate, if any, in that jurisdiction will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue could be materially reduced.

Table of Contents

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for our drugs, drug candidates and other discoveries, we also rely on trade secrets, including unpatented

know-how,

technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into

non-disclosure

and confidentiality agreements with parties who have access to them, such as our employees, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. To the extent that we are unable to timely enter into confidentiality and invention or patent assignment agreements with our employees and consultants, our ability to protect our business through trade secrets and patents may be harmed. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. To the extent inventions are made by a third party under an agreement that does not grant us an assignment of their rights in inventions, we may choose or be required to obtain a license.

Not all of our trademarks are registered. Failure to secure those registrations could adversely affect our business.

As of ~~October 25, 2018, four~~November 1, 2019, five of our trademarks, including XPOVIO, are registered in the United States. We also have ~~six~~9 pending

intent-to-use

applications in the United States, ~~one~~six of which ~~has~~have been allowed, meaning that we can perfect our registration when we have commenced use in commerce. Outside the United States, we have registrations in the European Union for ~~six~~seven trademarks (potential drug names for selinexor). and pending applications for two others. Applications for the same ~~six~~nine trademarks were filed in 15 other jurisdictions, some of which have also proceeded to registration. Applications for one of those marks (XPOVIO) have been filed in an14 additional ~~eight~~jurisdictions, and applications for three of those marks (NEXPOVIO, XPOVI and XPOVIE) have been filed in 20 additional jurisdictions. We have also filed trademark applications for XPOVIO in Katakana in Japan, Hangul in South Korea and Chinese characters in Taiwan. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could adversely affect our business. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.

In addition, any proprietary name we propose to use with our key drug candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any of our proposed proprietary drug names for any of our drug candidates, if approved, we may be required to expend significant additional resources in an effort to identify a suitable proprietary drug name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.

Risks Related to Employee Matters and Managing Growth

Our future success depends on our ability to retain our Chief Executive Officer, our President and Chief Scientific Officer and other key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on Michael Kauffman, M.D., Ph.D., our Chief Executive Officer, and Sharon Shacham, Ph.D., M.B.A., our President and Chief Scientific Officer, as well as the other principal members of our management and scientific teams. Although we have entered into formal employment agreements with Drs. Kauffman and Shacham, these agreements do not prevent them from terminating their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees. The loss of the services of any of our key employees could impede the achievement of our research, development, commercialization and other business objectives.

Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

Table of Contents

Drs. Kauffman and Shacham are married to each other. The separation or divorce of the couple in the future could adversely affect our business.

Dr. Kauffman, our Chief Executive Officer and member of our board of directors, and Dr. Shacham, our President and Chief Scientific Officer, are married to each other. They are two of our executive officers and are a vital part of our operations. If they were to become separated or divorced or could otherwise not amicably work with each other, one or both of them may decide to cease his or her employment with us or it could negatively impact our working environment. Alternatively, their work performance may not be satisfactory if they become preoccupied with issues relating to their personal situation. In these cases, our business could be materially harmed.

We have expanded and expect to continue to expand our development, regulatory and ~~future~~ sales, marketing and ~~marketing~~distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

We have experienced and expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs, sales, marketing and ~~sales and marketing.~~distribution. To manage our current and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing ~~a company with~~ such ~~anticipated~~ growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The ~~physical~~ expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

Our business and operations may be materially adversely affected in the event of computer system failures or security breaches, and the costs and consequences of implementing data protection measures could be significant.

Despite the implementation of security measures, our internal computer systems, and those of our contract research organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber attacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development ~~programs.~~programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach ~~results~~were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our reputation or competitive position could be damaged, and the further development and commercialization of our drug candidates could be ~~delayed.~~delayed or halted. We may also be vulnerable to cyber attacks by hackers, or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or result in legal proceedings. In addition, the cost and operational consequences of implementing further data protection measures could be significant. Moreover, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate security measures.

Risks Related to Our Common Stock

Our executive officers, directors and principal stockholders maintain the ability to control all matters submitted to stockholders for approval.

As of September 30, ~~2018,~~2019, our executive officers, directors and a small number of stockholders own more than a majority of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.

Table of Contents

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

establish a classified board of directors such that not all members of the board are elected at one time;

allow the authorized number of our directors to be changed only by resolution of our board of directors;

limit the manner in which stockholders can remove directors from the board;

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;

limit who may call stockholder meetings;

authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and

require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

An active trading market for our common stock may not be sustained.

Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for you to sell shares of our common stock without depressing the market price for the shares, or at all. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.

If securities analysts do not continue to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that analysts will provide favorable coverage or continue to cover us. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

The price of our common stock has been and may be volatile in the future and fluctuate substantially.

Our stock price has been and is likely to be volatile and may fluctuate substantially. For example, since January 1, 2015, our common stock has traded at prices per share as high as $38.47 and as low as ~~$4.83.~~$3.92. On ~~November 2, 2018,~~October 29, 2019, the closing sale price of our common stock on The Nasdaq Global Select Market was ~~$11.24~~$11.52 per share. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:

our success in launching and commercializing XPOVIO;

Table of Contents

the success of competitive drugs or technologies;

results of clinical trials of our drug candidates or those of our competitors;

our success in commercializing our drug candidates, if and when approved;

regulatory or legal developments in the United States and other countries;

developments or disputes concerning patent applications, issued patents or other proprietary rights;

the recruitment or departure of key personnel;

the level of expenses related to the commercial launch of XPOVIO and clinical development programs for any of our drug ~~candidates or clinical development programs;~~

candidates;

the results of our efforts to discover, develop, acquire or

in-license

additional drug candidates or drugs;

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

variations in our financial results or those of companies that are perceived to be similar to us;

changes in the structure of healthcare payment systems;

market conditions in the pharmaceutical and biotechnology sectors;

general economic, industry and market conditions; and

the other factors described in this “Risk Factors” section.

Securities litigation or other litigation could ~~be subject to securities class action litigation.~~

result in substantial damages and may divert management’s time and attention from our business.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. IfWe are a target of this type of litigation. See Part II, Item 1, “Legal Proceedings” in this Quarterly Report on Form

10-Q

for information concerning securities litigation recently initiated against us and certain of our executive officers and directors and certain other defendants. We may become the target of additional securities litigation in the future. For example, we may face additional securities class action litigation or other litigation if we fail to successfully launch and commercialize XPOVIO, or if we cannot obtain regulatory approvals for, or if we otherwise fail to successfully commercialize and launch, our drug candidates. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. We currently maintain insurance coverage for some of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover damages awarded. In addition, certain types of damages may not be covered by insurance, and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. A decision adverse to our interests on one or more legal matters or litigation it could result in the payment of substantial ~~costs~~damages, or possibly fines, and could have a ~~diversion~~material adverse effect on our reputation, financial condition and results of ~~management’s attention and our resources, which could harm our business.~~

operations.

We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.

Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our drug candidates. Pending their use to fund our operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.

~~We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.~~

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company through 2018. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We have ~~irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards~~incurred and ~~therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.~~

We will continue to incur increased costs as a result of operating as a public company, and our management ~~will need to continue~~is required to devote substantial time to compliance initiatives and corporate governance practices.

As a public company, ~~and particularly after~~ we ~~are no longer an “emerging growth company,” we will~~ incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management

Table of Contents

and other personnel ~~will need to continue to~~ devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations ~~will increase~~have increased our legal and financial compliance costs and ~~will make~~have made some activities more time-consuming and ~~costly.~~

~~We cannot predict with certainty~~costly especially since we are no longer an “emerging growth company,” as defined in the ~~amount~~Jumpstart Our Business Startups Act of ~~additional costs we may incur~~2012, and are no longer able to ~~continue to operate as a public company, nor can we predict the timing~~take advantage of ~~such costs. In addition, the rules and regulations~~certain exemptions from various reporting requirements that are applicable to public companies that are ~~often subject~~“emerging growth companies” and that were applicable to ~~varying interpretations, in many cases due~~us prior to ~~their lack~~January 1, 2019.

Section 404 of ~~specificity,~~the Sarbanes-Oxley Act of 2002 requires us, on an annual basis, to review and ~~as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies which could result in continuing uncertainty regarding~~evaluate our internal controls. To maintain compliance ~~matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.~~

~~Pursuant to~~with Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we are not required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which ishas been both costly and challenging. ~~In this regard, we~~We will need to continue to dedicate internal resources, ~~potentially~~continue to engage outside consultants and ~~adopt~~follow a detailed work plan to continue to assess and document the adequacy of internal control over financial reporting, continue ~~steps~~ to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. ~~This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if~~If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.

A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. We had ~~60,664,857~~62,705,481 shares outstanding as of September 30, ~~2018.~~2019. Of such shares, at least ~~11.2~~7.8 million shares are eligible for sale in the public market under Rule 144 of the Securities Act of 1933, as amended, or the Securities Act, subject to the volume limitations and other conditions of Rule 144. The holders of these shares may at any time decide to sell their shares in the public market.

Moreover, holders of an aggregate of at least 9.5 million shares of our common stock as of September 30, 2018 have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also registered all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, to the extent applicable.

Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations.

Under the provisions of the Internal Revenue Code of 1986, as amended, or the Code, our net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (and state tax authorities under relevant state tax rules). In addition, as a result of the ~~Tax Cuts and Jobs Act of 2017, or~~ Tax Act, for U.S. federal income tax purposes, the use of net operating loss carryforwards arising in taxable years beginning after December 31, 2017 is limited to 80% of our taxable income in any future taxable year, although such losses may be carried forward indefinitely. It is uncertain how various states will respond to the Tax Act. Furthermore, the use of net operating loss and tax credit carryforwards may become subject to an annual limitation under Sections 382 and 383 of the Code, respectively, and similar state provisions in the event of certain cumulative changes in the ownership interest of significant shareholders in excess of 50 percent over a three-year period. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of a company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Our company has completed several financings since its inception which resulted in an ownership change under Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, some of which are outside of our control, could result in ownership changes in the future. For these reasons, we may not be able to use some or all of our net operating loss and tax credit carryforwards, even if we attain profitability.

The comprehensive tax reform bill could adversely affect our business and financial condition.

The Tax Act significantly revises the Internal Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 34% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses),

Table of Contents

limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain how various states will respond to the Tax Act.

Table of Contents

Item 6. Exhibits.

Exhibit
Number

Form
   Incorporated by Reference
Provided
Herewith


Description of Exhibit
   File Number    Date of Filing    Exhibit Number
  10.1    Open Market Sale Agreement^SM, dated August 17, 2018, by and between Karyopharm Therapeutics Inc. and Jefferies LLC.    8-K    001-36167    August 17, 2018    10.1
  31.1    Certification of principal executive officer pursuant toRule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.                X
  31.2    Certification of principal financial officer pursuant toRule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.                X
  32.1    Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                X
  32.2    Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                X
101.INS    Instance Document                X
101.SCH    Scheme Document                X
101.CAL    Calculation Linkbase Document                X
101.DEF    Definition Linkbase Document                X
101.LAB    Labels Linkbase Document                X
101.PRE    Presentation Linkbase Document                X

Exhibit

Number

Form

Incorporated by Reference

Provided

Herewith

Description of Exhibit

File Number

Date of Filing

Exhibit Number

10.1

Annual Bonus Plan of the Registrant.

8-K

001-36167

August 6, 2019

10.1

10.2*

Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P.

31.1

Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2

Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1

Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document

The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document

101.SCH

Inline XBRL Schema Document

101.CAL

Inline XBRL Calculation Linkbase Document

101.DEF

Inline XBRL Definition Linkbase Document

101.LAB

Inline XBRL Label Linkbase Document

101.PRE

Inline XBRL Presentation Linkbase Document

104

Cover Page Interactive Data File

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

* Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	KARYOPHARM THERAPEUTICS INC.

Date: November 4, 2019	By:	/s/ MICHAEL KAUFFMAN
		~~KARYOPHARM THERAPEUTICS INC.~~

~~Date: November 8, 2018~~		~~By:~~	~~/s/ MICHAEL KAUFFMAN~~ Michael Kauffman, M.D., Ph.D.
			~~Michael Kauffman, M.D., Ph.D.~~ Chief Executive Officer
		(Principal executive officer)
	~~Chief Executive Officer~~
Date: November 4, 2019	By:	/s/ MICHAEL MASON
			~~(Principal executive officer)~~


	September 30, 2018			December 31, 2017
Assets
Current assets:
Cash and cash equivalents	$	101,600		$	68,997
Short-term investments		105,170			77,472
Prepaid expenses and other current assets		4,792			1,754
Restricted cash		—			200

Total current assets		211,562			148,423
Property and equipment, net		2,914			2,185
Long-term investments		4,804			29,396
Restricted cash		712			290

Total assets	$	219,992		$	180,294

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,238		$	5,665
Accrued expenses		29,155			21,445
Deferred revenue		9,362			21,921
Deferred rent		256			303
Other current liabilities		556			133

Total current liabilities		41,567			49,467
Deferred revenue, net of current portion		4,532			—
Deferred rent, net of current portion		2,815			1,363

Total liabilities		48,914			50,830
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding		—			—
Common stock, $0.0001 par value; 100,000,000 shares authorized; 60,664,857 and 49,533,150 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		6			5
Additionalpaid-in capital		786,763			625,017
Accumulated other comprehensive loss		(153	)		(217	)
Accumulated deficit		(615,538	)		(495,341	)

Total stockholders’ equity		171,078			129,464

Total liabilities and stockholders’ equity	$	219,992		$	180,294


	Nine Months Ended September 30,
	2018			2017
Operating activities
Net loss	$	(120,197	)	$	(89,944	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		541			539
Net amortization of premiums and discounts on investments		280			903
Stock-based compensation expense		13,378			15,906
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(3,039	)		18
Accounts payable		(3,425	)		(2,867	)
Accrued expenses and other liabilities		8,139			6,423
Deferred revenue		(8,027	)		1,050
Deferred rent		1,405			(207	)

Net cash used in operating activities		(110,945	)		(68,179	)
Investing activities
Purchases of property and equipment		(1,270	)		(7	)
Proceeds from maturities of investments		94,378			94,033
Purchases of investments		(97,662	)		(74,017	)

Net cash (used in) provided by investing activities		(4,554	)		20,009
Financing activities
Proceeds from the issuance of common stock, net of issuance costs		145,706			52,323
Proceeds from the exercise of stock options and shares issued under employee stock purchase plan		2,627			463

Net cash provided by financing activities		148,333			52,786
Effect of exchange rate on cash, cash equivalents and restricted cash		(9	)		181

Net increase in cash, cash equivalents and restricted cash		32,825			4,797
Cash, cash equivalents and restricted cash at beginning of period		69,487			50,142

Cash, cash equivalents and restricted cash at end of period	$	102,312		$	54,939

Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets
Cash and cash equivalents	$	101,600		$	54,450
Short-term restricted cash		—			200
Long-term restricted cash		712			289

Total cash, cash equivalents and restricted cash	$	102,312		$	54,939

	Common Shares
	Shares		Amount			Additional Paid-In Capital			Accumulated Other Comprehensive Income (Loss)				Accumulated Deficit				Total Stockholders’ Equity
Balance at June 30, 2019		60,965,505		$	6		$	865,726		$	61			$	(783,324	)		$	82,469
Vesting of restricted stock		5,000			—			—			—				—				—
Exercise of stock options and shares issued under the employee stock purchase plan		100,525			—			577			—				—				577
Issuance of common stock, net of issuance costs of $0.3 million		1,634,451			—			14,563			—				—				14,563
Stock-based compensation expense		—			—			3,719			—				—				3,719
Unrealized loss on investments		—			—			—			(59	)			—				(59	)
Foreign currency translation adjustment		—			—			—			(32	)			—				(32	)
Net loss		—			—			—			—				(41,367	)			(41,367	)

Balance at September 30, 2019		62,705,481		$	6		$	884,585		$	(30	)		$	(824,691	)		$	59,870

Balance at June 30, 2018		60,501,260		$	6		$	781,176		$	(260	)		$	(567,455	)		$	213,467
Vesting of restricted stock		—			—			—			—				—				—
Exercise of stock options and shares issued under the employee stock purchase plan		163,597			—			812			—				—				812
Stock-based compensation expense		—			—			4,775			—				—				4,775
Unrealized gain on investments		—			—			—			110				—				110
Foreign currency translation adjustment		—			—			—			(3	)			—				(3	)
Net loss		—			—			—			—				(48,083	)			(48,083	)

Balance at September 30, 2018		60,664,857		$	6		$	786,763		$	(153	)		$	(615,538	)		$	171,078

Balance at December 31, 2018		60,829,308		$	6			857,156		$	(244	)		$	(673,748	)		$	183,170
Vesting of restricted stock		10,000			—			—			—				—				—
Exercise of stock options and shares issued under the employee stock purchase plan		231,722			—			1,124			—				—				1,124
Issuance of common stock, net of issuance costs of $0.3 million		1,634,451			—			14,563			—				—				14,563
Stock-based compensation expense		—			—			11,742			—				—				11,742
Unrealized gain on investments		—			—			—			250				—				250
Foreign currency translation adjustment		—			—			—			(36	)			—				(36	)
Net loss		—			—			—			—				(150,943	)			(150,943	)

Balance at September 30, 2019		62,705,481		$	6		$	884,585		$	(30	)		$	(824,691	)		$	59,870

Balance at December 31, 2017		49,533,150		$	5		$	625,053		$	(217	)		$	(495,341	)		$	129,500
Vesting of restricted stock		103,800			—			—			—				—				—
Exercise of stock options and shares issued under the employee stock purchase plan		502,483			—			2,627			—				—				2,627
Issuance of common stock, net of issuance costs of $0.2 million		10,525,424			1			145,705			—				—				145,706
Stock-based compensation expense		—			—			13,378			—				—				13,378
Unrealized gain on investments		—			—			—			105				—				105
Foreign currency translation adjustment		—			—			—			(41	)			—				(41	)
Net loss		—			—			—			—				(120,197	)			(120,197	)

Balance at September 30, 2018		60,664,857		$	6		$	786,763		$	(153	)		$	(615,538	)		$	171,078


	Estimated Useful Life Years		September 30, 2018			December 31, 2017
Laboratory equipment		4	$	593		$	593
Furniture and fixtures		5		601			381
Office and computer equipment		3		408			378
Construction in process		N/A		491			—
Leasehold improvements		Lesser of useful life or lease term		3,920			3,391

				6,013			4,743
Less accumulated depreciation and amortization				(3,099	)		(2,558	)

			$	2,914		$	2,185


	September 30, 2018		December 31, 2017
Research and development costs	$	18,118	$	16,198
Payroll and employee-related costs		7,349		3,982
Professional fees		3,443		972
Other		245		293

	$	29,155	$	21,445


	Number of Shares Underlying RSUs			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2017		30,000		$	10.52
Granted		—			—
Forfeited		—			—
Vested		(5,000	)		10.27

Unvested at September 30, 2018		25,000		$	10.57


	Nine Months Ended September 30,
	2018			2017			$ Change			% Change
	(in thousands)
License and other revenue	$	30,130		$	71		$	30,059			N/A
Operating expenses:
Research and development		122,482			72,440			50,042			69	%
General and administrative		30,076			18,717			11,359			61	%

Loss from operations		(122,428	)		(91,086	)		(31,342	)		34	%
Other income, net		2,240			1,196			1,044			87	%

Loss before income taxes		(120,188	)		(89,890	)		(30,298	)		34	%
Income tax provision		(9	)		(54	)		45			(83	)%

Net loss	$	(120,197	)	$	(89,944	)	$	(30,253	)		34	%


Remainder of 2018	$	433
2019		2,983
2020		3,208
2021		3,277
2022		3,447
2023		3,718
Thereafter		6,735

Total future minimum lease payments	$	23,801

~~Date: November 8, 2018~~

~~/s/ MICHAEL F. FALVEY~~
Michael Mason

~~Michael F. Falvey~~
Senior Vice President,
Chief Financial Officer and Treasurer

~~Executive Vice President,~~
~~Chief Financial Officer and Treasurer~~

(Principal financial and accounting officer)